

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
27 September 2001 (27.09.2001)

PCT

(10) International Publication Number  
**WO 01/70245 A1**

(51) International Patent Classification<sup>7</sup>: **A61K 35/28** (74) Agents: PARENT, Annette, S. et al.; Townsend and Townsend and Crew LLP, Two Embarcadero Center, Eighth Floor, San Francisco, CA 94111-3834 (US).

(21) International Application Number: PCT/US01/09616

(22) International Filing Date: 22 March 2001 (22.03.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

60/191,274	22 March 2000 (22.03.2000)	US
60/204,249	15 May 2000 (15.05.2000)	US
60/264,003	23 January 2001 (23.01.2001)	US

(71) Applicant (for all designated States except US): CORIXA CORPORATION [US/US]; 1124 Columbia Street, Suite 200, Seattle, WA 98104 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): CARTER, Darrick [US/US]; 321 Summit Avenue East, Seattle, WA 98102 (US). ZHU, Shirley [US/US]; 152 Oxford Lane, Apt. 1, San Bruno, CA 94066 (US). ARIMILLI, Subhashini [US/US]; 4789 Ridgewood Drive, Fremont, CA 94555 (US). WANG, Aijun [CN/US]; 3106 213th Place SE, Issaquah, WA 98029 (US).

(83) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



**WO 01/70245 A1**

(54) Title: IMMUNE MEDIATORS AND RELATED METHODS

(57) Abstract: The present invention relates to nucleic acids encoding single chain MHC class II molecules that form multimers via inter-chain multimerization domains, and methods of treating autoimmune disease using the same.

Docket: COUL-012/01US  
USSN: 09/875,494  
Ref. No. F1

## IMMUNE MEDIATORS AND RELATED METHODS

### CROSS-REFERENCES TO RELATED APPLICATIONS

This application is related to U.S. Serial No. 60/191,274, filed March 22,

- 5 2000; U.S. Serial No. 60/204,249, filed May 15, 2000; and U.S. Serial No. 60/264,003,  
filed January 23, 2001. Each of the aforementioned applications are herein incorporated  
by reference in their entirety.

- This application is also related to U.S. Serial No. 09/261,811, filed March  
3, 1999; which is a continuation of U.S. Serial No. 08/657,581, filed June 7, 1996, now  
10 abandoned; which is a continuation in part of U.S. Serial No. 08/480,002, filed June 7,  
1995, now abandoned; U.S. Serial No 09/184,692, filed November 2, 1998, now  
abandoned; U.S. Serial No. 08/483,241, filed June 7, 1995; U.S. Serial No. 08/482,133,  
filed June 7, 1995; and U.S. Provisional Application No. 60/005,964, filed October 27,  
1995.

15

### BACKGROUND OF THE INVENTION

T cells, unlike B cells, do not directly recognize antigens. Instead, an  
accessory cell must first process an antigen and present it in association with an MHC  
molecule in order to elicit a T cell-mediated immunological response. The major function  
20 of MHC glycoproteins appears to be the binding and presentation of processed antigen in  
the form of short antigenic peptides.

In addition to binding foreign or "non-self antigenic peptides," MHC  
molecules can also bind "self" peptides. If T lymphocytes then respond to cells  
presenting "self" or autoantigenic peptides, a condition of autoimmunity results. Over 30  
25 autoimmune diseases are presently known, including myasthenia gravis (MG), multiple  
sclerosis (MS), systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), insulin-  
dependent diabetes mellitus (IDDM) , etc. Characteristic of these diseases is an attack by  
the immune system on the tissues of the host. In non-diseased individuals, such attack  
does not occur because the immune system recognizes these tissues as "self."  
30 Autoimmunity occurs when a specific adaptive immune response is mounted against self  
tissue antigens.

There is therefore currently a great interest in developing pharmaceuticals  
based on the growing understanding of the structure and function of the major

histocompatibility complex (MHC) antigens. Identification of synthetic autoantigenic peptides, and demonstration that these peptides bind selectively to MHC molecules associated with disease and that stimulates T cells would help to implicate a particular peptide or peptide:MHC complex in susceptibility to an autoimmune disease. In particular, the development of single chain MHC class II complexes would be particularly useful in treatment of a number of diseases associated with antigen presentation by MHC molecules. Furthermore, the development of single chain, multimeric complexes would be of interest (see, e.g., WO 93/10220, WO 98/05684, WO 97/35991, WO 98/03552, WO 99/13095, WO 98/06749, WO 99/09064, and U.S. Patent 5,869,270).

10

#### SUMMARY OF THE INVENTION

The present invention provides recombinant nucleic acid constructs that encode single chain, recombinant MHC class II molecules comprising a  $\beta$ 1 domain and an  $\alpha$ 1 domain that may or may not be further linked to an antigenic peptide. In one embodiment, the single chain polypeptide is a  $\beta$ 1 domain and an  $\alpha$ 1 domain. In another embodiment, the single chain polypeptide is a  $\beta$ 1 domain- $\beta$ 2 domain (a  $\beta$  chain) and an  $\alpha$ 1 domain-  $\alpha$ 2 domain (an  $\alpha$  chain). The single chain constructs of the invention can be further dimerized or multimerized by inter-chain fusion. The fusion sequence (also referred to as a dimerization or multimerization sequence) can be any sequence that allows for covalent or non-covalent linkages between the molecules of the invention. As shown below, a preferred means for carrying this out is through use of segments from immunoglobulin family proteins (e.g., antibodies, MHC molecules, T cell receptors and the like) that have cysteine residues capable of forming interchain disulfide bonds (e.g., constant regions from Ig light chains, e.g. C $\kappa$  or C $\lambda$ , or constant regions from Ig heavy chains, e.g., CH1, hinge, CH2, or CH3). In another embodiment, a leucine zipper domain forms a non-covalent linkage. One of skill will recognize that any of a number of polypeptide sequences can be used for this purpose. The single chain molecules of the invention thus can be multimers wherein each single chain molecule is from a different MHC class II allele. In addition, each single chain molecule in the multimer can be bound to a different antigen.

In one embodiment, monomeric and dimeric forms of recombinant single chain mouse I-AS-peptide complexes, fused to an antigenic MBP 90-101 peptide with

## 3

flexible linkers were constructed. The recombinant single chain I-AS proteins share structural similarity to that of crystallized native human MHC class II protein as determined by protein modeling. The recombinant single chain proteins were expressed in *E. coli* and in an insect expression system and purified by affinity chromatography and FPLC. The purified single chain recombinant I-AS proteins showed *in vitro* biological activity as assayed using an antigen-specific mouse T cell clone. The *in vivo* activity of the recombinant single chain I-AS fusion proteins in the EAE model using susceptible SJL mice shows that treatment with the recombinant single chain I-AS proteins prevents mortality and significantly reduces paralysis induced by myelin homogenate.

Histological examination of sections from animal spinal cord reveals that these treatments also reduce the inflammatory lesions. These results demonstrate that the single chain MHC class II molecules have therapeutic benefit as antigen-specific drugs for the treatment of autoimmune diseases.

In another embodiment, novel linkers are provided for forming single chain MHC class II molecules. These linkers can be used with the multimer constructs described above. In another embodiment, the constructs of the invention are optimized for prokaryotic expression, using codons adjusted for *E. coli* codon bias.

The present invention also provides MHC class II heterodimers, wherein a recombinant  $\beta$  chain and a recombinant  $\alpha$  chain are covalently linked using polypeptide fusion segments, e.g., from immunoglobulin family proteins (e.g., antibodies, MHC molecules, T cell receptors and the like) that have cysteine residues capable of forming interchain disulfide bonds (e.g., constant regions from Ig light chains, e.g. C $\kappa$  or C $\lambda$ , or constant regions from Ig heavy chains, e.g., CH1, hinge, CH2, or CH3). Such a heterodimer can also be "dimerized" or "multimerized" by the use of additional fusion domains, such as leucine zipper domains or immunoglobulin domains (see Figure 10).

#### BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1. Schematic structure of the recombinant single chain I-AS.MBP. $\beta$ 1 $\alpha$ 1 (monomer) and I-AS.MBP. $\beta$ 1 $\beta$ 2 $\alpha$ 1 $\alpha$ 2.CK (dimer) proteins.

Figure 2. *In vitro* biological activities of the recombinant I-AS proteins compared with APC+ antigenic peptide in the mouse T cell clone, HS-1.

A. I-AS.MBP. $\beta$ 1 $\alpha$ 1, monomer, B. I-AS.MBP.Ck, dimer, and C. APC+ antigenic

peptide. The positive (anti-CD3) and the negative (HS-1 cell alone) controls are also shown in each panel.

Figure 3. Diagram of the EAE model and standard for EAE scoring.

Figure 4. The EAE model studies. The recombinant I-AS proteins were administered to SJL mice on day 1, 4, 7, and II by i.v. injection after inducing the disease with myelin emulsified in CFA. The animals were evaluated for neurological dysfunction. Panel A: Untreated, injected with same amount of PBS solution. Panel B. Treated with the recombinant I-AS.MBP.Ck protein, a dimer form. Panel C: Treated with the recombinant I-AS. $\beta$ 1 $\alpha$ 1. This recombinant molecule does not carry the antigenic peptide. Panel D: Treated with the recombinant I-AS.MBP. $\beta$ 1 $\alpha$ 1, a monomer form.

Figure 5 shows a schematic representation of a  $\beta$ 1- $\alpha$ 1 single chain MHC class II peptide complex that is a dimer with two peptide specificities.

Figure 6 shows a schematic representation of a  $\beta$ 1 $\beta$ 2- $\alpha$ 1 $\alpha$ 2 single chain MHC class II peptide complex that is a dimer with two peptide specificities.

Figure 7 shows a schematic representation of a  $\beta$ 1 $\beta$ 2- $\alpha$ 1 $\alpha$ 2 single chain MHC class II peptide complex that is a tetramer with four peptide specificities.

Figure 8 shows a schematic representation of a  $\beta$ 1 $\beta$ 2- $\alpha$ 1 $\alpha$ 2 single chain MHC class II peptide complex that is a tetramer with two peptide specificities and two different MHC class II alleles.

Figure 9 shows the effect of different recombinant MHC class II molecules on the development of EAD (day 60+).

Figure 10. Diagram of  $\beta$ 1- $\alpha$ 1 single chain MHC class II peptide complex; diagram of recombinant  $\beta$ 1 $\beta$ 2 chains fused to recombinant  $\alpha$ 1 $\alpha$ 2 chains via a fusion domain from an immunoglobulin; and diagram of multimerized MHC class II molecules.

Figure 11. Sequence comparison of mouse CO608 single chain molecules.

Figure 12. Sequence comparison of mouse CO561 single chain molecules.

## DETAILED DESCRIPTION OF THE INVENTION

### Introduction

The present invention provides recombinant DNA constructs that encode single chain MHC class II molecules that may or may not be further linked to an antigenic peptide. Typically, the constructs comprise a first DNA segment encoding a  $\beta$ 1 domain

of a selected MHC class II molecule; a second DNA segment encoding a  $\alpha 1$  domain of the selected MHC class II molecule; and a first linker DNA segment connecting in-frame the first and second DNA segments; wherein linkage of the first DNA segment to the second DNA segment by the first linker DNA segment results in a fused first DNA-first linker-second DNA polysegment. The constructs of the invention may also comprise a third DNA segment encoding an antigenic peptide capable of associating with a peptide binding groove of the selected MHC class II molecule and a second linker DNA segment connecting in-frame the third DNA segment to the fused first DNA-first linker-second DNA polysegment.

In another embodiment, the present invention also provides recombinant components of an MHC class II heterodimer, which comprise a fusion domain. One recombinant component comprises a  $\beta 1$  domain, or optionally a  $\beta 1$  domain- $\beta 2$  domain (i.e., a  $\beta$  chain). One recombinant component comprises an  $\alpha 1$  domain, or optionally an  $\alpha 1$  domain-  $\alpha 2$  domain (i.e., an  $\alpha$  chain). The two recombinant chains are linked, either covalently, e.g., via a disulfide bond, or non covalently, using the fusion domain. Such molecules can also be made into multimers using additional fusion or multimerization domains. In one embodiment, the invention provides the following recombinant components of an MHC class II heterodimer: pCB220, which is an IAS.MBP.alpha chain fused to an IgG2a CH1 and truncated hinge region; pCB223, which is an IAS.MBP.alpha chain fused to an IgG2a CH1.H.CH2.CH3; and pCB229, which is an IAS.MBP.beta chain fused to a mouse C $\kappa$  domain. These recombinant components can be fused via the fusion domain to form a MHC class II heterodimer molecule that is covalently linked via a disulfide bond at the fusion domain.

The present invention provides single chain MHC class II molecules that comprise an additional polypeptide sequence that allows for inter-chain dimerization of the single chain molecules of the invention. The additional polypeptide allows multimerization of the single chain MHC class II molecules, to produce, e.g., dimers and tetramers. The sequence can be any sequence that allows for covalent or non-covalent linkages between the molecules of the invention. In one embodiment, the single chain molecules are covalently linked using chemical methods known to those of skill in the art, e.g., photoaffinity methods or homo-bifunctional protein cross-linkers (see, e.g., Hermanson *et al.*, *Bioconjugate Techniques*, (1996)). In one embodiment, the molecules

are covalently linked using heterobifunctional protein cross-linkers. As shown below, one means for carrying this out is through use of segments from immunoglobulin family proteins (e.g., antibodies, MHC molecules, T cell receptors and the like) that have cysteine residues capable of forming interchain disulfide bonds. An example shown 5 below is the use of the constant region of the kappa chain of an antibody (C<sub>k</sub>), from either a heavy or a light chain. Other dimerization sequences include a leucine zipper, a STAT protein N-terminal domain, or the FK506 binding protein (see, e.g., O'Shea, *Science* 254: 539 (1991), Barahmand-Pour *et al.*, *Curr. Top. Microbiol. Immunol.* 211:121-128 (1996); Klemm *et al.*, *Annu. Rev. Immunol.* 16:569-592 (1998); Ho *et al.*, *Nature* 382:822-826 10 (1996)). One of skill will recognize that any of a number of polypeptide sequences can be used for this purpose.

In addition, the multimeric, single chain class II molecules of the invention comprise at least two different MHC class II alleles that are associated with an autoimmune disease state, and/or at least two different autoantigenic peptides that are 15 associated with a particular autoimmune disease state. In one example, the multimeric, single chain class II molecules have chains from different DR2 alleles, e.g., DRB5\*0101 and DRB1\*1501. In another embodiment, the autoantigenic peptides are peptides associated with multiple sclerosis, e.g., MBP (e.g., amino acid residues 83-102Y83), PLP (e.g., amino acid residues 40-60, 89-106, 95-117, and 185-206); and MOG. In addition, 20 other antigens associated with autoimmune disease, such as acetylcholine receptor and type II collagen, can be linked to the single chain molecules of the invention..

In a further embodiment, the single chain class II molecules of the invention have novel linkers, as described herein. The mammalian MHC class II single chain constructs of the invention may also be constructed to use preferred prokaryotic codons, for expression, e.g., in *E. coli*, using codon preference tables and methods known 25 to those of skill in the art.

### Definitions

Prior to setting forth the invention, it may be helpful to an understanding 30 thereof to provide definitions of certain terms to be used hereinafter:

Single chain MHC class II molecule: As used herein this term refers to a fusion protein such as the recombinant single chain MHC class II complex of the

invention, which optionally also is fused to a peptide to form a single chain MHC class:peptide complex. The fusion proteins of the invention can also be multimers, having two, four or more single chain molecules linked covalently or non-covalently through multimerization domains in the single chain molecule. A single chain molecule 5 of the invention typically comprises at least an MHC class II  $\beta$ 1 domain and an MHC class II  $\alpha$ 1 domain, optionally  $\beta$ 1  $\beta$ 2  $\alpha$ 1  $\alpha$ 2 domains or any combination thereof in any order. Such molecules are also known as "fused heterodimers." Optionally, the single chain molecules are soluble, that is, they lack the naturally occurring cytoplasmic and transmembrane MHC class II domains.

10           A domain of a selected MHC molecule: A portion of an MHC domain which is sufficient to form, either alone, or in combination with another portion of an MHC domain, a peptide binding site which is capable of presenting an antigenic peptide in such a fashion that it is recognized by a T cell receptor. Such MHC domains would include the extracellular portion of the two polypeptide chains of Class II MHC. This 15 would include the  $\alpha$  chain ( $\alpha$ 1 and  $\alpha$ 2 domains) and  $\beta$  chain ( $\beta$ 1 and  $\beta$ 2 domains) of Class II MHC. This would include  $\beta$ 1 and  $\alpha$ 1,  $\beta$ 1,  $\beta$ 2 and  $\alpha$ 1,  $\alpha$ 2,  $\alpha$ 1 or  $\alpha$ 2 independent of the other, or  $\alpha$ 1 and  $\alpha$ 2 in tandem ( $\alpha$ 1 $\alpha$ 2). It would also include  $\beta$ 1 or  $\beta$ 2 independent of the other, or  $\beta$ 1 and  $\beta$ 2 in tandem ( $\beta$ 1 $\beta$ 2). This would also include any suitable combination 20 of the  $\alpha$ 1,  $\alpha$ 2,  $\beta$ 1, and  $\beta$ 2 domains. The domains can be directly linked, or can be linked via an amino acid linker.

Linker DNA segment: A segment of DNA encoding from about 1 to about 50, preferably from about 5 to about 25 amino acids, which forms a flexible link between two DNA segments. This flexible link allows the two DNA segments to attain a proper configuration, such as an MHC peptide binding groove, or allows a peptide to properly 25 bind into such a groove.

Antigenic peptide: The immunological properties of MHC histocompatibility proteins are largely defined by the antigenic peptide that is bound to them. An antigenic peptide is one which contains an epitope (an amino acid sequence) recognized by immune cells, e.g., T cells, and is capable of stimulating an MHC-mediated 30 immune response.. Antigenic peptides for a number of autoimmune diseases are known. For example, in experimentally induced autoimmune diseases, antigens involved in pathogenesis have been characterized: in arthritis in rat and mouse, native type II collagen

is identified in collagen-induced arthritis, and mycobacterial heat shock protein in adjuvant arthritis (Stuart *et al.*, *Ann. Rev. Immunol.* 2:199-218, 1984; and van Eden *et al.*, *Nature* 331:171-173, 1988); thyroglobulin has been identified in experimental allergic thyroiditis (EAT) in mice (Marion *et al.*, *J. Exp. Med.* 152:1115-1120, 1988); acetyl-choline receptor (AChR) in experimental allergic myasthenia gravis (EAMG) (Lindstrom *et al.*, *Adv. Immunol.* 42:233-284, 1988); and myelin basic protein (MBP) and proteolipid protein (PLP) in experimental allergic encephalomyelitis (EAE) in mouse and rat (Acha-Orbea *et al.*, *Ann. Rev. Imm.* 7:377-405, 1989). In addition, target antigens have been identified in humans: type II collagen in human rheumatoid arthritis (Holoshitz *et al.*, *Lancet* ii:305-309, 1986), acetylcholine receptor in myasthenia gravis (Lindstrom *et al.*, *Adv. Immunol.* 42.:233-284, 1988), and MBP, PLP, and MOG in multiple sclerosis in humans.

**MHC:** The major histocompatibility complex (MHC) is a family of highly polymorphic proteins, divided into two classes, Class I and Class II, which are membrane-associated and present antigen to T lymphocytes (T cells). MHC Class I and Class II molecules are distinguished by the types of cells on which they are expressed, and by the subsets of T cells which recognize them. Class I MHC molecules (e.g., HLA-A, -B and -C molecules in the human system) are expressed on almost all nucleated cells and are recognized by cytotoxic T lymphocytes (CTL), which then destroy the antigen-bearing cells. Class II MHC molecules (HLA-DP, -DQ and -DR, for example, in humans) are expressed primarily on the surface of antigen-presenting cells, such as B lymphocytes, dendritic cells, macrophages, and the like. Class II MHC is recognized by CD4<sup>+</sup> T helper lymphocytes (T<sub>H</sub>). T<sub>H</sub> cells induce proliferation of both B and T lymphocytes, thus amplifying the immune response to the particular antigenic peptide that is displayed (Takahashi, *Microbiol. Immunol.*, 37:1-9, 1993).

Two distinct antigen processing pathways are associated with the two MHC classes. Intracellular antigens, synthesized inside of the cell, such as from viral or newly synthesized cellular proteins, for example, are processed and presented by Class I MHC. Exogenous antigens, taken up by the antigen-presenting cell (APC) from outside of the cell through endocytosis, are processed and presented by Class II MHC. After the antigenic material is proteolytically processed by the MHC-bearing cell, the resulting antigenic peptide forms a complex with the antigen binding groove of the MHC molecule

through various noncovalent associations. The MHC-peptide complex on the cell surface is recognized by a specific T cell receptor on a cytotoxic or helper T cell.

The MHC of humans (also referred to as human leukocyte antigens (HLA)) on chromosome 6 has three loci, HLA-A, HLA-B and HLA-C, the first two of which have a large number of alleles encoding alloantigens. An adjacent region, known as **HLA-D**, is subdivided into **HLA-DR**, **HLA-DQ** and **HLA-DP**. The **HLA** region is now known as the human MHC region, and is equivalent to the H-2 region in mice. HLA-A, -B and -C resemble mouse H-2K, -D, and -L and are the Class I MHC molecules. HLA-DP, -DQ and -DR resemble mouse I-A and I-E and are the Class II molecules. MHC glycoproteins of both classes have been isolated and characterized (*see Fundamental Immunology*, 2d Ed., Paul (ed.), (1989); and Roitt *et al.*, *Immunology*, 2d Ed., (1989) , which are both incorporated herein by reference).

Human MHC Class I molecules consist of a polymorphic type I integral membrane glycoprotein heavy chain of about 46 kD, noncovalently associated with a 12 kD soluble subunit,  $\beta_2$ -microglobulin. The heavy chain consists of two distinct extracellular regions, the membrane distal, peptide binding region formed by the  $\alpha_1$  and  $\alpha_2$  domains, and the membrane proximal, CD8-binding region derived from the  $\alpha_3$  domain.  $\beta_2$ - microglobulin is a single, compact immunoglobulin-like domain that lacks a membrane anchor, and exists either associated with the class I heavy chain or free in plasma (Germain and Margulies, *Annu. Rev. Immunol.* 11:403-50, 1993).

Human MHC Class II is a heterodimeric integral membrane protein. Each dimer consists of one  $\alpha$  and one  $\beta$  chain in noncovalent association. The two chains are similar to each other, with the  $\alpha$  chain having a molecular weight of 32-34 kD and the  $\beta$  chain having a molecular weight of 29-32 kD. Both polypeptide chains contain N-linked oligosaccharide groups and have extracellular amino termini and intracellular carboxy termini.

The extracellular portions of the  $\alpha$  and  $\beta$  chain that comprise the class II molecule have been subdivided into two domains of about 90 amino acids each, called  $\alpha_1$ ,  $\alpha_2$ , and  $\beta_1$ ,  $\beta_2$ , respectively. The  $\alpha_2$  and  $\beta_2$  domains each contain a disulfide-linked loop. The peptide-binding region of the class II molecule is formed by the interaction of the  $\alpha_1$  and  $\beta_1$  domains. This interaction results in an open-ended, antigenic peptide-binding groove made up of two  $\alpha$  helices, and an eight-stranded  $\beta$ -pleated sheet platform.

10

The  $\alpha$  and  $\beta$  chains of Class II molecules are encoded by different MHC genes and are polymorphic (see Addas *et al.*, *Cellular and Molecular Immunology*, 2d Ed. (1994), which is incorporated by reference in its entirety). Within the present invention, a preferred  $\alpha$  chain is DRA\*0101 and a preferred  $\beta$  chain is DR $\beta$ 1\*1501.

5

### MHC Class II alleles

The single chain MHC class II:peptide complexes of the present invention can incorporate cDNA from any allele that predisposes or increases the likelihood of susceptibility to a specific autoimmune disease. Specific autoimmune diseases are correlated with specific MHC types. Specific haplotypes have been associated with many of the autoimmune diseases. For example, HLA-DR2 $^+$  and HLA-DR3 $^+$  individuals are at a higher risk than the general population to develop systemic lupus erythematosus (SLE) (Reinertsen *et al.*, *N. Engl. J. Med.* 299:515-18, 1970). Myasthenia gravis has been linked to HLA-D (Safwenberg *et al.*, *Tissue Antigens* 12:136-42, 1978. Susceptibility to rheumatoid arthritis is associated with HLA-D/DR in humans. Methods for identifying which alleles, and subsequently which MHC-encoded polypeptides, are associated with an autoimmune disease are known in the art. Exemplary alleles for IDDM include DR4, DQ8, DR3, DQ3.2.

20     **Uses of single chain MHC class II molecules**

Single chain MHC class II molecules and/or single chain MHC class II:peptide complexes of the present invention can be used as antagonists to therapeutically block the binding of particular T cells and antigen-presenting cells. In addition, the molecules can induce anergy, or proliferative nonresponsiveness, and possibly apoptosis, in targeted T cells, both *in vivo* and *in vitro*. A single chain MHC class II:peptide molecule directed toward a desired autoimmune disease contains the antigenic peptide implicated for that autoimmune disease properly positioned in the binding groove of the MHC molecule, without need for solubilization of MHC or exogenous loading of an independently manufactured peptide.

30     Previous methods for producing desirable MHC Class II histocompatibility proteins have provided material that contains a mixture of antigenic peptides (Buus *et al.*, *Science* 242:1045-1047, 1988; and Rudensky *et al.*, *Nature* 353:622-627, 1991), which

can be only partially loaded with a defined antigenic peptide (Watts and McConnel, *Pro. Natl. Acad. Sci. USA* 83:9660-64, 1986; and Cappellini *et al.*, *Nature* 339:392-94, 1989). Various methods have been developed to produce heterodimers that do not present endogenous antigens (Stern and Wiley, *Cell* 68:465-77, 1992; Ljunggren *et al.*, *Nature* 346:476-80, 1990; and Schumacher *et al.*, *Cell* 62:563-67, 1990) that can be loaded with a peptide of choice. WO 95/23814 and Kozono *et al.* have described production of soluble murine Class II molecules, I-E<sup>dk</sup> and I-A<sup>d</sup>, each with a peptide attached by a linker to the N terminus of the  $\beta$  chain. Ignatowicz *et al.* (*J. Immunol.* 154:38-62, 1995) have expressed membrane-bound I-A<sup>d</sup> with peptide attached. These methods incorporate the use of both membrane-bound heterodimer and soluble heterodimer.

The current invention offers the advantage of a recombinant single chain MHC class II molecule made up of two or more MHC domains joined together via a flexible linkage, and onto which is tethered (via an additional flexible linkage) an antigenic peptide which is able to bind to the peptide binding groove presented by the single chain MHC class II molecule. Such a complex provides an MHC molecule which is soluble and, because the MHC class II components and corresponding antigenic peptide are permanently linked into a single chain configuration, there is no need for complex heterodimer truncation or formation. These complexes eliminate inefficient and nonspecific peptide loading. Producing the claimed MHC:peptide complexes by recombinant methodology results in specific, high yield protein production, where the final product contains only the properly configured MHC:peptide complex of choice.

As used herein, a soluble MHC class II molecules is one that does not contain the naturally occurring membrane-associated MHC class II sequences. The soluble MHC molecules of the present invention has never been membrane-associated. Further, the soluble MHC class II molecules do not contain an amino acid sequence that acts as a transmembrane domain or as a cytoplasmic domain.

The present invention therefore provides a single chain MHC class II molecule which optionally includes an antigenic peptide covalently attached to the amino terminal portion of an  $\alpha$  or  $\beta$  chain of MHC through a peptide linkage, and the C terminal of the linked  $\alpha$  or  $\beta$  chain may be attached to the N terminal portion of another  $\alpha$  or  $\beta$  chain, thereby creating a two, three, or four domain MHC molecule. The invention further provides a multimerization domain to provide a multimeric single chain MHC

## 12

class II molecules. The invention further provides novel linkers, and multimeric MHC class II molecules that are bound to different antigenic peptides.

The amino acid sequence of each of a number of Class I and Class II proteins are known, and the genes or cDNAs have been cloned. Thus, these nucleic acids 5 can be used to express MHC polypeptides. If a desired MHC gene or cDNA is not available, cloning methods known to those skilled in the art may be used to isolate the genes. One such method that can be used is to purify the desired MHC polypeptide, obtain a partial amino acid sequence, synthesize a nucleotide probe based on the amino acid sequence, and use the probe to identify clones that harbor the desired gene from a 10 cDNA or genomic library.

### Linkers

Linkers of the current invention may be from about 1 to about 50 amino acids in length, depending on the molecular model of the MHC or MHC:peptide complex.

15 In one embodiment, flexible linkers are made of repeating Gly residues separated by one or more Ser residues to permit a random, flexible motion. In the case of Class II MHC complexes this flexibility accommodates positioning of the  $\alpha$  and  $\beta$  segments to properly configure the binding groove, and also allows for maximum positioning of the peptide in the groove. In another embodiment, the linker comprises a CD4 binding site, as 20 described below in the Example section (see also Table 1). In another embodiment, longer linkers between the chains contain flexible residues (e.g. alanine or glycine) and polar residues (e.g. serine and threonine). To inhibit the continuation of secondary structure across the linker, prolines can be added to bracket the linkers. These prolines are known to inhibit the formation of alpha helices and beta sheets. In another 25 embodiment, flexible regions present in the human MHC and in the murine MHC could be used to make a linker by extending the region of interest and ligating the ends together. Finally, a combination of these types of linkers could also be used.

Linker position and length can be modeled based on the crystal structure of MHC Class II molecules (Brown *et al.*, *Nature* 364:33-39, 1993), where  $\alpha 1$  and  $\beta 1$  are 30 assembled to form the peptide binding groove. Linkers joining segments of the  $\alpha$  and  $\beta$  chains together are based on the geometry of the region in the hypothetical binding site and the distance between the C terminus and the N terminus of the relevant segments.

Molecular modeling based on the X-ray crystal structure of Class II MHC (Stern *et al.*, *Nature* 368:215-221, 1994) dictates the length of linkers joining antigenic peptide,  $\alpha$  chain segments and  $\beta$  chain segments. The recombinant portions of the molecules of the invention can also be directly linked, without additional amino acids linkers.

5

#### **Identification of autoantigens**

The invention also provides methods for preparing responder T-cell clones that proliferate when combined with a selected antigenic peptide presented by a stimulator cell. Such clones can be used to identify and map antigenic peptides associated with autoimmune disease. These peptides can then be incorporated into the single chain MHC class II molecule:peptide complexes of the invention. The method provides isolation and enrichment of non-adherent, CD56<sup>-</sup>, CD8<sup>-</sup> T cells that are reactive with a selected antigenic peptide. These cells are herein referred to as responder cells.

10     Suitable responder cells can be isolated, for example, from peripheral blood mononuclear cells (PBMNC) obtained from patients prior to or after onset of an autoimmune disease of interest. For example, PBMNCs can be obtained from prediabetic and new onset diabetic patients. These patients can be pre-screened for specific HLA markers, such as DR3-DR4 or DQ3.2, which have the highest association with susceptibility to IDDM. From 15     the collected PBMNCs, a portion is kept to serve as stimulator cells. From the remainder, the desired autoreactive responder cells are purified and isolated by two rounds of plating, to remove adherent cells from the population, followed by removal of monocytes and B cells with nylon wool. Enrichment for non-adherent CD4<sup>+</sup> T cells is completed by sequential plating of the cells onto plates coated with anti-CD8 and anti-CD6 antibodies.

25

The stimulator cells are pulsed or primed with whole GAD or an appropriate antigenic peptide. For example, stimulator cells from the PBMNCs of IDDM patients can be stimulated with antigenic GAD peptides then combined with PBMNCs or responder cells. After seven or 14 days, responder cell (T cell) clones are generated through limiting dilution and tested for antigen reactivity.

30

These responder cell (T cell) clones can then be used, for example, to map epitopes which bind to MHC and are recognized by a particular T cell. One such method uses overlapping peptide fragments of the autoantigen which are generated by tryptic

digestion, or more preferably, overlapping peptides are synthesized using known peptide synthesis techniques. The peptide fragments are then tested for their ability to stimulate the responder T cell clones or lines (for example, Ota *et al.*, *Nature* 346:183-187, 1990).

Once such a peptide fragment has been identified, synthetic antigenic peptides can be specifically designed, for example, to enhance the binding affinity for MHC and to out-compete any naturally processed peptides. Such synthetic peptides, when combined into a single chain MHC class II molecule:peptide complex, would allow manipulation of the immune system *in vivo*, in order to tolerize or anergize disease-associated activated T cells, thereby ameliorating the autoimmune disease.

Dissecting the functional role of individual peptides and peptide clusters in the interaction of a peptide ligand with an MHC molecule, and also in subsequent T cell recognition and reactivity, is a difficult undertaking due to the degeneracy of peptide binding to the MHC. Changes in T cell recognition or in the ability of an altered peptide to associate with MHC can be used to establish that a particular amino acid or group of amino acids comprises part of an MHC or T cell determinant. The interactions of altered peptides can be further assessed by competition with the parental peptide for presentation to a T cell, or through development of direct peptide-MHC binding assays. Changes to a peptide that do not involve MHC binding could well affect T cell recognition. For example, in a peptide, specific MHC contact points might only occur within a central core of a few consecutive or individual amino acids, whereas those amino acids involved in T cell recognition may include a completely different subset of residues.

In a preferred method, residues that alter T cell recognition are determined by substituting amino acids for each position in the peptide in question, and by assessing whether such change in residues alters the peptide's ability to associate with MHC (Allen *et al.*, *Nature* 327:713-15, 1987; Sette *et al.*, *Nature* 328:395-99, 1987; O'Sullivan *et al.*, *J. Immunol.* 147:2663-69, 1991; Evavold *et al.*, *J. Immunol.* 148:347-53, 1992; Jorgensen *et al.*, *Annu. Rev. Immunol.* 10:835-73, 1992; Hammer *et al.*, *Cell* 74:197-203, 1993; Evavold *et al.*, *Immunol. Today* 14:602-9, 1993; Hammer *et al.*, *Proc. Natl. Acad. Sci. USA* 91:4456-60, 1994; and Reich *et al.*, *J. Immunol.* 154:2279-88, 1994). One method would involve generating a panel of altered peptides wherein individual or groups of amino acid residues are substituted with conservative, semi-conservative or non-conservative residues. A preferred variant of this method is an alanine scan (Ala scan)

where a series of synthetic peptides are synthesized wherein each individual amino acid is substituted with L-alanine (L-Ala scan). Alanine is the amino acid of choice because it is found in all positions (buried and exposed), in secondary structure, it does not impose steric hindrances, or add additional hydrogen bonds or hydrophobic side chains. Alanine substitutions can be done independently or in clusters depending on the information desired. Where the information pertains to specific residues involved in binding, each residue in the peptide under investigation can be converted to alanine and the binding affinity compared to the unsubstituted peptide. Additional structural and conformational information regarding each residue and the peptide as a whole can be gained, for example, by synthesizing a series of analogs wherein each residue is substituted with a D-amino acid such as D-alanine (D-Ala scan) (Galantino *et al.*, in Smith, J. and Rivier, J. (eds.), *Peptides Chemistry and Biology (Proceedings of the Twelfth American Peptide Symposium)*, ESCOM, Leiden, 1992, pp. 404-05). Essential residues can be identified, and nonessential residues targeted for modification, deletion or replacement by other residues that may enhance a desired quality (Cunningham and Wells, *Science* 244:1081-1085, 1989; Cunningham and Wells, *Natl. Acad. Sci. USA*, 88:3407-3411, 1991; Ehrlich *et al.*, *J. Biol. Chem.* 267:11606-11, 1992; Zhang *et al.*, *Proc. Natl. Acad. Sci. USA* 90:4446-50, 1993; see also "Molecular Design and Modeling: Concepts and Applications Part A Proteins, Peptides, and Enzymes," *Methods in Enzymology*, Vol. 202, Langone (ed.), Academic Press, San Diego, CA, 1991).

Truncated peptides can be generated from the altered or unaltered peptides by synthesizing peptides wherein amino acid residues are truncated from the N- or C-terminus to determine the shortest active peptide, or between the N- and C-terminus to determine the shortest active sequence. Such peptides could be specifically developed to stimulate a response when joined to a particular MHC to form a peptide ligand to induce anergy in appropriate T cells *in vivo* or *in vitro*.

#### Analysis of single chain MHC class II molecule:peptide complexes

The physical and biological properties of the single chain MHC class II molecule:peptide complexes may be assessed in a number of ways. Mass spectral analysis methods such as electrospray and Matrix-Assisted Laser Desorption/Ionization Time Of Flight mass spectrometry (MALDI TOF) analysis are routinely used in the art to

provide such information as molecular weight and confirm disulfide bond formation. FACS analysis can be used to determine proper folding of the single chain complex.

An ELISA (Enzyme-linked Immunosorbent Assay) can be used to measure concentration and confirm correct folding of the single chain MHC class II molecule:peptide complexes. This assay can be used with either whole cells; solubilized MHC, removed from the cell surface; or free single chain MHC class II molecule:peptide complexes of the current invention. In an exemplary ELISA, an antibody that detects the recombinant MHC haplotype is coated onto wells of a microtiter plate. In a preferred embodiment, the antibody is L243, a monoclonal antibody that recognizes only correctly folded HLA-DR MHC dimers. One of skill in the art will recognize that other MHC Class II-specific antibodies are known and available. Alternatively, there are numerous routine techniques and methodologies in the field for producing antibodies (for example, Hurrell, (ed.), *Monoclonal Hybridoma Antibodies: Techniques and Applications*, CRC Press Inc., Boca Raton, FL, 1982), if an appropriate antibody for a particular haplotype does not exist. Anti-MHC Class II antibodies can also be used to purify Class II molecules through techniques such as affinity chromatography, or as a marker reagent to detect the presence of Class II molecules on cells or in solution. Such antibodies are also useful for Western analysis or immunoblotting, particularly of purified cell-secreted material. Polyclonal, affinity purified polyclonal, monoclonal and single chain antibodies are suitable for use in this regard. In addition, proteolytic and recombinant fragments and epitope binding domains can be used herein. Chimeric, humanized, veneered, CDR-replaced, reshaped or other recombinant whole or partial antibodies are also suitable.

In the ELISA format, bound MHC molecules can be detected using an antibody or other binding moiety capable of binding MHC molecules. This binding moiety or antibody may be tagged with a detectable label, or may be detected using a detectably labeled secondary antibody or binding reagent. Detectable labels or tags are known in the art, and include fluorescent, colorimetric and radiolabels, for instance.

Other assay strategies can incorporate specific T-cell receptors to screen for their corresponding MHC-peptide complexes, which can be done either *in vitro* or *in vivo*. For example, an *in vitro* anergy assay determines if non-responsiveness has been induced in the T cells being tested. Briefly, an MHC molecule containing antigenic peptide in the peptide binding groove can be mixed with responder cells, preferably

5 peripheral blood mononuclear cells (PBMN) (a heterogeneous population including B and T lymphocytes, monocytes and dendritic cells), PBMNC lymphocytes, freshly isolated T lymphocytes, *in vivo* primed splenocytes, cultured T cells, or established T cell lines or clones. Responder cells from mammals immunized with, or having a demonstrable cellular immune response to, the antigenic peptide are particularly preferred.

Subsequently, these responder cells are combined with stimulator cells (antigen presenting cells; APCs) that have been pulsed or primed with the same antigenic peptide. In a preferred embodiment, the stimulator cells are antigenic peptide-presenting cells, such as PBMNCs, PBMNCs that have been depleted of lymphocytes, appropriate 10 antigenic peptide-presenting cell lines or clones (such as EBV-transformed B cells), EBV transformed autologous and non-autologous PMNCs, genetically engineered antigen presenting cells, such as mouse L cells or bare lymphocyte cells BLS-1, in particular, DRB1\*0401, DRB1\*0404 and DRB1\*0301 (Kovats *et al.*, *J. Exp. Med.* 179:2017-22, 1994), or *in vivo* or *in vitro* primed or pulsed splenocytes. Stimulator cells from 15 mammals immunized with, or having a demonstrable cellular immune response to, the antigenic peptide are particularly preferred. For certain assay formats, it is preferred to inhibit the proliferation of stimulator cells prior to mixing with responder cells. This inhibition may be achieved by exposure to gamma irradiation or to an anti-mitotic agent, such as mitomycin C, for instance. Appropriate negative controls are also included 20 (nothing; syngeneic APC; experimental peptide; APC + Peptide; MHC:peptide complex; control peptide +/- APC). Further, to assure that non-responsiveness represents anergy, the proliferation assay may be set up in duplicate, +/- recombinant IL-2 since it has been demonstrated that IL-2, can rescue anergized cells.

After an approximately 72 hour incubation, the activation of responder 25 cells in response to the stimulator cells is measured. In a preferred embodiment, responder cell activation is determined by measuring proliferation using  $^3\text{H}$ -thymidine uptake (Crowley *et al.*, *J. Immunol. Meth.* 133:55-66, 1990). Alternatively, responder cell activation can be measured by the production of cytokines, such as IL-2, or by determining the presence of responder cell-specific, and particularly T cell-specific, 30 activation markers. Cytokine production can be assayed by testing the ability of the stimulator + responder cell culture supernatant to stimulate growth of cytokine-dependent

cells. Responder cell- or T cell-specific activation markers may be detected using antibodies specific for such markers.

Preferably, the single chain MHC class II molecule:peptide complex induces non-responsiveness (for example, anergy) in the antigenic peptide-reactive responder cells. In addition to single chain MHC class II molecule:peptide complex recognition, responder cell activation requires the involvement of co-receptors on the stimulator cell (the APC) that have been stimulated with co-stimulatory molecules. By blocking or eliminating stimulation of such co-receptors (for instance, by exposing responder cells to purified single chain MHC class II molecule:peptide complex, by 10 blocking with anti-receptor or anti-ligand antibodies, or by "knocking out" the gene(s) encoding such receptors), responder cells can be rendered non-responsive to antigen or to single chain MHC class II molecule:peptide complex.

In a preferred embodiment, responder cells are obtained from a source manifesting an autoimmune disease or syndrome. Alternatively, autoantigen-reactive T 15 cell clones or lines are preferred responder cells. In another preferred embodiment, stimulator cells are obtained from a source manifesting an autoimmune disease or syndrome. Alternatively, APC cell lines or clones that are able to appropriately process and/or present autoantigen to responder cells are preferred stimulator cells. In a particularly preferred embodiment, responder and stimulator cells are obtained from a 20 source with diabetes or multiple sclerosis.

At this point, the responder T cells can be selectively amplified and/or stimulated, thereby producing a subset of T cells that are specific for the antigenic peptide. For instance, antigenic peptide-reactive responder cells may be selected by flow cytometry, and particularly by fluorescence activated cell sorting. This subset of 25 responder cells can be maintained by repetitive stimulation with APCs presenting the same antigenic peptide. Alternatively, responder cell clones or lines can be established from this responder cell subset. Further, this subset of responder cells can be used to map epitopes of the antigenic peptide and the protein from which it is derived.

Other methods to assess the biological activity of the single chain MHC 30 class II molecule:peptide complexes are known in the art and can be used herein, such as using a microphysiometer, to measure production of acidic metabolites in T cells following interaction with antigenic peptide. Other assay methods include competition

assays, comparing single chain MHC class II molecule:complex response with that to the normal antigen. Also measurement production of such indicators as cytokines or  $\gamma$  interferon can provide an indication of complex response.

5   **Animal models of autoimmune disease**

Similar assays and methods can be developed for and used in animal models. For instance, the therapeutic effect of a pharmaceutical composition of the single chain molecule or multimer or a polynucleotide encoding the single chain molecule or multimer can be tested *in vivo* in a number of animal models of HLA-DR-associated 10 autoimmune disease. These diseases include, but are not limited to, insulin-dependent diabetes mellitus, multiple sclerosis, myasthenia gravis, pernicious anemia, rheumatoid arthritis, and systemic lupus erythematosus.

For example, NOD mice are a spontaneous model of IDDM. Treatment with the pharmaceutical compositions prior to or after onset of disease can be monitored 15 by assay of urine glucose levels in the NOD mouse, as well as by *in vitro* T cell proliferation assays to assess reactivity to known autoantigens (*see, e.g., Kaufman et al., Nature* 366:69-72 (1993)) for example). Alternatively, induced models of autoimmune disease, such as EAE, can be treated with pharmaceutical composition. Treatment in a preventive or intervention mode can be followed by monitoring the clinical symptoms of 20 EAE.

Following is a description of several other animal models of HLA-DR-associated autoimmune disease which can be used to assay *in vivo* effects of the peptide. It will be obvious to one of skill in the art that other suitable animal models for autoimmune diseases can be utilized in a similar manner.

25

Systemic Lupus Erythematosus (SLE)

*F<sub>1</sub>* hybrids of autoimmune New Zealand black (NZB) mice and the phenotypically normal New Zealand White (NZW) mouse strain develop severe systemic autoimmune disease, more fulminant than that found in the parental NZB strain. These 30 mice manifest several immune abnormalities, including antibodies to nuclear antigens and subsequent development of a fatal, immune complex-mediated glomerulonephritis with

20

female predominance, remarkably similar to SLE in humans (Knight *et al.*, *J. Exp. Med.* 147:1653 (1978)), which is incorporated hereby by reference.

In both the human and murine forms of the disease, a strong association with MHC gene products has been reported. HLA-DR2 and HLA-DR3 individuals are at 5 a higher risk than the general population to develop SLE (Reinertsen *et al.*, *N. Engl. J. Med.* 299:515 (1970)), while in NZB/W F<sub>1</sub> mice (H-2<sup>d/u</sup>), a gene linked to the h-2<sup>u</sup> haplotype derived from the NZW parent contributes to the development of the lupus-like nephritis.

The effect of the invention can be measured by survival rates and by the 10 progress of development of the symptoms, such as proteinuria and appearance of anti-DNA antibodies.

Proteinuria can be measured by any method known to those of skill in the art, e.g. colorimetrically by the use of Uristix (Miles Laboratories, Inc., Elkhart, IN), giving an approximation of proteinuria as follows: trace, 10 mg/dl; 1+, 30 mg/dl; 100 mg/dl; 3+, 300 mg/dl; and 4+, 1000 mg/dl.

The presence of anti-DNA specific antibodies in NZB/W F<sub>1</sub> mice can be determined by using a modification of a linked immunosorbent assay (ELISA) described by Zouali *et al.*, *J. Immunol. Methods* 90:105 (1986) which is incorporated herein by reference.

20

#### Myasthenia Gravis (MG)

Myasthenia gravis is one of several human autoimmune diseases linked to HLA-D (Safenberg, *et al.*, *Tissue Antigens* 12:136 (1978); McDevitt *et al.*, *Arth. Rheum.* 20:59 (1977)) which are incorporated herein by reference. In MG antibodies to the acetyl 25 choline receptors (AcChoR) impair neuromuscular transmission by mediating loss of AcChoR in the postsynaptic membrane.

SJL/J female mice are a model system for human MG. In these animals, experimental autoimmune myasthenia gravis (EAMG) can be induced by immunizing the mice with soluble AcChoR protein from another species. Susceptibility to EAMG is 30 linked in part to the MHC and has been mapped to the region within H-2 (Christadoss *et al.*, *J. Immunol.* 123:2540 (1979)).

AcChoR protein can purified from *Torpedo californica* and assayed according to the method of Waldor *et al.*, *Proc. Natl. Acad. Sci. USA* 80:2713 (1983), incorporated by reference. For example, emulsified AcChoR, 15 µg in complete Freund adjuvant, is injected intradermally among six sites on the back, the hind foot pads, and the 5 base of the tail. Animals are reimmunized with this same regimen 4 weeks later.

Evaluation can be made by measurement of anti-AcChoR antibodies by any method known to those of skill in the art, e.g., a microtiter ELISA assay as described in Waldor *et al.*, *supra*. In an exemplary assay, the standard reagent volume is 50 µl per well. Reagents are usually incubated in the wells for 2 hr at RT. Five µg of AcChoR 10 diluted in bicarbonate buffer, pH 9.6, is added to each well. After incubation with AcChoR, the plates are rinsed four times with a wash solution consisting of phosphate-buffer saline containing 0.05% Tween and 0.05% NaN<sub>3</sub>. Mouse sera are diluted in 0.01M PBS (pH 7.2), 1.5 mM MgCl<sub>2</sub>, 2.0 mM 2-mercaptoethanol, 0.05% Tween-80, 0.05% NaN<sub>3</sub> (p-Tween buffer) and incubated on the plate. After the plate is washed, beta- 15 galactosidase-conjugated sheep anti-mouse antibody diluted in P-Tween buffer is added to each well. After a final washing, the enzyme substrate, p-nitrophenylgalctopyranoside is added to the plate, and the degree of substrate catalysis is determined from the absorbance at 405 nm after 1 hr.

Anti-AcChoR antibodies are expected to be present in the mice immunized 20 with AcChoR as compared to nonimmunized mice. Treatment with complex is expected to significantly reduce the titer of anti-AcChoR antibodies in the immunized mice.

The effect of treatment with the invention on clinical EAMG can also be assessed by any method known to those of skill in the art. Myasthenia symptoms include a characteristic hunched posture with drooping of the head and neck, exaggerated arching 25 of the back, splayed limbs, abnormal walking, and difficulty in righting. Mild symptoms are present after a standard stress test, and should be ameliorated by administration of complex.

#### Rheumatoid Arthritis (RA)

In humans, susceptibility to rheumatoid arthritis is associated with HLA D/DR. The immune response in mice to native type II collagen has been used to establish 30 an experimental model for arthritis with a number of histological and pathological

features resembling human RA. Susceptibility to collagen-induced arthritis (CIA) in mice has been mapped to the H-2 I region, particularly the I-A subregion (Huse *et al.*, *Fed. Proc.* 43:1820 (1984)).

Mice from a susceptible strain, DEA-1 can be caused to have CIA by 5 treatment of the mice with native type II collagen, using the technique described in Wooley *et al.*, *J. Immunol.* 134:2366 (1985), incorporated herein by reference.

In another model adjuvant arthritis in rats is an experimental model for 10 human arthritis, and a prototype of autoimmune arthritis triggered by bacterial antigens (Holoschitz *et al.*, *Prospects of Immunology* (1986); Pearson, *Arthritis Rheum.* 7:80 (1964)). The disease is the result of a cell-mediated immune response, as evidenced by its transmissibility by a clone of T cells which were reactive against the adjuvant (MT); the target self-antigen in the disease, based upon studies with the same cloned cells, appears 15 to be part(s) of a proteoglycan molecule of cartilage.

Adjuvant disease in rats is produced as described by Pearson *supra*, *i.e.*, by 15 a single injection of Freund's adjuvant (killed tubercle bacilli or chemical fractions of it, mineral oil, and an emulsifying agent) given into several depot sites, preferably intracutaneously or into a paw or the base of the tail. The adjuvant is given in the absence of other antigens.

The effect of the invention treatment on manifestations of the disease can 20 be monitored by any method known to those of skill in the art. These manifestations are histopathological, and include an acute and subacute synovitis with proliferation of synovial lining cells, predominantly a mononuclear infiltration of the articular and particular tissues, the invasion of bone and articular cartilage by connective tissue pannus, and periosteal new bone formation, especially adjacent to affected joints. In severe or 25 chronic cases, destructive changes occur, as do fibrous or bony ankylosis. These histopathological symptoms are expected to appear in control animals at about 12 days after sensitization to the Freund's adjuvant.

#### Insulin Dependent Diabetes Mellitus (IDDM)

IDDM is observed as a consequence of the selective destruction of insulin-secreting cells within the Islets of Langerhans of the pancreas. Involvement of the 30 immune system in this disease is suggested by morphologic evidence of early infiltration

of the Islets by mononuclear cells, by the detection of anti-islet cell antibodies, by the high frequency of HLA-DR3 and -DR4 alleles in IDDM populations, and by clinical associations between IDDM and various autoimmune diseases. An animal model for spontaneous IDDM and thyroiditis has been developed in the BB rat. As in humans, the 5 rat disease is controlled in part by the genes encoding the MHC antigens, is characterized by islet infiltration, and is associated with the presence of anti-islet antibodies. The I-E equivalent class II MHC antigens appear to be involved in manifestation of the autoimmune diseases in the BB rat. Biotard *et al.*, *Proc. Natl. Acad. Sci. USA* 82:6627 (1985).

10 In morphologic evaluation, insulitis is characterized by the presence of mononuclear inflammatory cells within the islets. Thyroiditis is characterized by focal interstitial lymphocytic infiltrate within the thyroid gland, as a minimum criterion. Most severe cases show diffuse extensive lymphocytic infiltrates, disruption of acini, fibrosis, and focal Hurthle cell change. See Biotard *et al. supra*.

15 Treatment of the BB rats with the invention is expected to ameliorate or prevent the manifestation of the clinical and morphological symptoms associated with IDDM and thyroiditis.

20 In another model, the NOD mouse strain ( $H-2K^d D^b$ ) is a murine model for autoimmune IDDM. The disease in these animals is characterized by anti-islet cell antibodies, severe insulitis, and evidence for autoimmune destruction of the beta-cells (Kanazawa, *et al.*, *Diabetologica* 27:113 (1984)). The disease can be passively transferred with lymphocytes and prevented by treatment with cyclosporin-A (Ikehara *et al.*, *Proc. Natl. Acad. Sci. USA* 82:7743 (1985)); Mori *et al.*, *Diabetologica* 29:244 (1986).

25 Untreated animals develop profound glucose intolerance and ketosis and succumb within weeks of the onset of the disease. Seventy to ninety percent of female and 20-30% of male animals develop diabetes within the first six months of life. Breeding studies have defined at least two genetic loci responsible for disease susceptibility, one of which maps to the MHC. Characterization of NOD Class II antigens at both the serologic and molecular level suggest that the susceptibility to autoimmune disease is linked to I-A<sub>B</sub> 30 (Acha-Orbea and McDevitt, *Proc. Natl. Acad. Sci. USA* 84:235 (1987)).

Treatment of Female NOD mice with complex is expected to lengthen the time before the onset of diabetes and/or to ameliorate or prevent the disease.

Experimental Allergic Encephalomyelitis (EAE)

Experimental allergic encephalomyelitis (EAE) is an induced autoimmune disease of the central nervous system which is a model for multiple sclerosis (MS). The 5 disease can be induced in many species, including mice and rats.

The disease is characterized by the acute onset of paralysis. Perivascular infiltration by mononuclear cells in the CNS is observed in both mice and rats. Methods of inducing the disease, as well as symptomology, are reviewed in Aranson, *The Autoimmune Diseases* (Rose and Mackay, eds., 1985), and in Acha-Orbea *et al.*, *Ann. Rev. Imm.* 7:377-405 (1989).

One of the genes mediating susceptibility is localized in the MHC class II region (Moore *et al.*, *J. Immunol.* 124:1815-1820 (1980)). The best analyzed 15 encephalitogenic protein is myelin basic protein (MBP), but other encephalitogenic antigens are found in the brain. The immunogenic epitopes have been mapped (*see*, Acha-Orbea *et al.*, *supra*). In the PL mouse strains (H-2<sup>u</sup>) two encephalitogenic peptides in MBP have been characterized: MBP peptide p35-47 (MBP 35-47), and acetylated NSF p1-9 (MBP 1-9).

The effect of the invention on ameliorating disease symptoms in individuals in which EAE has been induced can be measured by survival rates, and by the 20 progress of the development of symptoms.

**Methods of making the complexes of the invention**

Expression systems suitable for production of appropriate recombinant single chain MHC class II molecule:peptide complexes are available and known in the art. Various prokaryotic, fungal, and eukaryotic host cells are suitable for expression of recombinant, single chain MHC class II molecule:peptide complexes, as well as for individual recombinant alpha and beta MHC class II chains.

Prokaryotes that are useful as host cells, according to the present invention, most frequently are represented by various strains of *Escherichia coli*. 30 However, other microbial strains can also be used, such as bacilli, for example *Bacillus subtilis*, various species of *Pseudomonas*, or other bacterial strains.

According to the invention, the single chain MHC class II molecule:peptide complexes are expressed from recombinantly engineered nucleotide sequences that encode the single chain MHC class II molecule:peptide polypeptides by operably linking the engineered nucleic acid coding sequence to signals that direct gene expression in prokaryotes. A nucleic acid is "operably linked" when it is placed into a functional relationship with another nucleic acid sequence. For instance, a promoter or enhancer is operably linked to a coding sequence if it effects the transcription of the sequence. Generally, operably linked means that the nucleic acid sequences being linked are contiguous and, where necessary to join two protein coding regions, contiguous and in reading frame.

The genes encoding the single chain MHC class II molecule:peptide complexes may be inserted into an "expression vector," "cloning vector," or "vector," terms which are used interchangeably herein and usually refer to plasmids or other nucleic acid molecules that are able to replicate in a chosen host cell. Expression vectors may replicate autonomously, or they can replicate by being inserted into the genome of the host cell, by methods well known in the art. Vectors that replicate autonomously will have an origin of replication or autonomous replicating sequence (ARS) that is functional in the chosen host cell(s).

Plasmid vectors that contain replication sites and control sequences derived from a species compatible with the chosen host are used. For example, *E. coli* is typically transformed using derivatives of pBR322, a plasmid derived from *E. coli* species by Bolivar *et al.*, *Gene* 2:95-113, 1977. Often, it is desirable for a vector to be usable in more than one host cell, e.g., in *E. coli* for cloning and construction, and in a *Bacillus* cell for expression.

The expression vectors typically contain a transcription unit or expression cassette that contains all the elements required for the expression of the DNA encoding the MHC molecule in the host cells. A typical expression cassette contains a promoter operably linked to the DNA sequence encoding a single chain MHC class II molecule:peptide complex and a ribosome binding site. The promoter is preferably positioned about the same distance from the heterologous transcription start site as it is from the transcription start site in its natural setting. As is known in the art, however, some variation in this distance can be accommodated without loss of promoter function.

In addition to a promoter sequence, the expression cassette can also contain a transcription termination region downstream of the structural gene to provide for efficient termination. The termination region may be obtained from the same gene as the promoter sequence or may be obtained from a different gene.

Commonly used prokaryotic control sequences which are defined herein to include promoters for transcription initiation, optionally with an operator, along with ribosome binding site sequences, include such commonly used promoters as the beta-lactamase (penicillinase) and lactose (lac) promoter systems (Change *et al.*, *Nature* 198:1056, 1977) and the tryptophan (trp) promoter system (Goeddel *et al.*, *Nucleic Acids Res.* 8:4057-74, 1980) and the lambda-derived P<sub>L</sub> promoter and N-gene ribosome binding site (Shimatake *et al.*, *Nature* 292:128-32, 1981). Any available promoter system that functions in prokaryotes can be used.

Either constitutive or regulated promoters can be used in the present invention. Regulated promoters can be advantageous because the host cells can be grown to high densities before expression of the single chain MHC class II molecule:peptide complexes is induced. High level expression of heterologous proteins slows cell growth in some situations. Regulated promoters especially suitable for use in *E. coli* include the bacteriophage lambda P<sub>L</sub> promoter, the hybrid trp-lac promoter (Amann *et al.*, *Gene* 25:167-78 1983; and the bacteriophage T7 promoter.

For expression of single chain MHC class II molecule:peptide complexes in prokaryotic cells other than *E. coli*, a promoter that functions in the particular prokaryotic species is required. Such promoters can be obtained from genes that have been cloned from the species, or heterologous promoters can be used. For example, the hybrid trp-lac promoter functions in *Bacillus* in addition to *E. coli*.

A ribosome binding site (RBS) is also necessary for expression of single chain MHC class II molecule:peptide complexes in prokaryotes. An RBS in *E. coli*, for example, consists of a nucleotide sequence 3-9 nucleotides in length located 3-11 nucleotides upstream of the initiation codon (Shine and Dalgarno, *Nature*, 254:34-40, 1975; Steitz, *In Biological regulation and development: Gene expression* (ed., Goldberger), vol. 1, p. 349, 1979).

Translational coupling may be used to enhance expression. The strategy uses a short upstream open reading frame derived from a highly expressed gene native to

the translational system, which is placed downstream of the promoter, and a ribosome binding site followed after a few amino acid codons by a termination codon. Just prior to the termination codon is a second ribosome binding site, and following the termination codon is a start codon for the initiation of translation. The system dissolves secondary 5 structure in the RNA, allowing for the efficient initiation of translation. See Squires, et. al., *J. Biol. Chem.* 263:16297-16302, 1988.

The single chain MHC class II molecule:peptide complexes can be expressed intracellularly, or can be secreted from the cell. Intracellular expression often results in high yields. However, some of the protein may be in the form of insoluble 10 inclusion bodies. Although some of the intracellularly produced MHC polypeptides of the present invention may be active upon being harvested following cell lysis, the amount of soluble, active MHC polypeptide may be increased by performing refolding procedures using methods known to those of skill in the art (see, e.g., Sambrook et al., *Molecular Cloning: A Laboratory Manual Second Edition*, Cold Spring Harbor, NY, 1989.; Marston 15 et al., *Bio/Technology* 2:800-804, 1985; Schoner et al., *Bio/Technology* 3:151-54, 1985). In one embodiment, for purification and refolding the cell pellet is lysed and refolded in urea-borate-DTT buffer followed by urea-borate buffer and reverse phase HPLC purification using either silica gel based Vydac (Hewlett Packard, Wilmington, DE) or polymer based Poros-R2 (PerSeptive Biosystems) resins, with bead size varying based on 20 the scale of the culture and is described in further detail below. In one embodiment, e.g., for large scale refolding, the sample can be ultrafiltered into a urea-borate buffer to which is then added 0.2  $\mu$ M to 1 mM copper sulfate, preferably 0.2 to 20  $\mu$ M, after which folding occurs immediately.

More than one MHC:peptide complex may be expressed in a single 25 prokaryotic cell by placing multiple transcriptional cassettes in a single expression vector, or by utilizing different selectable markers for each of the expression vectors which are employed in the cloning strategy.

A second approach for expressing the MHC:peptide complexes of the invention is to cause the polypeptides to be secreted from the cell, either into the 30 periplasm or into the extracellular medium. The DNA sequence encoding the MHC polypeptide is linked to a cleavable signal peptide sequence. The signal sequence directs translocation of the MHC:peptide complex through the cell membrane. An example of a

suitable vector for use in *E. coli* that contains a promoter-signal sequence unit is pTA1S29, which has the *E. coli* phoA promoter and signal sequence *see*, e.g., Sambrook *et al.*, *supra*; Oka *et al.*, *Proc. Natl. Acad. Sci. USA* 82:7212-16, 1985; Talmadge *et al.*, *Proc. Natl. Acad. Sci. USA* 77:39892, 1980; Takahara *et al.*, *J. Biol. Chem.* 260: 2670-74, 1985). Once again, multiple polypeptides can be expressed in a single cell for periplasmic association. Eukaryotic signal sequences are also well known to those of skill in the art, and cause the MHC:peptide complexes of the invention to be secreted into the extracellular medium.

The MHC:peptide complexes of the invention can also be produced as fusion proteins. This approach often results in high yields, because normal prokaryotic control sequences direct transcription and translation. In *E. coli*, lacZ fusions are often used to express heterologous proteins. Suitable vectors are readily available, such as the pUR, pEX, and pMR100 series (*see*, e.g., Sambrook *et al.*, *supra*). For certain applications, it may be desirable to cleave the non-MHC amino acids from the fusion protein after purification. This can be accomplished by any of several methods known in the art, including cleavage by cyanogen bromide, a protease, or by Factor X, (*see*, e.g., Sambrook *et al.*, *supra*; Goeddel *et al.*, *Proc. Natl. Acad. Sci. USA* 76:106-10, 1979; Nagai *et al.*, *Nature* 309:810-12, 1984; Sung *et al.*, *Proc. Natl. Acad. Sci. USA* 83:561-65, 1986). Cleavage sites can be engineered into the gene for the fusion protein at the desired point of cleavage.

Foreign genes, such as single chain MHC class II molecule:peptide complexes, can be expressed in *E. coli* as fusions with binding partners, such as glutathione-S-transferase (GST), maltose binding protein, or thioredoxin. These binding partners are highly translated and can be used to overcome inefficient initiation of translation of eukaryotic messages in *E. coli*. Fusion to such binding partner can result in high-level expression, and the binding partner is easily purified and then excised from the protein of interest. Such expression systems are available from numerous sources, such as Invitrogen Inc. (San Diego, CA) and Pharmacia LKB Biotechnology Inc. (Piscataway, NJ).

A method for obtaining recombinant proteins from *E. coli* which maintains the integrity of their N-termini has been described by Miller *et al.* *Biotechnology* 7:698-704 (1989). In this system, the gene of interest is produced as a C-terminal fusion to the

first 76 residues of the yeast ubiquitin gene containing a peptidase cleavage site.

Cleavage at the junction of the two moieties results in production of a protein having an intact authentic N-terminal residue.

The vectors containing the nucleic acids that code for the single chain

- 5 MHC class II molecule:peptide complexes are transformed into prokaryotic host cells for expression. "Transformation" refers to the introduction of vectors containing the nucleic acids of interest directly into host cells by well known methods. The particular procedure used to introduce the genetic material into the host cell for expression of the single chain MHC class II molecule:peptide complex is not particularly critical. Any of the well  
10 known procedures for introducing foreign nucleotide sequences into host cells may be used. It is only necessary that the, particular host cell utilized be capable of expressing the gene.

Transformation methods, which vary depending on the type of the prokaryotic host cell, include electroporation; transfection employing calcium chloride, rubidium chloride calcium phosphate, or other substances; microprojectile bombardment; infection (where the vector is an infectious agent); and other methods. See, generally, Sambrook *et al., supra*, and Ausubel *et al.*, (eds.) *Current Protocols in Molecular Biology*, John Wiley and Sons, Inc., NY, 1987. Reference to cells into which the nucleic acids described above have been introduced is meant to also include the progeny of such cells.

- 20 Transformed prokaryotic cells that contain expression vectors for single chain MHC class II molecule:peptide complexes are also included in the invention.

After standard transfection or transformation methods are used to produce prokaryotic cell lines that express large quantities of the single chain MHC class II molecule:peptide complex polypeptide, the polypeptide is then purified using standard techniques. See, e.g., Colley *et al.*, *J. Chem.* 64:17619-22, 1989; and *Methods in Enzymology*, "Guide to Protein Purification", Deutscher, ed., Vol. 182 (1990). The recombinant cells are grown and the single chain MHC class II molecule:peptide complex is expressed. The purification protocol will depend upon whether single chain MHC class II molecule:peptide complex is expressed intracellularly, into the periplasm, or secreted  
25 from the cell. For intracellular expression, the cells are harvested, lysed, and the polypeptide is recovered from the cell lysate (Sambrook *et al., supra*). Periplasmic MHC polypeptide is released from the periplasm by standard techniques (Sambrook *et al.*,

*supra*). If the MHC polypeptide is secreted from the cells, the culture medium is harvested for purification of the secreted protein. The medium is typically clarified by centrifugation or filtration to remove cells and cell debris.

The MHC polypeptides can be concentrated by adsorption to any suitable resin (such as, for example, CDP-Sepharose, Asialoprothrombin-Sepharose 4B, or Q Sepharose), or by use of ammonium sulfate fractionation, polyethylene glycol precipitation, or by ultrafiltration. Other means known in the art may be equally suitable.

Further purification of the MHC polypeptides can be accomplished by standard techniques, for example, affinity chromatography, ion exchange chromatography, sizing chromatography, reverse phase HPLC, or other protein purification techniques used to obtain homogeneity. The purified proteins are then used to produce pharmaceutical compositions.

For secretion of a polypeptide or protein of interest, recombinant nucleic acid constructs of the invention may include sequences that encode signal sequences or other sequences that direct secretion. Secretory signal sequences, also called leader sequences, prepro sequences and/or pre sequences, are amino acid sequences that play a role in secretion of mature polypeptides or proteins from a cell. Such sequences are characterized by a core of hydrophobic amino acids and are typically (but not exclusively) found at the amino termini of newly synthesized proteins. The secretory signal sequence may be that of the protein of interest, or may be derived from another secreted protein (e.g., t-PA, a preferred mammalian secretory leader) or synthesized de novo. The secretory signal sequence is joined to the DNA sequence encoding a protein of the present invention in the correct reading frame. Secretory signal sequences are commonly positioned 5' to the DNA sequence encoding the polypeptide of interest, although certain signal sequences may be positioned elsewhere in the DNA sequence of interest (see, e.g., Welch *et al.*, U.S. Patent No. 5,037,743; Holland *et al.*, U.S. Patent No. 5,143,830). Very often the secretory peptide is cleaved from the mature protein during secretion. Such secretory peptides contain processing sites that allow cleavage of the secretory peptide from the mature protein as it passes through the secretory pathway. An example of such a processing site is a dibasic cleavage site, such as that recognized by the *Saccharomyces cerevisiae* KEX2 gene or a Lys-Arg processing site. Processing sites

may be encoded within the secretory peptide or may be added to the peptide by, for example, *in vitro* mutagenesis.

Secretory signals include the  $\alpha$  factor signal sequence (prepro sequence: Kurjan & Herskowitz, *Cell* 3:933-943, 1982; Kurjan *et al.*, U.S. Patent No. 4,546,082; 5 Brake, EP 116, 201), the *PHO5* signal sequence (Beck *et al.*, WO 86/00637), the *BAR1* secretory signal sequence (MacKay *et al.*, U.S. Patent No. 4,613,572; MacKay, WO 87/002670), the *SUC2* signal sequence (Carlsen *et al.*, *Molecular and Cellular Biology* 3: 439-447, 1983), the  $\alpha$ -1-antitrypsin signal sequence (Kurachi *et al.*, *Proc. Natl. Acad. Sci. USA* 78: 6826-6830, 1981), the  $\alpha$ -2 plasmin inhibitor signal sequence (Tone *et al.*, *J. Biochem. (Tokyo)* 102: 1033-1042, 1987) and the tissue plasminogen activator signal sequence (Pennica *et al.*, *Nature* 301: 214-221, 1983). Alternately, a secretory signal sequence may be synthesized according to the rules established, for example, by von Heinje (*European Journal of Biochemistry* 133: 17-21, 1983; *Journal of Molecular Biology* 184: 99-105, 1985; *Nucleic Acids Research* 14: 4683-4690; 1986). Another 10 signal sequence is the synthetic signal LaC212 spx (1-47). ERLE described in WO 90/10075.

Secretory signal sequences may be used singly or may be combined. For example, a first secretory signal sequence may be used in combination with a sequence encoding the third domain of barrier (described in U.S. Patent No. 5,037,243, which is 20 incorporated by reference herein in its entirety). The third domain of barrier may be positioned in proper reading frame 3' of the DNA segment of interest or 5' to the DNA segment and in proper reading frame with both the secretory signal sequence and a DNA segment of interest.

The choice of suitable promoters, terminators and secretory signals for all 25 expression systems, is well within the level of ordinary skill in the art. Methods for expressing cloned genes in *Saccharomyces cerevisiae* are generally known in the art (see, "Gene Expression Technology," *Methods in Enzymology*, Vol. 185, Goeddel (ed.), Academic Press, San Diego, CA, 1990 and "Guide to Yeast Genetics and Molecular Biology," *Methods in Enzymology*, Guthrie and Fink (eds.), Academic Press, San Diego, 30 CA, 1991; which are incorporated herein by reference). Proteins of the present invention can also be expressed in filamentous fungi, for example, strains of the fungi *Aspergillus* (McKnight *et al.*, U.S. Patent No. 4,935,349, which is incorporated herein by reference).

Expression of cloned genes in cultured mammalian cells and in *E. coli*, for example, is discussed in detail in Sambrook *et al.* (*Molecular Cloning: A Laboratory Manual. Second Edition*, Cold Spring Harbor, NY, 1989; which is incorporated herein by reference). As would be evident to one skilled in the art, one could express the proteins 5 of the instant invention in other host cells such as avian, insect and plant cells using regulatory sequences, vectors and methods well established in the literature.

In yeast, suitable yeast vectors for use in the present invention include YRp7 (Struhl *et al.*, *Proc. Natl. Acad. Sci. USA* 76:1035-1039, 1978), YEpl3 (Broach *et al.*, *Gene* 8: 121-133, 1979), POT vectors (Kawasaki *et al.*, U.S. Patent No. 4,931,373, 10 which is incorporated by reference herein), pJDB249 and pJDB219 (Beggs, *Nature* 275:104-108, 1978) and derivatives thereof. Preferred promoters for use in yeast include promoters from yeast glycolytic genes (Hitzeman *et al.*, *J. Biol. Chem.* 255: 12073-12080, 1980; Alber and Kawasaki, *J. Mol. Appl. Genet.* 1: 419-434, 1982; Kawasaki, U.S. Patent No. 4,599,311) or alcohol dehydrogenase genes (Young *et al.*, in *Genetic Engineering of 15 Microorganisms for Chemicals*, Hollaender *et al.*, (eds.), p. 355, 1982; Ammerer, *Meth. Enzymol.* 101: 192-201, 1983). Other promoters are the TPI1 promoter (Kawasaki, U.S. Patent No. 4,599,311, 1986) and the ADH2-4<sup>c</sup> promoter (Russell *et al.*, *Nature* 304: 652-654, 1983; Irani and Kilgore, U.S. Patent Application Serial No. 07/784,653, CA 20 1,304,020 and EP 284 044, which are incorporated herein by reference). The expression units may also include a transcriptional terminator such as the TPI1 terminator (Alber and Kawasaki, *ibid.*).

Yeast cells, particularly cells of the genus *Pichia* or *Saccharomyces*, are a preferred host for use in producing compound of the current invention. Methods for transforming yeast cells with exogenous DNA and producing recombinant proteins 25 therefrom are disclosed by, for example, Kawasaki, U.S. Patent No. 4,599,311; Kawasaki *et al.*, U.S. Patent No. 4,931,373; Brake, U.S. Patent No. 4,870,008; Welch *et al.*, U.S. Patent No. 5,037,743; and Murray *et al.*, U.S. Patent No. 4,845,075, which are incorporated herein by reference. Transformed cells are selected by phenotype determined by a selectable marker, commonly drug resistance or the ability to grow in the 30 absence of a particular nutrient (e.g., leucine). A preferred vector system for use in yeast is the POT1 vector system disclosed by Kawasaki *et al.* (U.S. Patent No. 4,931,373), which allows transformed cells to be selected by growth in glucose-containing media. A

preferred secretory signal sequence for use in yeast is that of the *S. cerevisiae* MFα1 gene (Brake, *ibid.*; Kurjan *et al.*, U.S. Patent No. 4,546,082). Suitable promoters and terminators for use in yeast include those from glycolytic enzyme genes (*see, e.g.*, Kawasaki, U.S. Patent No. 4,599,311; Kingsman *et al.*, U.S. Patent No. 4,615,974; and Bitter, U.S. Patent No. 4,977,092, which are incorporated herein by reference) and **alcohol dehydrogenase genes**. *See also* U.S. Patent Nos. 4,990,446; 5,063,154; 5,139,936 and 4,661,454, which are incorporated herein by reference. Transformation systems for other yeasts, including *Hansenula polymorpha*, *Schizosaccharomyces pombe*, *Kluyveromyces lactis*, *Kluyveromyces fragilis*, *Ustilago maydis*, *Pichia pastoris*, *Pichia methanolica*, *Pichia guillermondii* and *Candida maltosa* are known in the art. See, for example, Gleeson *et al.*, *J. Gen. Microbiol.* 132:3459-65, 1986; Cregg, U.S. Patent No. 4,882,279; and Stroman *et al.*, U.S. Patent No. 4,879,231.

Other fungal cells are also suitable as host cells. For example, *Aspergillus* cells may be utilized according to the methods of McKnight *et al.*, U.S. Patent No. 4,935,349, which is incorporated herein by reference. Methods for transforming *Acremonium chrysogenum* are disclosed by Sumino *et al.*, U.S. Patent No. 5,162,228, which is incorporated herein by reference. Methods for transforming *Neurospora* are disclosed by Lambowitz, U.S. Patent No. 4,486,533, which is incorporated herein by reference.

Host cells containing DNA constructs of the present invention are then cultured to produce the heterologous proteins. The cells are cultured according to standard methods in a culture medium containing nutrients required for growth of the particular host cells. A variety of suitable media are known in the art and generally include a carbon source, a nitrogen source, essential amino acids, vitamins, minerals and growth factors. The growth medium will generally select for cells containing the DNA construct by, for example, drug selection or deficiency in an essential nutrient which is complemented by a selectable marker on the DNA construct or co-transfected with the DNA construct.

Yeast cells, for example, are preferably cultured in a chemically defined medium, comprising a non-amino acid nitrogen source, inorganic salts, vitamins and essential amino acid supplements. The pH of the medium is preferably maintained at a pH greater than 2 and less than 8, preferably at pH 6.5. Methods for maintaining a stable

pH include buffering and constant pH control, preferably through the addition of sodium hydroxide. Preferred buffering agents include succinic acid and Bis-Tris (Sigma Chemical Co., St. Louis, MO). Yeast cells having a defect in a gene required for asparagine-linked glycosylation are preferably grown in a medium containing an osmotic stabilizer. A preferred osmotic stabilizer is sorbitol supplemented into the medium at a concentration between 0.1 M and 1.5 M, preferably at 0.5 M or 1.0 M. Cultured mammalian cells are generally cultured in commercially available serum-containing or serum-free media. Selection of a medium appropriate for the particular host cell used is within the level of ordinary skill in the art.

10 Methods for introducing exogenous DNA into mammalian host cells include calcium phosphate-mediated transfection (Wigler *et al.*, *Cell* 14:725, 1978; Corsaro and Pearson, *Somatic Cell Genetics* 7:603, 1981; Graham and Van der Eb, *Virology* 52:456, 1973), electroporation (Neumann *et al.*, *EMBO J.* 1:841-45, 1982) and DEAE-dextran mediated 'transfection (Ausubel *et al.*, (eds), *Current Protocols in Molecular Biology*, John Wiley and Sons, Inc., NY, 1987), which are incorporated herein by reference. Cationic lipid transfection using commercially available reagents, including the Boehringer Mannheim TRANSFECTION-REAGENT (N-[1-(2,3-dioleoyloxy)propyl] -N,N,N-trimethyl ammoniummethylsulfate; Boehringer Mannheim, Indianapolis, IN) or LIPOFECTIN reagent (N-[1-(2,3-dioleoyloxy)propyl]-N,N,N-trimethylammonium chloride and dioleoyl phosphatidylethanolamine; GIBCO-BRL, Gaithersburg, MD) using the manufacturer-supplied directions, may also be used. A preferred mammalian expression plasmid is Zem229R (deposited under the terms of the Budapest Treaty with American Type Culture Collection, 12301 Parklawn Drive, Rockville, MD on September 28, 1993 as an *E. coli* HB101 transformant and assigned Accession Number 69447). The production of recombinant proteins in cultured mammalian cells is disclosed, for example, by Levinson *et al.*, U.S. Patent No. 4,713,339; Hagen *et al.*, U.S. Patent No. 4,784,950; Palmiter *et al.*, U.S. Patent No. 4,579,821; and Ringold, U.S. Patent No. 4,656,134, which are incorporated herein by reference. Preferred cultured mammalian cells include the COS-1 (ATCC No. CRL 1650), COS-7 (ATCC No. CRL 1651), BHK (ATCC No. CRL 1632), BHK 570 (ATCC No. CRL 10314), DG44, and 293 (ATCC No. CRL 1573; Graham *et al.*, *J. Gen. Virol.* 36:59-72, 1977) cell lines. Additional suitable cell lines are known in the art and available from

public depositories such as the American Type Culture Collection, Rockville, Maryland. In general, strong transcription promoters are preferred, such as promoters from SV-40 or cytomegalovirus. See, e.g., U.S. Patent No. 4,956,288. Other suitable promoters include those from metallothionein genes (U.S. Patents Nos. 4,579,821 and 4,601,978, which are 5 incorporated herein by reference) and the adenovirus major late promoter.

Drug selection is generally used to select for cultured mammalian cells into which foreign DNA has been inserted. Such cells are commonly referred to as "transfectants." Cells that have been cultured in the presence of the selective agent and are able to pass the gene of interest to their progeny are referred to as "stable 10 transfectants." A preferred selectable marker is a gene encoding resistance to the antibiotic neomycin. Selection is carried out in the presence of a neomycin-type drug, such as G-418 or the like. Selection systems may also be used to increase the expression level of the gene of interest, a process referred to as "amplification." Amplification is carried out by culturing transfecants in the presence of a low level of the selective agent 15 and then increasing the amount of selective agent to select for cells that produce high levels of the products of the introduced genes. A preferred amplifiable selectable marker is dihydrofolate reductase, which confers resistance to methotrexate. Other drug resistance genes (e.g. hygromycin resistance, multi-drug resistance, puromycin acetyltransferase) can also be used.

20 The soluble, fused MHC:peptide complexes of the present invention can be purified by first isolating the polypeptides from the cells followed by conventional purification methods, such as by ion-exchange and partition chromatography as described by, for example, Coy *et al.* (*Peptides Structure and Function*, Pierce Chemical Company, Rockford, IL, pp 369-72, 1983) or by reverse-phase chromatography as described, for 25 example, by Andreu and Merrifield (*Eur. J. Biochem.* 164: 585-90, 1987), or by HPLC as described, for example, by Kofod *et al.* (*Int. J. Peptide and Protein Res.* 32.: 436-40, 1988). Additional purification can be achieved by additional conventional purification means, such as liquid chromatography, gradient centrifugation, and gel electrophoresis, among others. Methods of protein purification are known in the art (see generally, 30 Scopes, R., *Protein Purification*, Springer-Verlag, NY, 1982, which is incorporated by reference herein) and can be applied to the purification of the recombinant polypeptides described herein. Single chain MHC class II molecule:peptide complexes of at least

about 50% purity are preferred, at least about 70-80% purity more preferred, and about 95-99% or more purity most preferred, particularly for pharmaceutical uses. Once purified, either partially or to homogeneity, as desired, the single chain MHC class II molecule:peptide complexes may then be used diagnostically or therapeutically, as further described below.

#### Methods of using single chain MHC class II molecule:peptide complexes

The single chain MHC class II molecule:peptide complexes of the present invention may be used within methods for down-regulating parts of the immune system that are reactive in autoimmune diseases. The single chain MHC class II molecule:peptide complexes of the present invention are contemplated to be advantageous for use as immunotherapeutics to induce immunological tolerance or nonresponsiveness (anergy) in patients predisposed to mount or already mounting an immune response those particular autoantigens. A patient having or predisposed to a particular autoimmune disease is identified and MHC type is determined by methods known in the art. The patient's T cells can be examined *in vitro* to determine autoantigenic peptide(s) recognized by the patient's autoreactive T cells using complexes and methods described herein. The patient can then be treated with complexes of the invention. Such methods will generally include administering single chain MHC class II molecule:peptide complex in an amount sufficient to lengthen the time period before onset of the autoimmune disease and/or to ameliorate or prevent that disease. Single chain MHC class II molecule:peptide complexes of the present invention are therefore contemplated to be advantageous for use in both therapeutic and diagnostic applications related to auto immune diseases.

Kits can also be supplied for therapeutic or diagnostic uses. Thus, the subject composition of the present invention may be provided, usually in a lyophilized form, in a container. The single chain MHC class II molecule:peptide complex is included in the kits with instructions for use, and optionally with buffers, stabilizers, biocides, and inert proteins. Generally, these optional materials will be present at less than about 5% by weight, based on the amount of single chain MHC class II molecule:peptide complex, and will usually be present in a total amount of at least about 0.001% by weight, based on the single chain MHC class II molecule:peptide complex

concentration. It may be desirable to include an inert extender or excipient to dilute the active ingredients, where the excipient may be present in from about 1 to 99% weight of the total composition.

Within one aspect of the present invention, single chain MHC class II molecule:peptide complexes are utilized to prepare antibodies for diagnostic or therapeutic uses. As used herein, the term "antibodies" includes polyclonal antibodies, monoclonal antibodies, antigen-binding fragments thereof such as F(ab')<sub>2</sub> and Fab fragments, as well as recombinantly produced binding partners. These binding partners incorporate the variable or CDR regions from a gene which encodes a specifically binding antibody. The affinity of a monoclonal antibody or binding partner may be readily determined by one of ordinary skill in the art (see, Scatchard, *Ann. NY Acad. Sci.* 51: 660-72, 1949)

Methods for preparing polyclonal and monoclonal antibodies have been well described in the literature (see, for example, Sambrook *et al.*, *Molecular Cloning: A Laboratory Manual, Second Edition*, Cold Spring Harbor, NY, 1989; and Hurrell, J. G. R., Ed., *Monoclonal Hybridoma Antibodies: Techniques and Applications*, CRC Press, Ind., Boca Raton, FL, 1982, which is incorporated herein by reference). As would be evident to one of ordinary skill in the art, polyclonal antibodies may be generated from a variety of warm-blooded animals, such as horses, cows, goats, sheep, dogs, chickens, rabbits, mice, or rats, for example. The immunogenicity of the single chain MHC class II molecule:peptide complexes may be increased through the use of an adjuvant, such as Freund's complete or incomplete adjuvant. A variety of assays known to those skilled in the art may be utilized to detect antibodies which specifically bind to a single chain MHC class II molecule:peptide complex. Exemplary assays are described in detail in *Antibodies: A Laboratory Manual*, Harlow and Lane (Eds.), Cold Spring Harbor Laboratory Press, 1988. Representative examples of such assays include: concurrent immunoelectrophoresis, radio-immunoassays, radio-immunoprecipitations, enzyme-linked immuno-sorbent assays, dot blot assays, inhibition or competition assays, and sandwich assays.

Additional techniques for the preparation of monoclonal antibodies may be utilized to construct and express recombinant monoclonal antibodies. Briefly, mRNA is isolated from a B cell population and used to create heavy and light chain

immunoglobulin cDNA expression libraries in a suitable vector such as the λIMMUNOZAP(H) and λIMMUNOZAP(L) vectors, which may be obtained from Stratagene Cloning Systems (La Jolla, CA). These vectors are then screened individually or are co-expressed to form Fab fragments or antibodies (Huse *et al.*, *Science* 246 1275-81, 1989; Sastry *et al.*, *Proc. Natl. Acad. Sci. USA* 86: 5728-32, 1989). Positive plaques are subsequently converted to a non-lytic plasmid which allows high level expression of monoclonal antibody fragments in *E. coli*.

Antibodies of the present invention may be produced by immunizing an animal selected from a wide variety of warm-blooded animals, such as horses, cows, goats, sheep, dogs, chickens, rabbits, mice, and rats, with a recombinant single chain MHC class II molecule:peptide complex. Serum from such animals are a source of polyclonal antibodies. Alternatively antibody producing cells obtained from the immunized animals are immortalized and screened. As the generation of human monoclonal antibodies to a human antigen, such as a single chain MHC class II molecule:peptide complex, may be difficult with conventional immortalization techniques, it may be desirable to first make non-human antibodies. Using recombinant DNA techniques, the antigen binding regions of the non-human antibody is transferred to the corresponding site of a human antibody coding region to produce a substantially human antibody molecules. Such methods are generally known in the art and are described in, for example, U.S. Patent No. 4,816,397, and EP publications 173,494 and 239,400, which are incorporated herein by reference.

In another aspect of the invention, the single chain MHC class II molecule:peptide complexes can be used to clone T cells which have specific receptors for the single chain MHC class II molecule:peptide complex. Once the single chain MHC class II molecule:peptide complex-specific T cells are isolated and cloned using techniques generally available to the skilled artisan, the T cells or membrane preparations thereof can be used to immunize animals to produce antibodies to the single chain MHC class II molecule:peptide complex receptors on T cells. The antibodies can be polyclonal or monoclonal. If polyclonal, the antibodies can be murine, lagomorph, equine, ovine, or from a variety of other mammals. Monoclonal antibodies will typically be murine in origin, produced according to known techniques, or human, as described above, or combinations thereof, as in chimeric or humanized antibodies. The anti-single chain

MHC class II molecule:peptide complex receptor antibodies thus obtained can then be administered to patients to reduce or eliminate T cell subpopulations that display such receptor. This T-cell population recognizes and participates in the immunological destruction of cells bearing the autoantigenic peptide in an individual predisposed to or 5 already suffering from a disease, such as an autoimmune disease related to the autoantigenic peptide.

The coupling of antibodies to solid supports and their use in purification of proteins is well known in the literature (*see, for example, Methods in Molecular Biology. Vol. 1*, Walker (Ed.), Humana Press, New Jersey, 1984, which is incorporated by 10 reference herein in its entirety). Antibodies of the present invention may be used as a marker reagent to detect the presence of MHC heterodimer:peptide complexes on cells or in solution. Such antibodies are also useful for Western analysis or immunoblotting, particularly of purified cell-secreted material. Polyclonal, affinity purified polyclonal, monoclonal and single chain antibodies are suitable for use in this regard. In addition, 15 proteolytic and recombinant fragments and epitope binding domains can be used herein. Chimeric, humanized, veneered, CDR-replaced, reshaped or other recombinant whole or partial antibodies are also suitable.

### Pharmaceutical compositions

20 Pharmaceutically acceptable carriers are determined in part by the particular composition being administered (*e.g., nucleic acid, protein*) as by the particular method used to administer the composition. Accordingly, there are a wide variety of suitable formulations of pharmaceutical compositions of the present invention (*see, e.g., Remington's Pharmaceutical Sciences* (17<sup>th</sup> ed., 1989)). Administration can be in any 25 convenient manner, *e.g., by injection, oral administration, inhalation, or transdermal application.*

Formulations suitable for oral administration can consist of (a) liquid solutions, such as an effective amount of the packaged nucleic acid or polypeptide suspended in diluents, such as water, saline or PEG 400; (b) capsules, sachets or tablets, 30 each containing a predetermined amount of the active ingredient, as liquids, solids, granules or gelatin; (c) suspensions in an appropriate liquid; and (d) suitable emulsions. Tablet forms can include one or more of lactose, sucrose, mannitol, sorbitol, calcium

phosphates, corn starch, potato starch, microcrystalline cellulose, gelatin, colloidal silicon dioxide, talc, magnesium stearate, stearic acid, and other excipients, colorants, fillers, binders, diluents, buffering agents, moistening agents, preservatives, flavoring agents, dyes, disintegrating agents, and pharmaceutically compatible carriers. Lozenge forms can 5 comprise the active ingredient in a flavor, e.g., sucrose, as well as pastilles comprising the active ingredient in an inert base, such as gelatin and glycerin or sucrose and acacia emulsions, gels, and the like containing, in addition to the active ingredient, carriers known in the art.

The compound of choice, alone or in combination with other suitable 10 components, can be made into aerosol formulations (*i.e.*, they can be “nebulized”) to be administered via inhalation. Aerosol formulations can be placed into pressurized acceptable propellants, such as dichlorodifluoromethane, propane, nitrogen, and the like.

Formulations suitable for parenteral administration, such as, for example, by intraarticular (in the joints), intravenous, intramuscular, intradermal, intraperitoneal, 15 and subcutaneous routes, include aqueous and non-aqueous, isotonic sterile injection solutions, which can contain antioxidants, buffers, bacteriostats, and solutes that render the formulation isotonic with the blood of the intended recipient, and aqueous and non-aqueous sterile suspensions that can include suspending agents, solubilizers, thickening agents, stabilizers, and preservatives. In the practice of this invention, compositions can 20 be administered, for example, by intravenous infusion, orally, topically, intraperitoneally, intravesically or intrathecally. Parenteral administration and intravenous administration are the preferred methods of administration. The formulations of compounds can be presented in unit-dose or multi-dose sealed containers, such as ampules and vials.

Injection solutions and suspensions can be prepared from sterile powders, 25 granules, and tablets of the kind previously described. Cells transduced by nucleic acids for *ex vivo* therapy can also be administered intravenously or parenterally as described above.

The polypeptides of the invention are administered prophylactically or to an individual already suffering from the disease. The compositions are administered to a 30 patient in an amount sufficient to elicit an effective immune response. An amount adequate to accomplish this is defined as “therapeutically effective dose” or “immunogenically effective dose.” Amounts effective for this use will depend on, e.g.,

the peptide composition, the manner of administration, the stage and severity of the disease being treated, the weight and general state of health of the patient, and the judgment of the prescribing physician, but generally range for the initial immunization dose (that is for therapeutic or prophylactic administration) from about 0.01 mg to about 5 50 mg per 70 kilogram patient, more commonly from about 0.5-1 mg to about 10-15 mg per 70 kg of body weight. Boosting dosages are typically from about 0.01 mg to about 50 mg of peptide, more commonly about 0.5-1 mg to about 10-15 mg, using a boosting regimen over weeks to months depending upon the patient's response and condition. A suitable protocol would include injection at time 0, 2, 6, 8, 10 and 14 weeks, followed by 10 booster injections at 24 and 28 weeks. Booster injections can be from one, two, three, four, five or more. Initial and booster injection amounts and timing are determined based on the judgment of the physician and the antigen being administered. In one embodiment, the initial and booster dose is 1.3 mg, 4 mg, or 13 mg, administered via intramuscular injection, with at least one and up to 3 booster injections at 8 week 15 intervals, or at least one and up to 4 booster injections at 6 week intervals.

The therapeutic methods of the present invention may involve oral tolerance (Weiner *et al.*, *Nature* 376: 177-80, 1995), or intravenous tolerance, for example. Tolerance can be induced in mammals, although conditions for inducing such tolerance will vary according to a variety of factors. To induce immunological tolerance 20 in an adult susceptible to or already suffering from an autoantigen-related disease such as IDDM, the precise amounts and frequency of administration will also vary. For instance for adults about 20-80 µg/kg can be administered by a variety of routes, such as parenterally, orally, by aerosols, intradermal injection, and the like. For neonates, tolerance can be induced by parenteral injection or more conveniently by oral 25 administration in an appropriate formulation. The precise amount administrated, and the mode and frequency of dosages, will vary.

The single chain MHC class II molecule:peptide complexes will typically be more tolerogenic when administered in a soluble form, rather than in an aggregated or particulate form. Persistence of a single chain MHC class II molecule:peptide complex of 30 the invention is generally needed to maintain tolerance in an adult, and thus may require more frequent administration of the complex, or its administration in a form which

extends the half-life of the complex. See for example, Sun *et al.*, *Proc. Natl. Acad. Sci. USA* 91: 10795-99, 1994.

Within another aspect of the invention, a pharmaceutical composition is provided which comprises a single chain MHC class II molecule:peptide complex of the present invention contained in a pharmaceutically acceptable carrier or vehicle for parenteral, topical, oral, or local administration, such as by aerosol or transdermally, for prophylactic and/or therapeutic treatment, according to conventional methods. The composition may typically be in a form suited for systemic injection or infusion and may, as such, be formulated with sterile water or an isotonic saline or glucose solution.

Formulations may further include one or more diluents, fillers, emulsifiers, preservatives, buffers, excipients, and the like, and may be provided in such forms as liquids, powders, emulsions, suppositories, liposomes, transdermal patches and tablets, for example.

Pharmaceutical compositions of the present invention are administered at daily to weekly intervals. An "effective amount" of such a pharmaceutical composition is an amount that provides a clinically significant decrease in a deleterious T cell-mediated immune response to an autoantigen, for example, those associated with IDDM, or provides other pharmacologically beneficial effects. Such amounts will depend, in part, on the particular condition to be treated, age, weight, and general health of the patient, and other factors evident to those skilled in the art. Preferably the amount of the single chain MHC class II molecule:peptide complex administered will be within the range of 20-80 µg/kg. Compounds having significantly enhanced half-lives may be administered at lower doses or less frequently.

#### Adjuvants

An immunostimulant refers to essentially any substance that enhances or potentiates an immune response (antibody and/or cell-mediated) to an exogenous antigen. One preferred type of immunostimulant comprises an adjuvant. Many adjuvants contain a substance designed to protect the antigen from rapid catabolism, such as aluminum hydroxide or mineral oil, and a stimulator of immune responses, such as lipid A, *Bordetella pertussis* or *Mycobacterium tuberculosis* derived proteins. Certain adjuvants are commercially available as, for example, Freund's Incomplete Adjuvant and Complete Adjuvant (Difco Laboratories, Detroit, MI); Merck Adjuvant 65 (Merck and Company,

- Inc., Rahway, NJ); AS-2 (SmithKline Beecham, Philadelphia, PA); aluminum salts such as aluminum hydroxide gel (alum) or aluminum phosphate; salts of calcium, iron or zinc; an insoluble suspension of acylated tyrosine; acylated sugars; cationically or anionically derivatized polysaccharides; polyphosphazenes; biodegradable microspheres; 5 monophosphoryl lipid A and quil A. Cytokines, such as GM-CSF, interleukin-2, -7, -12, and other like growth factors, may also be used as adjuvants.

The compositions may also include a *Mycobacterium* species CWS adjuvant, as described above. The effectiveness of an adjuvant may be determined by measuring the amount of antibodies directed against the immunogenic peptide.

- 10 Certain adjuvants for eliciting a predominantly Th1-type response include, for example, a combination of monophosphoryl lipid A, preferably 3-de-O-acylated monophosphoryl lipid A, together with an aluminum salt. MPL® adjuvants are available from Corixa Corporation (Seattle, WA; see, for example, US Patent Nos. 4,436,727; 4,877,611; 4,866,034 and 4,912,094). CpG-containing oligonucleotides (in which the 15 CpG dinucleotide is unmethylated) also induce a predominantly Th1 response. Such oligonucleotides are well known and are described, for example, in WO 96/02555, WO 99/33488 and U.S. Patent Nos. 6,008,200 and 5,856,462. Immunostimulatory DNA sequences are also described, for example, by Sato *et al.*, *Science* 273:352, 1996. Another preferred adjuvant comprises a saponin, such as Quil A, or derivatives thereof, 20 including QS21 and QS7 (Aquila Biopharmaceuticals Inc., Framingham, MA); Escin; Digitomin; or *Gypsophila* or *Chenopodium quinoa* saponins. Other preferred formulations include more than one saponin in the adjuvant combinations of the present invention, for example combinations of at least two of the following group comprising QS21, QS7, Quil A, β-escin, or digitonin.

- 25 Alternatively the saponin formulations may be combined with vaccine vehicles composed of chitosan or other polycationic polymers, polylactide and poly(lactide-co-glycolide) particles, poly-N-acetyl glucosamine-based polymer matrix, particles composed of polysaccharides or chemically modified polysaccharides, liposomes and lipid-based particles, particles composed of glycerol monoesters, etc. The 30 saponins may also be formulated in the presence of cholesterol to form particulate structures such as liposomes or ISCOMs. Furthermore, the saponins may be formulated together with a polyoxyethylene ether or ester, in either a non-particulate solution or

suspension, or in a particulate structure such as a paucilamellar liposome or ISCOM. The saponins may also be formulated with excipients such as Carbopol<sup>R</sup> to increase viscosity, or may be formulated in a dry powder form with a powder excipient such as lactose.

In one embodiment, the adjuvant system includes the combination of a monophosphoryl lipid A and a saponin derivative, such as the combination of QS21 and 3D-MPL<sup>®</sup> adjuvant, as described in WO 94/00153, or a less reactogenic composition where the QS21 is quenched with cholesterol, as described in WO 96/33739. Other formulations comprise an oil-in-water emulsion and tocopherol. Another adjuvant formulation employs QS21, 3D-MPL<sup>®</sup> adjuvant and tocopherol in an oil-in-water emulsion is described in WO 95/17210.

Another enhanced adjuvant system involves the combination of a CpG-containing oligonucleotide and a saponin derivative particularly the combination of CpG and QS21 as disclosed in WO 00/09159. Preferably the formulation additionally comprises an oil in water emulsion and tocopherol.

Additional illustrative adjuvants for use in the pharmaceutical compositions of the invention include Montanide ISA 720 (Seppic, France), SAF (Chiron, California, United States), ISCOMS (CSL), MF-59 (Chiron), the SBAS series of adjuvants (e.g., SBAS-2 or SBAS-4, available from SmithKline Beecham, Rixensart, Belgium), Detox (Enhanzym<sup>®</sup>) (Corixa, Hamilton, MT), RC-529 (Corixa, Hamilton, MT) and other aminoalkyl glucosaminide 4-phosphates (AGPs), such as those described in pending U.S. Patent Application Serial Nos. 08/853,826 and 09/074,720, the disclosures of which are incorporated herein by reference in their entireties, and polyoxyethylene ether adjuvants such as those described in WO 99/52549A1.

Other preferred adjuvants include adjuvant molecules of the general formula (I): HO(CH<sub>2</sub>CH<sub>2</sub>O)<sub>n</sub>-A-R, wherein n is 1-50, A is a bond or -C(O)-, R is C<sub>1-50</sub> alkyl or Phenyl C<sub>1-50</sub> alkyl.

One embodiment of the present invention consists of a vaccine formulation comprising a polyoxyethylene ether of general formula (I), wherein n is between 1 and 50, preferably 4-24, most preferably 9; the R component is C<sub>1-50</sub>, preferably C<sub>4</sub>-C<sub>20</sub> alkyl and most preferably C<sub>12</sub> alkyl, and A is a bond. The concentration of the polyoxyethylene ethers should be in the range 0.1-20%, preferably from 0.1-10%, and most preferably in the range 0.1-1%. Preferred polyoxyethylene ethers are selected from the following

group: polyoxyethylene-9-lauryl ether, polyoxyethylene-9-stearyl ether, polyoxyethylene-8-stearyl ether, polyoxyethylene-4-lauryl ether, polyoxyethylene-35-lauryl ether, and polyoxyethylene-23-lauryl ether. Polyoxyethylene ethers such as polyoxyethylene lauryl ether are described in the Merck index (12<sup>th</sup> edition: entry 7717). These adjuvant molecules are described in WO 99/52549.

The polyoxyethylene ether according to the general formula (I) above may, if desired, be combined with another adjuvant. For example, a preferred adjuvant combination is preferably with CpG as described in the pending UK patent application GB 9820956.2.

10

#### Liposome-, Nanocapsule-, and Microparticle-Mediated Delivery

In certain embodiments, the inventors contemplate the use of liposomes, nanocapsules, microparticles, microspheres, lipid particles, vesicles, and the like, for the introduction of the compositions of the present invention into the subjects. In particular, the compositions of the present invention may be formulated for delivery either encapsulated in a lipid particle, a liposome, a vesicle, a nanosphere, or a nanoparticle or the like.

Such formulations may be preferred for the introduction of pharmaceutically-acceptable formulations of the compositions disclosed herein. The formation and use of liposomes is generally known to those of skill in the art (see, for example, Couvreur *et al.*, 1977; Couvreur, 1988; Lasic, 1998; which describes the use of liposomes and nanocapsules in the targeted antibiotic therapy for intracellular bacterial infections and diseases). Recently, liposomes were developed with improved serum stability and circulation half-times (Gabizon & Papahadjopoulos, 1988; Allen and Choun, 1987; U. S. Patent 5,741,516, specifically incorporated herein by reference in its entirety). Further, various methods of liposome and liposome-like preparations as potential drug carriers have been reviewed (Takakura, 1998; Chandran *et al.*, 1997; Margalit, 1995; U. S. Patent 5,567,434; U. S. Patent 5,552,157; U. S. Patent 5,565,213; U. S. Patent 5,738,868 and U. S. Patent 5,795,587, each specifically incorporated herein by reference in its entirety).

Liposomes have been used effectively to introduce genes, drugs (Heath & Martin, 1986; Heath *et al.*, 1986; Balazs *et al.*, 1989; Fresta & Puglisi, 1996),

radiotherapeutic agents (Pikul *et al.*, 1987), enzymes (Imaizumi *et al.*, 1990a; Imaizumi *et al.*, 1990b), viruses (Faller & Baltimore, 1984), transcription factors and allosteric effectors (Nicolau & Gersonde, 1979) into a variety of cultured cell lines and animals. In addition, several successful clinical trials examining the effectiveness of liposome-mediated drug delivery have been completed (Lopez-Berestein *et al.*, 1985a; 1985b; Courne, 1988; Sculier *et al.*, 1988). Furthermore, several studies suggest that the use of liposomes is not associated with autoimmune responses, toxicity or gonadal localization after systemic delivery (Mori & Fukatsu, 1992).

Liposomes are formed from phospholipids that are dispersed in an aqueous medium and spontaneously form multilamellar concentric bilayer vesicles (also termed multilamellar vesicles (MLVs). MLVs generally have diameters of from 25 nm to 4  $\mu\text{m}$ . Sonication of MLVs results in the formation of small unilamellar vesicles (SUVs) with diameters in the range of 200 to 500 Å, containing an aqueous solution in the core.

Liposomes bear resemblance to cellular membranes and are contemplated for use in connection with the present invention as carriers for the compositions. They are widely suitable as both water- and lipid-soluble substances can be entrapped, *i.e.*, in the aqueous spaces and within the bilayer itself, respectively. It is possible that the drug-bearing liposomes may even be employed for site-specific delivery of active agents by selectively modifying the liposomal formulation.

In addition to the teachings of Couvreur *et al.* (1977, 1988), the following information may be utilized in generating liposomal formulations. Phospholipids can form a variety of structures other than liposomes when dispersed in water, depending on the molar ratio of lipid to water. At low ratios the liposome is the preferred structure. The physical characteristics of liposomes depend on pH, ionic strength and the presence of divalent cations. Liposomes can show low permeability to ionic and polar substances, but at elevated temperatures undergo a phase transition which markedly alters their permeability. The phase transition involves a change from a closely packed, ordered structure, known as the gel state, to a loosely packed, less-ordered structure, known as the fluid state. This occurs at a characteristic phase-transition temperature and results in an increase in permeability to ions, sugars and drugs.

In addition to temperature, exposure to proteins can alter the permeability of liposomes. Certain soluble proteins, such as cytochrome c, bind, deform and penetrate

the bilayer, thereby causing changes in permeability. Cholesterol inhibits this penetration of proteins, apparently by packing the phospholipids more tightly. It is contemplated that the most useful liposome formations for antibiotic and inhibitor delivery will contain cholesterol.

5           The ability to trap solutes varies between different types of liposomes. For example, MLVs are moderately efficient at trapping solutes, but SUVs are extremely inefficient. SUVs offer the advantage of homogeneity and reproducibility in size distribution. However, a compromise between size and trapping efficiency is offered by large unilamellar vesicles (LUVs). These are prepared by ether evaporation and are three  
10 to four times more efficient at solute entrapment than MLVs.

In addition to liposome characteristics, an important determinant in entrapping compounds is the physicochemical properties of the compound itself. Polar compounds are trapped in the aqueous spaces and nonpolar compounds bind to the lipid bilayer of the vesicle. Polar compounds are released through permeation or when the  
15 bilayer is broken, but nonpolar compounds remain affiliated with the bilayer unless it is disrupted by temperature or exposure to lipoproteins. Both types show maximum efflux rates at the phase transition temperature.

Liposomes interact with cells via four different mechanisms: endocytosis by phagocytic cells of the reticuloendothelial system such as macrophages and  
20 neutrophils; adsorption to the cell surface, either by nonspecific weak hydrophobic or electrostatic forces, or by specific interactions with cell-surface components; fusion with the plasma cell membrane by insertion of the lipid bilayer of the liposome into the plasma membrane, with simultaneous release of liposomal contents into the cytoplasm; and by transfer of liposomal lipids to cellular or subcellular membranes, or vice versa, without  
25 any association of the liposome contents. It often is difficult to determine which mechanism is operative and more than one may operate at the same time.

The fate and disposition of intravenously injected liposomes depend on their physical properties, such as size, fluidity, and surface charge. They may persist in tissues for hours or days, depending on their composition, and half lives in the blood  
30 range from minutes to several hours. Larger liposomes, such as MLVs and LUVs, are taken up rapidly by phagocytic cells of the reticuloendothelial system, but physiology of the circulatory system restrains the exit of such large species at most sites. They can exit

only in places where large openings or pores exist in the capillary endothelium, such as the sinusoids of the liver or spleen. Thus, these organs are the predominant site of uptake. On the other hand, SUVs show a broader tissue distribution but still are sequestered highly in the liver and spleen. In general, this *in vivo* behavior limits the potential targeting of liposomes to only those organs and tissues accessible to their large size. These include the blood, liver, spleen, bone marrow, and lymphoid organs.

Targeting is generally not a limitation in terms of the present invention. However, should specific targeting be desired, methods are available for this to be accomplished. Antibodies may be used to bind to the liposome surface and to direct the antibody and its drug contents to specific receptors located on a particular cell-type surface. Carbohydrate determinants (glycoprotein or glycolipid cell-surface components that play a role in cell-cell recognition, interaction and adhesion) may also be used as recognition sites as they have potential in directing liposomes to particular cell types. Mostly, it is contemplated that intravenous injection of liposomal preparations would be used, but other routes of administration are also conceivable.

Alternatively, the invention provides for pharmaceutically-acceptable nanocapsule formulations of the compositions of the present invention. Nanocapsules can generally entrap compounds in a stable and reproducible way (Henry-Michelland *et al.*, 1987; Quintanar-Guerrero *et al.*, 1998; Douglas *et al.*, 1987). To avoid side effects due to intracellular polymeric overloading, such ultrafine particles (sized around 0.1  $\mu\text{m}$ ) should be designed using polymers able to be degraded *in vivo*. Biodegradable polyalkyl-cyanoacrylate nanoparticles that meet these requirements are contemplated for use in the present invention. Such particles may be easily made, as described (Couvreur *et al.*, 1980; 1988; zur Muhlen *et al.*, 1998; Zambaux *et al.* 1998; Pinto-Alphandry *et al.*, 1995 and U. S. Patent 5,145,684, specifically incorporated herein by reference in its entirety).

All publications and patent applications cited in this specification are herein incorporated by reference as if each individual publication or patent application were specifically and individually indicated to be incorporated by reference.

Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, it will be readily apparent to one of ordinary skill in the art in light of the teachings of this invention that

certain changes and modifications may be made thereto without departing from the spirit or scope of the appended claims.

The following example is provided by way of illustration only and not by way of limitation. Those of skill in the art will readily recognize a variety of noncritical parameters that could be changed or modified to yield essentially similar results.

## EXAMPLES

Example 1: Construction of DNA sequences encoding human single chain MHC class II peptide complexes, HLA-DR4 molecules(CO563 and CO564).

10 DNA constructs encoding gp39  $\beta 1/\alpha 1$  human molecules were prepared from a cDNA encoding the gp39 peptide fused to the  $\beta 1/\alpha 1$  domains of HLA-DR4 according to standard techniques. For the production of "empty"  $\beta 1/\alpha 1$  DR4 molecules, a cDNA encoding the fused  $\beta 1/\alpha 1$  domains of HLA-DR4 was prepared using cloned  $\alpha$  and  $\beta$  chains from DR4.

15 Amino acid sequence of the gp39- $\beta 1/\alpha 1$  HLA-DR4 human single chain molecule (linkers are shown in bold)

MGDTGRSFTLASSETGVGASGGGGSGGGDTRPRFLEQVKHECH  
FFNGTERVRFLDRYFYHQEEYVRFSDVGEYRAVTELGRPDAEYWNSQKDLLEQ  
KRAAVDTYCRHNYGVGESFTVQRRGGIKEEHVIIQAEFYLNPDQSDFMFDFDG  
20 DEIFHVVDMAKKETVWRLEEFGRFASFEAQGALANIAVDKANLEIMTKRSNYTPIT  
N\*

aa1 - aa4: leader sequence

aa5 - aa18: gp39 peptide

aa19 - aa28: linker

25 aa29 - aa122: HLA-DR4  $\beta 1$  domain

aa123 - aa124: linker

aa125 - aa 208: HLA-DR4  $\alpha 1$  domain

Amino acid sequence of the "empty"  $\beta 1/\alpha 1$  HLA-DR4 human single chain molecule (linkers in bold):

30 MGDTPRFLEQVKHECHFFNGTERVRFLDRYFYHQEEYVRFSDVGEYRAVTEL  
GRPDAEYWNSQRDLLEQKRAAVDTYCRHNYGVGESFTVQRRGGIKEEHVIIQAE

50

FYLNPDQSGEFMFDGDEIFHVDMAKKETVWRLEFGFASFEAQGALANIAV  
DKANLEIMTKRSNYTPITN\*

aa 1 – aa95: HLA-DR4  $\beta$ 1 domain

aa96- aa97: linker

5 aa98- aa181: HLA-DR4  $\alpha$ 1 domain

For the production of recombinant proteins, the bacteria (pLysS) were grown in LB (containing ampicillin (50  $\mu$ g / ml) and chloramphenicol (5  $\mu$ g / ml)) at 37°C until OD 600 = 0.5. IPTG was added at the final concentration of 0.5 mM final and the bacteria were further incubated for 3 hours at 37°C with shaking. The bacteria were 10 centrifuged at 4°C, 4000xg for 20 min and the pellet was frozen at -80°C. The following day, the pellet was resuspended in 40 ml of lysis buffer (50 mM Tris-HCl pH 8, 50 mM NaCl, 2 mM EDTA, 1 protease inhibitor cocktail tablet, 1% Triton X100 and 1% deoxycholate), and incubated for 1 hour at 4°C under continuous agitation with a magnetic stirrer. The sample was then homogenized using a French Press with a 16,000 15 psi setting, and centrifuged at 4°C, 9000g for 20 min. The pellet was then resuspended in 30 ml of lysis buffer without Triton and deoxycholate and centrifuged at 4°C, 9000 g for 20 min. The new pellet was resuspended in 10 ml of 20 mM ethanolamine/6 M urea pH 10, and eventually frozen at -80°C. The recombinant protein was then purified by FPLC 20 ion-exchange chromatography using Source 30Q anion-exchange media in an XK26/20 column using a step gradient going from 1 mM to 1 M NaCl in 20 mM ethanolamine/6M urea pH 10. Fractions were analyzed by SDS/PAGE and those corresponding to the proteins of interest are pooled and dialyzed against PBS 1X.

Example 2: Production of additional single chain constructs

25 Additional constructs with different composition and length of the 2<sup>nd</sup> linker (between  $\beta$ 1 and  $\alpha$ 1) were engineered by using standard techniques using CO567 as the template. Specifically, PCR primers were designed to replace the old sequence in CO567 with the new sequence. For example, to make CO581, the primers were designed with the following sequences (note these primers were phosphorylated at 5').

30 Primer 1:

5' pCACCAAGGAGGAGAGCCGCCACGCCGGTCTCGCTGG

Primer 2:

51

5' pGACCACCTGGATCTGGGGACACCCGACCACGTTTC

PCR reaction (100 µl) was made of the following components: 2 µl CO567 (80 ng) as template, 2 µl each of primer 1 and primer 2 (10 µM), 2 µl of dNTP mix (20 mM each), 10 µl of 10X pfu buffer, and 80 µl of sterile water. After all the  
5 components were mixed, 2 µl of Turbo pfu (5U total) was added, mixed and put on PCR machine. The PCR cycles has a pre-denaturation at 95°C for 30 sec, then 10 cycles of 95°C for 30°C, 60°C for 1 min, and 72°C for 7 min. Then another 22 cycles of 95°C for 30°C, 65°C for 1 min and 72°C for 7 min, followed by a final 10 min at 72°C.

The PCR mixture was digested with 2 µl of DpnI (10U) for 2h at 37°C.  
10 Then the PCR product at ~6 kb was purified from agarose gel after electrophoresis. The purified PCR product was ligated by T4 DNA ligase for 1 h at room temperature then used to transform into NovaBlue (Novagen)competent cells by standard protocol. Cells were plated on LB (+Carb) and grow overnight at 37°C.

15 Next day, about a dozen single colony from the transformation were randomly picked for overnight culture in 5 ml LB (+Carb) at 37°C. Plasmids from these culture were purified with Wizard Miniprep kit, and analyzed by Xho I digestion. A few plasmids that passed the Xho I digestion were further confirmed by DNA sequencing.

To express the recombinant proteins, a clone with confirmed DNA sequence was used to transform BL21(DE3)CodonPlus-RIL (Stratagene) by standard  
20 transformation protocol and plated on LB (Carb+Cam) plates overnight at 37°C. Next morning, a single colony was picked to inoculate 100 ml LB (+Carb+Cam) and the culture was grown till OD reach between 0.8-1.0, and stored overnight at 4°C. Next day, the culture was pellet down and used to inoculate into 2xYT (+Carb+Cam) at ratio of 25 ml culture per liter new media. These large cultures were grown at 37°C till OD=0.5-0.6,  
25 and IPTG was added to induce recombinant protein at 37°C for 3 h. The induced cultures were pellet and stored at -80°C till purification.

Table 1 provides a listing of various constructs made according to the invention.

52  
TABLE I

<b>Construct</b>	<b>peptide</b>	<b>upstream linker</b>	<b>downstream linker</b>
C0523	yes	GGGG	GG
C0543	none	none	GG
C0563	yes	ASGGGSGGG	GG
C0567	yes	ASGGGSGGG	TSGGGGSGGGGSSS
C0580	yes	ASGGGSGGG	GSPGGGSGGGPGS
C0581	yes	ASGGGSGGG	GSPPGGPPGS
C0582	yes	ASGGGSGGG	GSPGGGGPGS
C0583	yes	ASGGGSGGG	TSGGGGS
C0584	yes	ASGGGSGGG	SGGSGGS
C0585	yes	ASGGGSGGG	FDAPSPLP
C0586	none	none	TSGGGGSGGGGSSS
C0587	none	none	GSPGGGGSGGGPGS
C0588	none	none	GSPPGGPPGS
C0589	none	none	GSPGGGGPGS
C0590	none	none	TSGGGGS
C0591	none	none	SGGSGGS
C0592	none	none	FDAPSPLP
C0593	yes	ASGGGSGGG	VYPEVTY
C0594	none	none	VYPEVTY
C0595	yes	ASGGGSGGG	GGGG
C0596	yes	ASGGGSGGG	GGGGS
C0597	yes	ASGGGSGGG	GGGSGG

Example 3: Four classes of novel linkers for MHC class II single chain molecules

Inspection of circular dichroism spectra of purified, refolded single chain constructs indicated that novel linkers could be used for the constructs. The atomic structures of the various murine and human MHC class II molecules, as determined by X-ray crystallography, indicated that these molecules have a high degree of structural similarity. The circular dichroism results were consistent with two folded molecules of clearly different secondary structure. Careful inspection of the structures reveals that the human MHC has a longer distance between chains than the equivalent murine molecule. This results led to proposing longer linkers between the chains which would contain flexible residues (e.g. alanine or glycine) and polar residues (e.g. serine and threonine). These constructs make up the first class of linkers. To inhibit the continuation of secondary structure across the linker, prolines were added to bracket the linkers. These prolines are known to inhibit the formation of alpha helices and beta sheets. These linkers make up the second class of linkers disclosed here.

Next, flexible regions present in the human MHC and in the murine MHC could be used to make a linker by extending the region of interest and ligating the ends together. These are the third class of linkers. Finally, a combination of these types of linkers could also be used. These are the fourth class of linkers.

Example 4: Human MHC class II single chain molecule with murine linkers

Another linker has been suggested based on a combination of murine and human MHC class II single chain molecules. This fusion would incorporate linker residues from the functional murine single chain MHC class II molecule and the alpha and beta chains of the human molecule. The protein sequence of the single chain molecule is provided below (the linker residues from the mouse construct are in bold):  
MGDTGRSFTLASSETGVGASGGGGSGGGDTRPRFLEQVKHECHFFNGTERVRF  
LDRYFYHQEEYVRFSDVGEGYRAVTELGRPDAEYWNSQKDLLEQKRAAVDTYC  
RHNYGVGESFTVLRRLLGGEDDEADHHVIIQAEFYLNPDQSGEFMFDFDGDEIFH  
VDMAKKETVWRLEEFGRFASFEAQGALANIAVDKANLEIMTKRSNYTPITN\*

Further MHC class II hybrid single chain molecules may be designed by fusing other portions of the alpha chain and the beta chain together using linkers as described elsewhere. A properly folded molecule may be obtained by putting appropriate

linkers between portions of the human MHC class II which are proximal to each other as determined by visual inspection of the atomic coordinates of residues of the native MHC available in the publicly accessible protein structure database. These structures would predict possible fusion proteins which covalently attach any part of the beta chain  
5 between residues 82 to 123 or between residues 148 to 164 to portions of the alpha chain such as the N-terminal residues, residues 79 to 84, or 92 to 106. The numbering system of residues in this example corresponds to those found in the coordinates of the structure described in: DESSEN, *et al.* *Immunity* 7:473 (1997). Other, homologous residues could be used to create equivalent constructs for genotypic and allelic variants of these  
10 molecules e.g. equivalent residues in DR2 or such. DNAs for such hybrids would be prepared and expressed in a recombinant expression system by someone skilled in the art and could be assayed for structure and function in appropriate assays.

Example 5: Use of CD4 binding site(s) of MHC class II molecules as linkers for the  
15 production of bioactive recombinant MHC class II:peptide complexes

HLA class II molecules present antigenic peptides to the T cell receptor of the CD4+ T lymphocytes and interact with CD4 during the antigen recognition process. Native MHC class II-peptide complexes have been shown to bind to MHC class II restricted and antigen specific TCRs on a particular T cell and induce T cell  
20 nonresponsiveness. It is proposed that the CD4 binding site is important in the docking of MHC class II-peptide complex with the TCR and induce nonresponsiveness. Since the binding of CD4 to MHC class II-peptide is important in antigen presentation and/or induction of T cell nonresponsiveness, it is proposed that recombinant MHC class II-peptide molecules (truncated or whole) containing CD4 binding site will be biologically  
25 active. Furthermore, a polypeptide fragment from MHC class II which binds the CD4, when used as a linker in preparation of MHC class II-peptide truncated molecules, provides resulting recombinant molecules that will be biologically active.

The following describes the concept of different linkers. Peptide is attached to a linker 1 (L1) which is attached to N-terminus of  $\beta$ 1 domain that is linked to  
30 L2. L2 is linked to L3, which in turn is linked to N-terminus of  $\alpha$ 1 chain of MHC class II. Here L2 represents the human CD4 binding sequences. It should be noted that L2 could also be directly linked to N-terminus of  $\alpha$ 1 domain by completely deleting L3.

Specific examples of L1 and L3 are given in a examples. The sequences of L2 are given below. These sequences are applicable to most of the DR-Peptide molecules.

RNGQEEKAGVVSTGLI, RNGQETKAGVVSTGLI, YNQQEEKAGGVSTGLI,  
FRNGQEEKAGVVSTGLI, FRNGQETKAGVVSTGLI, FYNQQEEKAGGVSTGLI,

5 and LNGQEEKAGMVSTGLI.

Example 6: I-As MBP. $\beta$ 1 $\beta$ 2 $\alpha$ 1 $\alpha$ 2.C $\kappa$  construct and activity

The “full anergix” single chain molecule, mouse I-As MBP. $\beta$ 1 $\beta$ 2 $\alpha$ 1 $\alpha$ 2.C $\kappa$ , was generated by overlap PCR using standard methodology. The molecules was expressed in 293T cells and baculoviral cells according to standard methodology, and purified according to standard methodology using affinity chromatography using goat-anti mouse antibodies. The structure of I-As MBP. $\beta$ 1 $\beta$ 2 $\alpha$ 1 $\alpha$ 2.C $\kappa$  is shown in Figure 1.

The amino acid sequence of the I-As MBP. $\beta$ 1 $\beta$ 2 $\alpha$ 1 $\alpha$ 2.C $\kappa$  shown in Figure 1 is as follows:

15 METDTLLLWVLLLWVPGSTGDFKNIVTPRTPPPASGGGGSGGGDSERHFVFQF  
KGECYFTNGTQRIRSVDRYTYNREEYLRFDSVDGEYRAVTELGRPDPEYYNKQY  
LEQTRAELDTVCRHNYEGVETHSLRRLEQPNVVISLSRTEALNHHTLVCSVTD  
FYPAKIKVRWFRNGQEETVGVSSTQLIRNGDWTFQVLVMLEMPRRGEVYTCH  
VEHPSLKSPITVEWTSGGGSGGGSGGGSSSEDDIEADHVGVYGTIV  
20 YQSPGDIGQYTHEFDGDEWFYVDLDKKETIWMLPEFGQLTSFDPQGGLQNIATG  
KYTLGILTKRSNSTPATNEAPQATVFPKSPVLLGQPNTLICFVDNIFPPVINITWLR  
NSKSVTDGVYETSLVNRDHSHFKLSYLTFLPSDDDIYDCKVEHWGLEEPVLKHW  
ASGGGGSGGGADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVWKIDG  
SERQNGVLNSWTDQDSKDSTYSMSSTLTKEYERHNSYTCEATHKTSTSPIVK  
25 SFNRNEC

The *in vitro* activity of recombinant I-As MBP. $\beta$ 1 $\beta$ 2 $\alpha$ 1 $\alpha$ 2.C $\kappa$  was tested using MBP90-101 specific IAs restricted mouse T cell clone HS1. This clone was prepared by the immunization of SJL mice with the MBP90-101 peptide, followed by cloning out CD4+ T cells by limited dilution techniques. These cells were maintained by stimulation every 10 days with irradiated SJF splenocytes and PBP90-101 peptide. The T cells are activated by a combination of soluble recombinant I-As MBP. $\beta$ 1 $\beta$ 2 $\alpha$ 1 $\alpha$ 2.C $\kappa$  and plate bound anti-CD28 antibody. T cell activation was assayed by  $^3$ H-thymidine

56

incorporation according to standard methodology. Figure 2 shows the results of this assay.

MS is a T cell dependent autoimmune disease caused by localized demyelination in the central nervous system. Experimental autoimmune encephalomyelitis is a accepted animal model of MS. The following results demonstrate that administration of I-As MBP. $\beta$ 1 $\beta$ 2 $\alpha$ 1 $\alpha$ 2.Ck reduces the incidence and severity of EAE. EAE was induced according to standard methodology according to the myelin model. Ten  $\mu$ g of recombinant I-As MBP. $\beta$ 1 $\beta$ 2 $\alpha$ 1 $\alpha$ 2.Ck was given intravenously in 100  $\mu$ l of PBS at days 1, 4, 7, and 11 after disease induction. 12 days after immunization, animals are observed daily for the onset of neurological dysfunction. Disease is graded by trained technicians according to standard methods (see Figure 3). Mice are followed for up to 60-70 days. The data shown in Figure 4 demonstrate that administration of the recombinant I-As MBP. $\beta$ 1 $\beta$ 2 $\alpha$ 1 $\alpha$ 2.Ck significantly reduced the incidence of myelin-induced EAE in SJL mice. In one experiment, 11 out of 20 mice developed EAE in the untreated group (55%), whereas only 2 out of 21 animal showed sign of the disease in the treated group (16.6%). Similarly, in another experiment, 12 out of 16 mice developed EAE in the untreated group (75%), while only 2 out of 16 developed EAE in the treated group (12.5%).

Histological examination from SJL mice in the EAE model studies: spinal cords were removed, fixed in formalin solution and embedded in paraffin. Sections were cut, stained with hematoxylin, eosin and graded for inflammatory lesions. A. Section of spinal cord from untreated mouse, score = 2.5; B. Section of spinal cord from mouse treated with the recombinant I-AS.MBP.Ck, score = 0; C. Section of spinal cord from mouse treated with the recombinant I-AS. $\beta$ 1 $\alpha$ 1 without antigenic peptide fusion, score = 2.0; D. Section of spinal cord from mouse treated with the recombinant I-AS.MBP. $\beta$ 1 $\alpha$ 1, score = 0.5. The histology score for each section is marked.

Example 7: Functional human anergix molecules optimized for *E. coli* expression with *E. coli* codons

Two human single chain MHC class II molecules (CO528-AC and CO608-AC) have been optimized for *E. coli* expression using "artificial codons," e.g.,

preferred *E. coli* codons encoding the mammalian protein. CO528-AC and CO608-AC were made according to standard PCR overlap technology.

Example 7: Recombinant MHC class II IAs-MBP-Ig multimeric complexes

5           Recombinant MHC class II (IAs)-peptide-Ig fusion complexes were constructed by fusing the mIgG leader, MBP 90-101, or MBP1-14 (as a control) to IAs single chain (b1b2a1a2), and mIgG.Ck, mIgG.CH1.H, mIgG.CH1.H.CH2, or mIgG.CH1.H.CH2.CH3 with flexible linkers, according to standard methodology. The recombinant IAs fusion proteins were expressed in both mammalian and insect cells and  
10          detected by western analysis and ELISA. The overexpressed and secreted recombinant IAs fusion proteins from both human 293 cell cultures or from insect culture medium were purified by affinity chromatography. The purified dimeric and tetrameric recombinant IAs proteins have *in vitro* biological activity as assayed using an antigen-specific mouse T cell clone. The *in vivo* activity of the recombinant IAs fusion proteins  
15          were studied with the experimental autoimmune encephalomyelitis (EAE) model using susceptible SJL mice. In these EAE studies, recombinant IAs fusion protein was delivered on days 1, 4, 7, and 11 by I.V. injections after induction of the disease with myelin. The animals were then examined for neurological dysfunction. The results indicate that treatment with the recombinant IAs fusion proteins prevents mortality and  
20          significantly reduces paralysis induced by myelin homogenate in CFA. In conclusion, these studies suggest that the recombinant MHC class II fusion protein has therapeutic benefit as antigen-specific drugs for the treatment of autoimmune diseases.

Example 8: Synthesis of mouse model equivalent of CO608

25          Four forms of the murine MHC Class II IAs  $\beta 1\alpha 1$  with MBP peptide linkers analogous to CO608 human were made. These constructs can be used, e.g., as murine clinical control for human 608. mCO608 (mouse CO608, lacking the first five amino acids, GDSER, as compared to native beta 1 domain), MCO608-A (same as m608 except lacking four amino acids, GSER, after the methionine as compared to m608), B.  
30          megaterium-mCO608-A (expressed in *Bacillus megaterium*), and mCO608-B (same as m608 except lacking first four amino acids, GSER, after the methionine as compared to m608; also lacking second amino acid, D, as compared to native beta 1 domain).

To make mCO608, the upstream linker of mouse CO521 (GGGS) was replaced with the human CO608 linker (ASGGGGSGGG) and the downstream linker of mouse CO521 (GG) was replaced with the downstream linker of CO608 (TSGGGGS), using PCR according to standard methodology. mCO608-A and m6O8-B were made  
5 from mCO608 using PCR according to standard methodology.

All publications and patent applications cited in this specification are herein incorporated by reference as if each individual publication or patent application were specifically and individually indicated to be incorporated by reference.

10 Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, it will be readily apparent to one of ordinary skill in the art in light of the teachings of this invention that certain changes and modifications may be made thereto without departing from the spirit or scope of the appended claims.

## SEQUENCE LISTING

5       <210> C0602  
 <211> 558  
 <212> DNA  
 <213> Homo sapiens

10      atgggggaca cccgaccacg tttcttggag caggttaaac atgagtgtca tttcttcaac 60  
 gggacggagc ggggtgcgggtt cctggacaga tacttttatac accaagagga gtacgtgcgc 120  
 ttcgacagcg acgtggggga gtaccgggcgt gtgacggagc tggggcggcc tgatgccgag 180  
 tactggaaaca gccagaagga cctcctggag cagaagcggg ccgcgggtgga cacctactgc 240  
 agacacaact acgggggttgg tgagagcttc acagtgtgc ggcgactcgg aggtgaagat 300  
 gacgaggcgat atcaccatgt gatcatccag gcccgggttct atctgaatcc tgaccaatca 360  
 15      ggcgagttta tggttgactt tgatgggtgat gagattttcc atgtggatat ggcaaagaag 420  
 gagacggctct ggccggcttga agaatttggaa cgatttgcca gctttgagggc tcaaggtgca 480  
 ttggccaaca tagctgtggaa caaagccaaac ctggaaatca tgacaaaagcg ctccaaactat 540  
 actccgatca ccaattaa 558

20      <210> C0601  
 <211> 558  
 <212> DNA  
 <213> Homo sapiens

25      atgggggaca cccgaccacg tttcttggag caggttaaac atgagtgtca tttcttcaac 60  
 gggacggagc ggggtgcgggtt cctggacaga tacttttatac accaagagga gtacgtgcgc 120  
 ttcgacagcg acgtggggga gtaccgggcgt gtgacggagc tggggcggcc tgatgccgag 180  
 tactggaaaca gccagaagga cctcctggag cagaagcggg ccgcgggtgga cacctactgc 240  
 agacacaact acgggggttgg tgagagcttc acagtgcagc ggcgaggagg tggaaagcggc 300  
 30      ggaatcaaag aagaacatgt gatcatccag gcccgggttct atctgaatcc tgaccaatca 360  
 ggcgagttta tggttgactt tgatgggtgat gagattttcc atgtggatat ggcaaagaag 420  
 gagacggctct ggccggcttga agaatttggaa cgatttgcca gctttgagggc tcaaggtgca 480  
 ttggccaaca tagctgtggaa caaagccaaac ctggaaatca tgacaaaagcg ctccaaactat 540  
 actccgatca ccaattaa 558

35      <210> C0600  
 <211> 555  
 <212> DNA  
 <213> Homo sapiens

40      atgggggaca cccgaccacg tttcttggag caggttaaac atgagtgtca tttcttcaac 60  
 gggacggagc ggggtgcgggtt cctggacaga tacttttatac accaagagga gtacgtgcgc 120  
 ttcgacagcg acgtggggga gtaccgggcgt gtgacggagc tggggcggcc tgatgccgag 180  
 tactggaaaca gccagaagga cctcctggag cagaagcggg ccgcgggtgga cacctactgc 240  
 45      agacacaact acgggggttgg tgagagcttc acagtgcagc ggcgaggagg tggaggcagc 300  
 atcaaagaag aacatgtgat catccaggcc gagtttatac tgaatcctga ccaatcaggc 360  
 gagtttatgt ttgactttga tgggtgatgag attttccatg tggatatggc aaagaaggag 420  
 acggcttggc ggcttgaaga atttggacga tttgcacgt ttgaggctca aggtgcattg 480  
 gccaacatacg ctgtggacaa agccaaacctg gaaatcatga caaagcgcctc caactatact 540  
 50      ccgatcacca attaa 555

<210> C0599  
 <211> 552  
 <212> DNA  
 55      <213> Homo sapiens

atgggggaca cccgaccacg tttcttggag caggttaaac atgagtgtca tttcttcaac 60

60

gggacggagc ggggtgcgggtt cctggacaga tactttatc accaagagga gtacgtgcgc 120  
 ttcgacagcg acgtggggga gtaccgggccc gtgacggagc tggggcgccc tgatgccgag 180  
 tactggaaaca gccagaagga cctcctggag cagaagcggg ccgcgggtgga cacctactgc 240  
 agacacaact acgggggttgg tgagagcttc acagtgcagc ggccgaggagg tggaggcattc 300  
 5 aaagaagaac atgtgatcat ccaggccgag ttctatctga atcctgacca atcaggcgag 360  
 tttatgtttg actttgatgg tgatgagatt ttccatgtgg atatggcaaa gaaggagacg 420  
 gtctggcgcc ttgaagaatt tgacgattt ggcagctttg aggctcaagg tgcattggcc 480  
 aacatagctg tggacaaagc caacctggaa atcatgacaa agcgtccaa ctatactccg 540  
 atcaccaatt aa 552

10 <210> C0594  
 <211> 561  
 <212> DNA  
 <213> Homo sapiens

15 atgggggaca cccgaccacg tttcttggag caggttaaac atgagtgtca tttcttcaac 60  
 gggacggagc ggggtgcgggtt cctggacaga tactttatc accaagagga gtacgtgcgc 120  
 ttcgacagcg acgtggggga gtaccgggccc gtgacggagc tggggcgccc tgatgccgag 180  
 tactggaaaca gccagaagga cctcctggag cagaagcggg ccgcgggtgga cacctactgc 240  
 20 agacacaact acgggggttgg tgagagcttc acagtgcagc ggccgaggatc ccctgaggta 300  
 actgtcatca aagaagaaca tttgtatcatc caggccgagt tctatctgaa tcctgaccaa 360  
 tcaggcgagt ttatgtttga ctttgtatggt gatgagattt tccatgtgg tatggcaaaag 420  
 aaggagacgg tctggcggtt tgaagaattt ggacgattt ggcagctttg ccagcttga ggctcaagg 480  
 25 gcattggcca acatagctgt ggacaaagcc aacctggaaa tcatgacaaa ggcgtccaaac 540  
 tatactccga tcaccaatta a 561

<210> C0592  
 <211> 564  
 <212> DNA  
 <213> Homo sapiens

30 atgggggaca cccgaccacg tttcttggag caggttaaac atgagtgtca tttcttcaac 60  
 gggacggagc ggggtgcgggtt cctggacaga tactttatc accaagagga gtacgtgcgc 120  
 ttcgacagcg acgtggggga gtaccgggccc gtgacggagc tggggcgccc tgatgccgag 180  
 tactggaaaca gccagaagga cctcctggag cagaagcggg ccgcgggtgga cacctactgc 240  
 35 agacacaact acgggggttgg tgagagcttc acagtgcagc ggccgatttca cgcaccttagc 300  
 ccactccccaa tcaaaaaga acaatgtgatc atccaggccg agtttatctt gaatccctgac 360  
 caatcaggcg agtttatgtt tgactttgtt ggtgtatgaga tttccatgtt ggatatggca 420  
 aagaaggaga cggctctggcg gcttgaagaa tttggacgat ttgccagctt tgaggctcaa 480  
 40 ggtgcattgg ccaacatagc tttggacaaa gccaacctgg aaatcatgac aaagcgctcc 540  
 aactatactc cgatcaccaaa tttaa 564

<210> C0591  
 <211> 561  
 <212> DNA  
 <213> Homo sapiens

45 atgggggaca cccgaccacg tttcttggag caggttaaac atgagtgtca tttcttcaac 60  
 gggacggagc ggggtgcgggtt cctggacaga tactttatc accaagagga gtacgtgcgc 120  
 50 ttcgacagcg acgtggggga gtaccgggccc gtgacggagc tggggcgccc tgatgccgag 180  
 tactggaaaca gccagaagga cctcctggag cagaagcggg ccgcgggtgga cacctactgc 240  
 agacacaact acgggggttgg tgagagcttc acagtgcagc ggccgaggatg ccgtatgtgc 300  
 ggtgtatca aagaagaaca tttgtatcatc caggccgagt tctatctgaa tcctgaccaa 360  
 tcaggcgagt ttatgtttga ctttgtatggt gatgagattt tccatgtgg tatggcaaaag 420  
 55 aaggagacgg tctggcggtt tgaagaattt ggacgattt ggcagctttg ccagcttga ggctcaagg 480  
 gcattggcca acatagctgt ggacaaagcc aacctggaaa tcatgacaaa ggcgtccaaac 540  
 tatactccga tcaccaatta a 561

<210> C0590

&lt;211&gt; 561

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

5 atgggggaca cccgaccacg tttcttggag caggtaaac atgagtgtca tttcttcaac 60  
 gggacggagc ggggtcggtt cctggacaga tacttctatc accaagagga gtacgtgcgc 120  
 ttcgacagcg acgtggggga gtaccggcg gtgacggagc tggggcgccc tgatgccgag 180  
 tactggaaaca gccagaagga cctcctggag cagaagcggg ccgcgggtgga cacctactgc 240  
 agacacaact acggggttgg tgagagcttc acagtgcagc ggcgaacttag tggtggcggt 300  
 10 ggcagcatca aagaagaaca tgtgatcatc caggccgagt tctatctgaa tcctgaccaa 360  
 tcagggcgagt ttatgttga ctttgatggt gatgagattt tccatgtgaa tatggcaaag 420  
 aaggagacgg tctggcgct tgaagaattt ggacgatttg ccagcttga ggctcaaggt 480  
 gcattggcca acatagctgt ggacaaagcc aacctggaaa tcatgacaaa ggcgtccaac 540  
 tatactccga tcaccaatta a 561

15

&lt;210&gt; CO589

&lt;211&gt; 570

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

20

atgggggaca cccgaccacg tttcttggag caggtaaac atgagtgtca tttcttcaac 60  
 gggacggagc ggggtcggtt cctggacaga tacttctatc accaagagga gtacgtgcgc 120  
 ttcgacagcg acgtggggga gtaccggcg gtgacggagc tggggcgccc tgatgccgag 180  
 tactggaaaca gccagaagga cctcctggag cagaagcggg ccgcgggtgga cacctactgc 240  
 25 agacacaact acggggttgg tgagagcttc acagtgcagc ggcgagggtc tcctggaggt 300  
 ggaggtcctg gatctatcaa agaagaacat gtgatcatcc aggccgagtt ctatctgaat 360  
 cctgaccaat caggcgagtt tatgtttgac tttgatggtg atgagattt ccatgtggat 420  
 atggcaaaga aggagacggt ctggcggtt gaagaattt gacgatttg cagctttgag 480  
 gctcaaggtg cattggccaa catagctgtg gacaaagcca acctggaaat catgacaaaag 540  
 30 cgctccaact atactccgat caccaattaa 570

&lt;210&gt; CO588

&lt;211&gt; 570

&lt;212&gt; DNA

35

&lt;213&gt; Homo sapiens

atgggggaca cccgaccacg tttcttggag caggtaaac atgagtgtca tttcttcaac 60  
 gggacggagc ggggtcggtt cctggacaga tacttctatc accaagagga gtacgtgcgc 120  
 ttcgacagcg acgtggggga gtaccggcg gtgacggagc tggggcgccc tgatgccgag 180  
 40 tactggaaaca gccagaagga cctcctggag cagaagcggg ccgcgggtgga cacctactgc 240  
 agacacaact acggggttgg tgagagcttc acagtgcagc ggcgagggtc tcctcctgg 300  
 ggaccacctg gatctatcaa agaagaacat gtgatcatcc aggccgagtt ctatctgaat 360  
 cctgaccaat caggcgagtt tatgtttgac tttgatggtg atgagattt ccatgtggat 420  
 atggcaaaga aggagacggt ctggcggtt gaagaattt gacgatttg cagctttgag 480  
 45 gctcaaggtg cattggccaa catagctgtg gacaaagcca acctggaaat catgacaaaag 540  
 cgctccaact atactccgat caccaattaa 570

&lt;210&gt; CO587

&lt;211&gt; 582

50

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

atgggggaca cccgaccacg tttcttggag caggtaaac atgagtgtca tttcttcaac 60  
 gggacggagc ggggtcggtt cctggacaga tacttctatc accaagagga gtacgtgcgc 120  
 ttcgacagcg acgtggggga gtaccggcg gtgacggagc tggggcgccc tgatgccgag 180  
 tactggaaaca gccagaagga cctcctggag cagaagcggg ccgcgggtgga cacctactgc 240  
 agacacaact acggggttgg tgagagcttc acagtgcagc ggcgagggtg tccaggcggt 300  
 ggcgggagcg ggcgggttcc tgggagtatc aaagaagaac atgtgatcat ccaggccgag 360  
 55 ttctatctga atcctgacca atcaggcgag tttatgtttg actttgatgg tgatgagatt 420

62

ttccatgtgg atatggcaaa gaaggagacg gtctggcggc ttgaagaatt tggacgattt 480  
 gccagcttg aggctcaagg tgattggcc aacatacgctg tggacaaaagc caacctggaa 540  
 atcatgacaa agcgctccaa ctatactccg atcaccaatt aa 582

5 &lt;210&gt; C0586

&lt;211&gt; 582

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

10 atggggaca cccgaccacg tttcttggag caggttaaac atgagtgtca tttcttcaac 60  
 gggacggagc ggggtgcgggtt cctggacaga tacttctatac accaagagaga gtacgtgcgc 120  
 ttcgacagcg acgtggggga gtaccggcgc gtgacggagc tggggcggcc tgatgccgag 180  
 tacttggaca gccagaagga cctcctggag cagaagcggg cccgcgggtgaa cacctactgc 240  
 agacacaact acggggttgg tgagagcttc acagtgcagc ggcgaactag tggtggcggt 300  
 15 ggcagcggcg gtgggtggttc ctcgagtatac aaagaagaac atgtgatcat ccagggccgag 360  
 ttctatctga atcctgacca atcaggcgag tttatgtttg actttgatgg tgatgagatt 420  
 ttccatgtgg atatggcaaa gaaggagacg gtctggcggc ttgaagaatt tggacgattt 480  
 gccagcttg aggctcaagg tgattggcc aacatacgctg tggacaaaagc caacctggaa 540  
 atcatgacaa agcgctccaa ctatactccg atcaccaatt aa 582

20 &lt;210&gt; C0602

&lt;211&gt; 186

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

25

Met	Gly	Asp	Thr	Arg	Pro	Arg	Phe	Leu	Glu	Gln	Val	Lys	His	Glu	Cys
5															15

30

His	Phe	Phe	Asn	Gly	Thr	Glu	Arg	Val	Arg	Phe	Leu	Asp	Arg	Tyr	Phe
20															30

Tyr	His	Gln	Glu	Glu	Tyr	Val	Arg	Phe	Asp	Ser	Asp	Val	Gly	Glu	Tyr
35															45

35

Arg	Ala	Val	Thr	Glu	Leu	Gly	Arg	Pro	Asp	Ala	Glu	Tyr	Trp	Asn	Ser
50															60

Gln	Lys	Asp	Leu	Leu	Glu	Gln	Lys	Arg	Ala	Ala	Val	Asp	Thr	Tyr	Cys
65															80

40

Arg	His	Asn	Tyr	Gly	Val	Gly	Glu	Ser	Phe	Thr	Val	Leu	Arg	Arg	Leu
85															95

45

Gly	Gly	Glu	Asp	Asp	Glu	Ala	Asp	His	His	Val	Ile	Ile	Gln	Ala	Glu
100															110

Phe	Tyr	Leu	Asn	Pro	Asp	Gln	Ser	Gly	Glu	Phe	Met	Phe	Asp	Phe	Asp
115															125

50

Gly	Asp	Glu	Ile	Phe	His	Val	Asp	Met	Ala	Lys	Lys	Glu	Thr	Val	Trp
130															140

Arg	Leu	Glu	Glu	Phe	Gly	Arg	Phe	Ala	Ser	Phe	Glu	Ala	Gln	Gly	Ala
145															160

55

Leu	Ala	Asn	Ile	Ala	Val	Asp	Lys	Ala	Asn	Leu	Glu	Ile	Met	Thr	Lys
165															175

Arg	Ser	Asn	Tyr	Thr	Pro	Ile	Thr	Asn
-----	-----	-----	-----	-----	-----	-----	-----	-----

	180	185	63
5	<210> CO601 <211> 186 <212> PRT <213> Homo sapiens		
10	Met Gly Asp Thr Arg Pro Arg Phe Leu Glu Gln Val Lys His Glu Cys 5 10 15		
	His Phe Phe Asn Gly Thr Glu Arg Val Arg Phe Leu Asp Arg Tyr Phe 20 25 30		
15	Tyr His Gln Glu Glu Tyr Val Arg Phe Asp Ser Asp Val Gly Glu Tyr 35 40 45		
20	Arg Ala Val Thr Glu Leu Gly Arg Pro Asp Ala Glu Tyr Trp Asn Ser 50 55 60		
	Gln Lys Asp Leu Leu Glu Gln Lys Arg Ala Ala Val Asp Thr Tyr Cys 65 70 75 80		
25	Arg His Asn Tyr Gly Val Gly Glu Ser Phe Thr Val Gln Arg Arg Gly 85 90 95		
	Gly Gly Ser Gly Gly Ile Lys Glu Glu His Val Ile Ile Gln Ala Glu 100 105 110		
30	Phe Tyr Leu Asn Pro Asp Gln Ser Gly Glu Phe Met Phe Asp Phe Asp 115 120 125		
	Gly Asp Glu Ile Phe His Val Asp Met Ala Lys Lys Glu Thr Val Trp 130 135 140		
35	Arg Leu Glu Glu Phe Gly Arg Phe Ala Ser Phe Glu Ala Gln Gly Ala 145 150 155 160		
40	Leu Ala Asn Ile Ala Val Asp Lys Ala Asn Leu Glu Ile Met Thr Lys 165 170 175		
	Arg Ser Asn Tyr Thr Pro Ile Thr Asn 180 185		
45	<210> CO600 <211> 185 <212> PRT <213> Homo sapiens		
50	Met Gly Asp Thr Arg Pro Arg Phe Leu Glu Gln Val Lys His Glu Cys 5 10 15		
55	His Phe Phe Asn Gly Thr Glu Arg Val Arg Phe Leu Asp Arg Tyr Phe 20 25 30		
	Tyr His Gln Glu Glu Tyr Val Arg Phe Asp Ser Asp Val Gly Glu Tyr 35 40 45		

64

	Arg Ala Val Thr Glu Leu Gly Arg Pro Asp Ala Glu Tyr Trp Asn Ser			
50	55	60		
5	Gln Lys Asp Leu Leu Glu Gln Lys Arg Ala Ala Val Asp Thr Tyr Cys			
	65	70	75	80
	Arg His Asn Tyr Gly Val Gly Glu Ser Phe Thr Val Gln Arg Arg Gly			
	85	90	95	
10	Gly Gly Gly Ser Ile Lys Glu Glu His Val Ile Ile Gln Ala Glu Phe			
	100	105	110	
	Tyr Leu Asn Pro Asp Gln Ser Gly Glu Phe Met Phe Asp Phe Asp Gly			
	115	120	125	
15	Asp Glu Ile Phe His Val Asp Met Ala Lys Lys Glu Thr Val Trp Arg			
	130	135	140	
20	Leu Glu Glu Phe Gly Arg Phe Ala Ser Phe Glu Ala Gln Gly Ala Leu			
	145	150	155	160
	Ala Asn Ile Ala Val Asp Lys Ala Asn Leu Glu Ile Met Thr Lys Arg			
	165	170	175	
25	Ser Asn Tyr Thr Pro Ile Thr Asn			
	180			
	<210> C0599			
30	<211> 184			
	<212> PRT			
	<213> Homo sapiens			
35	Met Gly Asp Thr Arg Pro Arg Phe Leu Glu Gln Val Lys His Glu Cys			
	5	10	15	
	His Phe Phe Asn Gly Thr Glu Arg Val Arg Phe Leu Asp Arg Tyr Phe			
	20	25	30	
40	Tyr His Gln Glu Glu Tyr Val Arg Phe Asp Ser Asp Val Gly Glu Tyr			
	35	40	45	
	Arg Ala Val Thr Glu Leu Gly Arg Pro Asp Ala Glu Tyr Trp Asn Ser			
	50	55	60	
45	Gln Lys Asp Leu Leu Glu Gln Lys Arg Ala Ala Val Asp Thr Tyr Cys			
	65	70	75	80
50	Arg His Asn Tyr Gly Val Gly Glu Ser Phe Thr Val Gln Arg Arg Gly			
	85	90	95	
	Gly Gly Gly Ile Lys Glu Glu His Val Ile Ile Gln Ala Glu Phe Tyr			
	100	105	110	
55	Leu Asn Pro Asp Gln Ser Gly Glu Phe Met Phe Asp Phe Asp Gly Asp			
	115	120	125	
	Glu Ile Phe His Val Asp Met Ala Lys Lys Glu Thr Val Trp Arg Leu			
	130	135	140	

65

Glu Glu Phe Gly Arg Phe Ala Ser Phe Glu Ala Gln Gly Ala Leu Ala  
 145                    150                    155                    160

5 Asn Ile Ala Val Asp Lys Ala Asn Leu Glu Ile Met Thr Lys Arg Ser  
     165                170                175

Asn Tyr Thr Pro Ile Thr Asn  
     180

10

&lt;210&gt; CO594

&lt;211&gt; 187

&lt;212&gt; PRT

15 &lt;213&gt; Homo sapiens

Met Gly Asp Thr Arg Pro Arg Phe Leu Glu Gln Val Lys His Glu Cys  
     5                    10                    15

20 His Phe Phe Asn Gly Thr Glu Arg Val Arg Phe Leu Asp Arg Tyr Phe  
     20                25                30

Tyr His Gln Glu Glu Tyr Val Arg Phe Asp Ser Asp Val Gly Glu Tyr  
     35                40                45

25 Arg Ala Val Thr Glu Leu Gly Arg Pro Asp Ala Glu Tyr Trp Asn Ser  
     50                55                60

30 Gln Lys Asp Leu Leu Glu Gln Lys Arg Ala Ala Val Asp Thr Tyr Cys  
     65                70                75                80

Arg His Asn Tyr Gly Val Gly Glu Ser Phe Thr Val Gln Arg Arg Val  
     85                90                95

35 Tyr Pro Glu Val Thr Val Ile Lys Glu Glu His Val Ile Ile Gln Ala  
     100                105                110

Glu Phe Tyr Leu Asn Pro Asp Gln Ser Gly Glu Phe Met Phe Asp Phe  
     115                120                125

40 Asp Gly Asp Glu Ile Phe His Val Asp Met Ala Lys Lys Glu Thr Val  
     130                135                140

Trp Arg Leu Glu Glu Phe Gly Arg Phe Ala Ser Phe Glu Ala Gln Gly  
     145                150                155                160

Ala Leu Ala Asn Ile Ala Val Asp Lys Ala Asn Leu Glu Ile Met Thr  
     165                170                175

50 Lys Arg Ser Asn Tyr Thr Pro Ile Thr Asn  
     180                185

55 <210> CO592

&lt;211&gt; 188

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

Met Gly Asp Thr Arg Pro Arg Phe Leu Glu Gln Val Lys His Glu Cys

		66		
	5		10	15
	His Phe Phe Asn Gly Thr Glu Arg Val Arg Phe Leu Asp Arg Tyr Phe			
	20	25	30	
5	Tyr His Gln Glu Glu Tyr Val Arg Phe Asp Ser Asp Val Gly Glu Tyr			
	35	40	45	
	Arg Ala Val Thr Glu Leu Gly Arg Pro Asp Ala Glu Tyr Trp Asn Ser			
10	50	55	60	
	Gln Lys Asp Leu Leu Glu Gln Lys Arg Ala Ala Val Asp Thr Tyr Cys			
	65	70	75	80
15	Arg His Asn Tyr Gly Val Gly Glu Ser Phe Thr Val Gln Arg Arg Phe			
	85	90	95	
	Asp Ala Pro Ser Pro Leu Pro Ile Lys Glu Glu His Val Ile Ile Gln			
	100	105	110	
20	Ala Glu Phe Tyr Leu Asn Pro Asp Gln Ser Gly Glu Phe Met Phe Asp			
	115	120	125	
	Phe Asp Gly Asp Glu Ile Phe His Val Asp Met Ala Lys Lys Glu Thr			
25	130	135	140	
	Val Trp Arg Leu Glu Glu Phe Gly Arg Phe Ala Ser Phe Glu Ala Gln			
	145	150	155	160
30	Gly Ala Leu Ala Asn Ile Ala Val Asp Lys Ala Asn Leu Glu Ile Met			
	165	170	175	
	Thr Lys Arg Ser Asn Tyr Thr Pro Ile Thr Asn			
	180	185		
35	<210> CO591			
	<211> 187			
	<212> PRT			
40	<213> Homo sapiens			
	Met Gly Asp Thr Arg Pro Arg Phe Leu Glu Gln Val Lys His Glu Cys			
	5	10	15	
45	His Phe Phe Asn Gly Thr Glu Arg Val Arg Phe Leu Asp Arg Tyr Phe			
	20	25	30	
	Tyr His Gln Glu Glu Tyr Val Arg Phe Asp Ser Asp Val Gly Glu Tyr			
	35	40	45	
50	Arg Ala Val Thr Glu Leu Gly Arg Pro Asp Ala Glu Tyr Trp Asn Ser			
	50	55	60	
	Gln Lys Asp Leu Leu Glu Gln Lys Arg Ala Ala Val Asp Thr Tyr Cys			
55	65	70	75	80
	Arg His Asn Tyr Gly Val Gly Glu Ser Phe Thr Val Gln Arg Arg Ser			
	85	90	95	

67

Gly Gly Ser Gly Gly Ser Ile Lys Glu Glu His Val Ile Ile Gln Ala  
 100 105 110

5      Glu Phe Tyr Leu Asn Pro Asp Gln Ser Gly Glu Phe Met Phe Asp Phe  
 115 120 125

Asp Gly Asp Glu Ile Phe His Val Asp Met Ala Lys Lys Glu Thr Val  
 130 135 140

10     Trp Arg Leu Glu Glu Phe Gly Arg Phe Ala Ser Phe Glu Ala Gln Gly  
 145 150 155 160

Ala Leu Ala Asn Ile Ala Val Asp Lys Ala Asn Leu Glu Ile Met Thr  
 165 170 175

15     Lys Arg Ser Asn Tyr Thr Pro Ile Thr Asn  
 180 185

20     <210> CO590  
 <211> 187  
 <212> PRT  
 <213> Homo sapiens

25     Met Gly Asp Thr Arg Pro Arg Phe Leu Glu Gln Val Lys His Glu Cys  
 5 10 15

His Phe Phe Asn Gly Thr Glu Arg Val Arg Phe Leu Asp Arg Tyr Phe  
 20 25 30

30     Tyr His Gln Glu Glu Tyr Val Arg Phe Asp Ser Asp Val Gly Glu Tyr  
 35 40 45

Arg Ala Val Thr Glu Leu Gly Arg Pro Asp Ala Glu Tyr Trp Asn Ser  
 35 50 55 60

Gln Lys Asp Leu Leu Glu Gln Lys Arg Ala Ala Val Asp Thr Tyr Cys  
 65 70 75 80

40     Arg His Asn Tyr Gly Val Gly Glu Ser Phe Thr Val Gln Arg Arg Thr  
 85 90 95

Ser Gly Gly Gly Ser Ile Lys Glu Glu His Val Ile Ile Gln Ala  
 100 105 110

45     Glu Phe Tyr Leu Asn Pro Asp Gln Ser Gly Glu Phe Met Phe Asp Phe  
 115 120 125

50     Asp Gly Asp Glu Ile Phe His Val Asp Met Ala Lys Lys Glu Thr Val  
 130 135 140

Trp Arg Leu Glu Glu Phe Gly Arg Phe Ala Ser Phe Glu Ala Gln Gly  
 145 150 155 160

55     Ala Leu Ala Asn Ile Ala Val Asp Lys Ala Asn Leu Glu Ile Met Thr  
 165 170 175

Lys Arg Ser Asn Tyr Thr Pro Ile Thr Asn  
 180 185

5           <210> CO589  
 <211> 190  
 <212> PRT  
 <213> Homo sapiens

Met	Gly	Asp	Thr	Arg	Pro	Arg	Phe	Leu	Glu	Gln	Val	Lys	His	Glu	Cys
5							5		10					15	

10          His Phe Phe Asn Gly Thr Glu Arg Val Arg Phe Leu Asp Arg Tyr Phe  
 20              25              30

15          Tyr His Gln Glu Glu Tyr Val Arg Phe Asp Ser Asp Val Gly Glu Tyr  
 35              40              45

20          Arg Ala Val Thr Glu Leu Gly Arg Pro Asp Ala Glu Tyr Trp Asn Ser  
 50              55              60

25          Gln Lys Asp Leu Leu Glu Gln Lys Arg Ala Ala Val Asp Thr Tyr Cys  
 65              70              75              80

30          Arg His Asn Tyr Gly Val Gly Glu Ser Phe Thr Val Gln Arg Arg Gly  
 85              90              95

35          Ser Pro Gly Gly Gly Pro Gly Ser Ile Lys Glu Glu His Val Ile  
 100              105              110

40          Ile Gln Ala Glu Phe Tyr Leu Asn Pro Asp Gln Ser Gly Glu Phe Met  
 115              120              125

45          Phe Asp Phe Asp Gly Asp Glu Ile Phe His Val Asp Met Ala Lys Lys  
 130              135              140

50          Glu Thr Val Trp Arg Leu Glu Glu Phe Gly Arg Phe Ala Ser Phe Glu  
 145              150              155              160

55          Ala Gln Gly Ala Leu Ala Asn Ile Ala Val Asp Lys Ala Asn Leu Glu  
 165              170              175

60          Ile Met Thr Lys Arg Ser Asn Tyr Thr Pro Ile Thr Asn  
 180              185

65          <210> CO588  
 <211> 190  
 <212> PRT  
 <213> Homo sapiens

70          Met Gly Asp Thr Arg Pro Arg Phe Leu Glu Gln Val Lys His Glu Cys  
 5              10              15

75          His Phe Phe Asn Gly Thr Glu Arg Val Arg Phe Leu Asp Arg Tyr Phe  
 20              25              30

80          Tyr His Gln Glu Glu Tyr Val Arg Phe Asp Ser Asp Val Gly Glu Tyr  
 35              40              45

85          Arg Ala Val Thr Glu Leu Gly Arg Pro Asp Ala Glu Tyr Trp Asn Ser

		69	
	50	55	60
	Gln Lys Asp Leu Leu Glu Gln Lys Arg Ala Ala Val Asp Thr Tyr Cys		
5	65	70	75
	Arg His Asn Tyr Gly Val Gly Glu Ser Phe Thr Val Gln Arg Arg Gly		
	85	90	95
10	Ser Pro Pro Gly Gly Pro Pro Gly Ser Ile Lys Glu Glu His Val Ile		
	100	105	110
	Ile Gln Ala Glu Phe Tyr Leu Asn Pro Asp Gln Ser Gly Glu Phe Met		
	115	120	125
15	Phe Asp Phe Asp Gly Asp Glu Ile Phe His Val Asp Met Ala Lys Lys		
	130	135	140
	Glu Thr Val Trp Arg Leu Glu Glu Phe Gly Arg Phe Ala Ser Phe Glu		
20	145	150	155
	160		
	Ala Gln Gly Ala Leu Ala Asn Ile Ala Val Asp Lys Ala Asn Leu Glu		
	165	170	175
25	Ile Met Thr Lys Arg Ser Asn Tyr Thr Pro Ile Thr Asn		
	180	185	
	<210> CO587		
30	<211> 194		
	<212> PRT		
	<213> Homo sapiens		
	Met Gly Asp Thr Arg Pro Arg Phe Leu Glu Gln Val Lys His Glu Cys		
35	5	10	15
	His Phe Phe Asn Gly Thr Glu Arg Val Arg Phe Leu Asp Arg Tyr Phe		
	20	25	30
40	Tyr His Gln Glu Glu Tyr Val Arg Phe Asp Ser Asp Val Gly Glu Tyr.		
	35	40	45
	Arg Ala Val Thr Glu Leu Gly Arg Pro Asp Ala Glu Tyr Trp Asn Ser		
	50	55	60
45	Gln Lys Asp Leu Leu Glu Gln Lys Arg Ala Ala Val Asp Thr Tyr Cys		
	65	70	75
	80		
	Arg His Asn Tyr Gly Val Gly Glu Ser Phe Thr Val Gln Arg Arg Gly		
50	85	90	95
	Ser Pro Gly Gly Gly Ser Gly Gly Pro Gly Ser Ile Lys Glu		
	100	105	110
55	Glu His Val Ile Ile Gln Ala Glu Phe Tyr Leu Asn Pro Asp Gln Ser		
	115	120	125
	Gly Glu Phe Met Phe Asp Phe Asp Gly Asp Glu Ile Phe His Val Asp		
	130	135	140

70

Met Ala Lys Lys Glu Thr Val Trp Arg Leu Glu Glu Phe Gly Arg Phe  
 145 150 155 160

5 Ala Ser Phe Glu Ala Gln Gly Ala Leu Ala Asn Ile Ala Val Asp Lys  
 165 170 175

Ala Asn Leu Glu Ile Met Thr Lys Arg Ser Asn Tyr Thr Pro Ile Thr  
 180 185 190

10 Asn.

<210> CO586

15 <211> 194

<212> PRT

<213> Homo sapiens

20 Met Gly Asp Thr Arg Pro Arg Phe Leu Glu Gln Val Lys His Glu Cys  
 5 10 15

His Phe Phe Asn Gly Thr Glu Arg Val Arg Phe Leu Asp Arg Tyr Phe  
 20 25 30

25 Tyr His Gln Glu Glu Tyr Val Arg Phe Asp Ser Asp Val Gly Glu Tyr  
 35 40 45

Arg Ala Val Thr Glu Leu Gly Arg Pro Asp Ala Glu Tyr Trp Asn Ser  
 50 55 60

30 Gln Lys Asp Leu Leu Glu Gln Lys Arg Ala Ala Val Asp Thr Tyr Cys  
 65 70 75 80

35 Arg His Asn Tyr Gly Val Gly Glu Ser Phe Thr Val Gln Arg Arg Thr  
 85 90 95

Ser Gly Gly Gly Ser Gly Gly Ser Ser Ser Ile Lys Glu  
 100 105 110

40 Glu His Val Ile Ile Gln Ala Glu Phe Tyr Leu Asn Pro Asp Gln Ser  
 115 120 125

Gly Glu Phe Met Phe Asp Phe Asp Gly Asp Glu Ile Phe His Val Asp  
 130 135 140

45 Met Ala Lys Lys Glu Thr Val Trp Arg Leu Glu Glu Phe Gly Arg Phe  
 145 150 155 160

50 Ala Ser Phe Glu Ala Gln Gly Ala Leu Ala Asn Ile Ala Val Asp Lys  
 165 170 175

Ala Asn Leu Glu Ile Met Thr Lys Arg Ser Asn Tyr Thr Pro Ile Thr  
 180 185 190

55 Asn

<210> CO598

&lt;211&gt; 639

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

5 atgggggaca ccggtcgcag cttcacccctg gcctccagcg agaccggcgt gggcgctagc 60  
 ggagggggcg gaagcggcgg agggggggac acccgaccac gtttcttsga gcaggttaaa 120  
 catgagtgtc atttcttcaa cgggacggag cgggtgcggc tcctggacag atacttctat 180  
 caccaggagg agtacgtgcg cttcgacagc gacgtggggg agtaccgggc ggtgacggag 240  
 ctggggcggc ctgatgccga gtactggAAC agccagaagg acctcctsga gcagaagcgg 300  
 10 gcccgggtgg acacctaactg cagacacaac tacggggttg gtgagagctt cacagtgtc 360  
 cggccactcg gaggtgaaga tgacgaggca gatcaccatg tgatcatcca ggccgagttc 420  
 tatctgaatc ctgaccaatc aggcgagttt atgtttgact ttgatggta tgagattttc 480  
 catgtggata tggcaaaagaa ggagacggtc tggcggcttg aagaattttg acgatttgcc 540  
 15 agcttgagg ctcaagggtgc attggccaac atagctgtgg acaaagccaa cctggaaatc 600  
 atgacaaaagc gctccaacta tactccgatc accaattaa 639

&lt;210&gt; C0597

&lt;211&gt; 639

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

atgggggaca ccggtcgcag cttcacccctg gcctccagcg agaccggcgt gggcgctagc 60  
 ggagggggcg gaagcggcgg agggggggac acccgaccac gtttcttsga gcaggttaaa 120  
 catgagtgtc atttcttcaa cgggacggag cgggtgcggc tcctggacag atacttctat 180  
 25 caccaggagg agtacgtgcg cttcgacagc gacgtggggg agtaccgggc ggtgacggag 240  
 ctggggcggc ctgatgccga gtactggAAC agccagaagg acctcctsga gcagaagcgg 300  
 gcccgggtgg acacctaactg cagacacaac tacggggttg gtgagagctt cacagtgcag 360  
 cggcgaggag gtggaaagcgg cggaatcaaa gaagaacatg tgatcatcca ggccgagttc 420  
 tatctgaatc ctgaccaatc aggcgagttt atgtttgact ttgatggta tgagattttc 480  
 30 catgtggata tggcaaaagaa ggagacggtc tggcggcttg aagaattttg acgatttgcc 540  
 agcttgagg ctcaagggtgc attggccaac atagctgtgg acaaagccaa cctggaaatc 600  
 atgacaaaagc gctccaacta tactccgatc accaattaa 639

&lt;210&gt; C0596

&lt;211&gt; 636

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

40 atgggggaca ccggtcgcag cttcacccctg gcctccagcg agaccggcgt gggcgctagc 60  
 ggagggggcg gaagcggcgg agggggggac acccgaccac gtttcttsga gcaggttaaa 120  
 catgagtgtc atttcttcaa cgggacggag cgggtgcggc tcctggacag atacttctat 180  
 caccaggagg agtacgtgcg cttcgacagc gacgtggggg agtaccgggc ggtgacggag 240  
 ctggggcggc ctgatgccga gtactggAAC agccagaagg acctcctsga gcagaagcgg 300  
 gcccgggtgg acacctaactg cagacacaac tacggggttg gtgagagctt cacagtgcag 360  
 45 cggcgaggag gtggaggcag catcaaagaa gaacatgtga tcatccagc cgagttctat 420  
 ctgaatcctg accaatcagg cgagtttatg tttgactttt atgggtatga gattttccat 480  
 gtggatatgg caaagaagga gacggcttg cggcttgaag aatttggacg atttgcacg 540  
 tttgaggctc aaggtgcatt ggccaacata gctgtggaca aagccaacct ggaaatcatg 600  
 acaaagcgct ccaactatac tccgatcacc aattaa 636

&lt;210&gt; C0595

&lt;211&gt; 633

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

55 atgggggaca ccggtcgcag cttcacccctg gcctccagcg agaccggcgt gggcgctagc 60  
 ggagggggcg gaagcggcgg agggggggac acccgaccac gtttcttsga gcaggttaaa 120  
 catgagtgtc atttcttcaa cgggacggag cgggtgcggc tcctggacag atacttctat 180  
 caccaggagg agtacgtgcg cttcgacagc gacgtggggg agtaccgggc ggtgacggag 240

72

ctggggcggc ctgatgccga gtactggAAC agccagaagg acctcctggA gcagaAGCGG 300  
 gcccgggtgg acacctaCTG cagacacaAC tacggggTTG gtgagAGCtt cacagtgcAG 360  
 cggcgaggAG gtggaggcat caaAGAAAGAA catgtatca tccaggCCGA gtttatCTG 420  
 aatcctgacc aatcaggcGA gtttatgttT gactttgatg gtgatgagat ttccatgtG 480  
 5 gatatggcaa agaaggAGAC ggtctggcGG cttgaAGAAAT ttggacGATT tgccAGCTT 540  
 gagggctcaag gtgcattggc caacataGCT gtggacAAAG ccaacctggA aatcatgaca 600  
 aaggcgtccCA actataCTCC gatcaccaAT taa 633

<210> CO593  
 10 <211> 642  
 <212> DNA  
 <213> Homo sapiens

atgggggaca ccggtcgcAG cttcacCCtG gcctccAGCG agaccggcgt gggcgctAGC 60  
 15 ggagggggcG gaagcggcGG aggGGGGGAc acccgaccAC gtttcttggA gcaggTTAAA 120  
 catgagtgtc atttcttcaa cgggacggAG cgggtgcGGt tcctggacAG atacttctat 180  
 cacaagagg agtacgtgcG cttcgacAGC gacgtgggg AGTACCGGGC ggtgacGGAG 240  
 ctggggcggc ctgatGCCGA gtactggAAC agccagaagg acctcctggA gcagaAGCGG 300  
 gccgcggTgg acacctaCTG cagacacaAC tacggggTTG gtgagAGCtt cacagtgcAG 360  
 20 cggcgagtct accctgaggT aactgtcatC aaagaAGAAAC atgtatcatC ccaggCCGAG 420  
 ttctatctGA atcctgacCA atcaggcGA gttatgttT actttgatgg tgatgagatt 480  
 ttcatgtgg atatggcaaA gaaggAGAC gtctggcGG ttaAGAAATT tggacgattt 540  
 gccagctttg aggctcaagg tgcattggc AACATAGCTG tggacAAAGC caacctggaa 600  
 atcatgacAA agcgtccCA ctataCTCC atcaccaATT aa 642

25 <210> CO585  
 <211> 645  
 <212> DNA  
 <213> Homo sapiens

atgggggaca ccggtcgcAG cttcacCCtG gcctccAGCG agaccggcgt gggcgctAGC 60  
 30 ggagggggcG gaagcggcGG aggGGGGGAc acccgaccAC gtttcttggA gcaggTTAAA 120  
 catgagtgtc atttcttcaa cgggacggAG cgggtgcGGt tcctggacAG atacttctat 180  
 cacaagagg agtacgtgcG cttcgacAGC gacgtgggg AGTACCGGGC ggtgacGGAG 240  
 ctggggcggc ctgatGCCGA gtactggAAC agccagaagg acctcctggA gcagaAGCGG 300  
 gccgcggTgg acacctaCTG cagacacaAC tacggggTTG gtgagAGCtt cacagtgcAG 360  
 35 cggcgattcg acgcacctAG cccactcccA atcaaAGAAAG aacatgtatC catccaggCC 420  
 gagttctatC tgaatcttGA ccaatcaggc gagtttatgt ttgactttGA tggatgtgAG 480  
 atttccatG tggatatggc aaagaaggAG acggctcGGC ggcttgaAGA atttggacGA 540  
 40 tttgcccAGt ttgaggctCA agtgcatttG gccaacatAG ctgtggacAA agccaacCTG 600  
 gaaatcatGA caaAGCGCTC caactataCT ccgatcacca ATTAA 645

<210> CO584  
 <211> 642  
 45 <212> DNA  
 <213> Homo sapiens

atgggggaca ccggtcgcAG cttcacCCtG gcctccAGCG agaccggcgt gggcgctAGC 60  
 50 ggagggggcG gaagcggcGG aggGGGGGAc acccgaccAC gtttcttggA gcaggTTAAA 120  
 catgagtgtc atttcttcaa cgggacggAG cgggtgcGGt tcctggacAG atacttctat 180  
 cacaagagg agtacgtgcG cttcgacAGC gacgtgggg AGTACCGGGC ggtgacGGAG 240  
 ctggggcggc ctgatGCCGA gtactggAAC agccagaagg acctcctggA gcagaAGCGG 300  
 gccgcggTgg acacctaCTG cagacacaAC tacggggTTG gtgagAGCtt cacagtgcAG 360  
 55 cggcgaagtG gcggtagtgg cgtagtataC aaagaAGAAAC atgtatcatC ccaggCCGAG 420  
 ttctatctGA atcctgacCA atcaggcGA gttatgttT actttgatgg tgatgagatt 480  
 ttcatgtgg atatggcaaA gaaggAGAC gtctggcGG ttaAGAAATT tggacgattt 540  
 gccagctttg aggctcaagg tgcattggc AACATAGCTG tggacAAAGC caacctggaa 600  
 atcatgacAA agcgtccCA ctataCTCC atcaccaATT aa 642

5       <210> CO583  
 <211> 642  
 <212> DNA  
 <213> Homo sapiens

```

atgggggaca ccggtcgcag cttcacccctg gcctccagcg agaccggcgt gggcgctagc 60
ggagggggcg gaagcggcgg agggggggac acccgaccac gtttcttsga gcaggttaaa 120
catgagtgtc atttcttcaa cgggacggag cgggtgcggc tcctggacag atacttctat 180
10      caccaggagg agtacgtgcg cttcgacacgc gacgtggggg agtaccgggc ggtgacggag 240
ctggggcggc ctgatgccga gtactggAAC agccagaagg acctccttggc gcagaaggcgg 300
gccgcgggtgg acacctactg cagacacaac tacggggttg gtgagagcTT cacagtgcag 360
cggcgaacta gtggtggcgg tggcagcatt aaagaagaac atgtgatcat ccaggccgag 420
ttctatctga atccctgacca atcaggcggag ttatgtttg actttgatgg tgatgagatt 480
15      ttccatgtgg atatggAAA gaaggagacg gtctggcggc ttgaagaatt tggacgattt 540
gccagtttg aggctcaagg tgcattggcc aacatagctg tggacaaaAGC caacctggaa 600
atcatgacaa agcgctccaa ctatactccg atcaccaatt aa 642
  
```

20      <210> CO582  
 <211> 651  
 <212> DNA  
 <213> Homo sapiens

```

atgggggaca ccggtcgcag cttcacccctg gcctccagcg agaccggcgt gggcgctagc 60
ggagggggcg gaagcggcgg agggggggac acccgaccac gtttcttsga gcaggttaaa 120
catgagtgtc atttcttcaa cgggacggag cgggtgcggc tcctggacag atacttctat 180
caccaggagg agtacgtgcg cttcgacacgc gacgtggggg agtaccgggc ggtgacggag 240
ctggggcggc ctgatgccga gtactggAAC agccagaagg acctccttggc gcagaaggcgg 300
gccgcgggtgg acacctactg cagacacaac tacggggttg gtgagagcTT cacagtgcag 360
30      cggcggaggct ctcctggagg tggaggtcct ggatctatca aagaagaaca tgtgatcatc 420
caggccgagt tctatctgaa tcctgaccaa tcaggcgagt ttatgtttga ctttgatggt 480
gatgagattt tccatgtggA tatggcaaAG aaggagacgg tctggcggct tgaagaattt 540
ggacgatttgc ctagcttga ggctcaagggt gcattggcca acatagctgt ggacaaaAGC 600
aacctggaaa tcatgacaaa gcgctccaa ctatactccg atcaccaatttta a 651
  
```

35      <210> CO581  
 <211> 651  
 <212> DNA  
 <213> Homo sapiens

```

atgggggaca ccggtcgcag cttcacccctg gcctccagcg agaccggcgt gggcgctagc 60
ggagggggcg gaagcggcgg agggggggac acccgaccac gtttcttsga gcaggttaaa 120
catgagtgtc atttcttcaa cgggacggag cgggtgcggc tcctggacag atacttctat 180
45      caccaggagg agtacgtgcg cttcgacacgc gacgtggggg agtaccgggc ggtgacggag 240
ctggggcggc ctgatgccga gtactggAAC agccagaagg acctccttggc gcagaaggcgg 300
gccgcgggtgg acacctactg cagacacaac tacggggttg gtgagagcTT cacagtgcag 360
cggcggaggct ctcctccctgg tggaccacct ggatctatca aagaagaaca tgtgatcatc 420
caggccgagt tctatctgaa tcctgaccaa tcaggcgagt ttatgtttga ctttgatggt 480
50      gatgagattt tccatgtggA tatggcaaAG aaggagacgg tctggcggct tgaagaattt 540
ggacgatttgc ctagcttga ggctcaagggt gcattggcca acatagctgt ggacaaaAGC 600
aacctggaaa tcatgacaaa gcgctccaa ctatactccg atcaccaatttta a 651
  
```

55      <210> CO580  
 <211> 663  
 <212> DNA  
 <213> Homo sapiens

74

	atggggggaca	ccggtcgcag	cttcacccctg	gcctccagcg	agaccggcgt	gggcgcctagc	60
	ggagggggcg	gaagcgccgg	aggggggggac	acccgaccac	gtttcttga	gcaggttaaa	120
	catgagtgtc	atttcttcaa	cgggacggag	cgggtgcggt	tcctggacag	atacttctat	180
	caccaagagg	agtaacgtgcg	cttcgacacgc	gacgtggggg	agtaccggc	ggtgacggag	240
5	ctggggcgcc	ctgatgccga	gtactggAAC	agccagaagg	acctccgtga	gcagaagcgg	300
	gcccgcgtgg	acacctactg	cagacacaaac	tacggggttg	gtgagagctt	cacagtgcag	360
	cggcgaggga	gtcccaggcgg	tggcgggagc	ggcggtggtc	ctggggagtat	caaagaagaa	420
	catgtgtatca	tccaggccga	gttctatctg	aatcctgacc	aatcaggcga	gtttatgttt	480
	gactttgatg	gtgatgagat	tttccatgtg	gatatggcaa	agaaggagac	ggtctggcgg	540
10	cttgaagaat	ttggacgatt	tgccagctt	gaggctcaag	gtgcattggc	caacatagct	600
	gtggacaaaag	ccaaccttga	aatcatgaca	aaggcgttca	actatactcc	gatcaccat	660
	taa						663

15 <210> CO567  
<211> 663  
<212> DNA  
<213> Homo sapiens

20	atgggggaca	ccggtcgcag	cttcacccctg	gcctccagcg	agaccggcgt	gggcgctagc	60
	ggagggggcg	gaagcggcgg	agggggggac	acccgaccac	gtttcttga	gcaggttaaa	120
	catgagtgtc	atttcttcaa	cgggacggag	cgggtgcggt	tcctggacag	atacttctat	180
	caccaagagg	agtaacgtgcg	cttcgacacgc	gacgtggggg	agtaccggc	ggtgacggag	240
	ctggggcggc	ctgatgccga	gtacttggAAC	agccagaagg	acctcccttga	gcagaagcgg	300
25	gccgcggtgt	acacctaactg	cagacacaaac	tacggggttg	gtgagagctt	cacagtgcag	360
	cggcgaacta	gtgggtggcgg	tggcagcggc	ggtgtgtgtt	cctcgagtat	caaagaagaa	420
	catgtgtatca	tccaggccga	gttctatctg	aatcctgacc	aatcaggcga	gtttatgttt	480
	gactttgatg	gtgatgagat	tttccatgtg	gatatggcaa	agaaggagac	ggtctggcgg	540
	cttgaagaat	ttggacgatt	tgccagctt	gaggctcaag	gtgcattggc	caacatagct	600
30	gtggacaaag	ccaaccttga	aatcatgaca	aaggcgttcca	actatactcc	gatcaccaat	660
	taa						663

35 <210> C0598  
<211> 213  
<212> PRT  
<213> *Homo sapiens*

40 Met Gly Asp Thr Gly Arg Ser Phe Thr Leu Ala Ser Ser Glu Thr Gly  
5 10 15

Val Gly Ala Ser Gly Gly Gly Ser Gly Gly Gly Asp Thr Arg  
20 25 30

45 Pro Arg Phe Leu Glu Gln Val Lys His Glu Cys His Phe Phe Asn Gly  
35 40 45

Thr Glu Arg Val Arg Phe Leu Asp Arg Tyr Phe Tyr His Gln Glu Glu  
 50 55 60

Tyr Val Arg Phe Asp Ser Asp Val Gly Glu Tyr Arg Ala Val Thr Glu  
65 70 75 80

55 Leu Gly Arg Pro Asp Ala Glu Tyr Trp Asn Ser Gln Lys Asp Leu Leu  
85 90 95

Glu Gln Lys Arg Ala Ala Val Asp Thr Tyr Cys Arg His Asn Tyr Gly  
100 105 110

75

Val Gly Glu Ser Phe Thr Val Leu Arg Arg Leu Gly Gly Glu Asp Asp  
       115                 120                 125  
  
 5   Glu Ala Asp His His Val Ile Ile Gln Ala Glu Phe Tyr Leu Asn Pro  
       130                 135                 140  
  
 Asp Gln Ser Gly Glu Phe Met Phe Asp Phe Asp Gly Asp Glu Ile Phe  
   145                 150                 155                 160  
  
 10   His Val Asp Met Ala Lys Lys Glu Thr Val Trp Arg Leu Glu Glu Phe  
       165                 170                 175  
  
 Gly Arg Phe Ala Ser Phe Glu Ala Gln Gly Ala Leu Ala Asn Ile Ala  
       180                 185                 190  
  
 15   Val Asp Lys Ala Asn Leu Glu Ile Met Thr Lys Arg Ser Asn Tyr Thr  
       195                 200                 205  
  
 20   Pro Ile Thr Asn  
       210  
  
 <210> CO597  
 <211> 213  
 25   <212> PRT  
 <213> Homo sapiens  
  
 Met Gly Asp Thr Gly Arg Ser Phe Thr Leu Ala Ser Ser Glu Thr Gly  
       5                 10                 15  
  
 30   Val Gly Ala Ser Gly Gly Gly Ser Gly Gly Gly Asp Thr Arg  
       20                 25                 30  
  
 Pro Arg Phe Leu Glu Gln Val Lys His Glu Cys His Phe Phe Asn Gly  
   35                 40                 45  
  
 Thr Glu Arg Val Arg Phe Leu Asp Arg Tyr Phe Tyr His Gln Glu Glu  
   50                 55                 60  
  
 40   Tyr Val Arg Phe Asp Ser Asp Val Gly Glu Tyr Arg Ala Val Thr Glu  
   65                 70                 75                 80  
  
 Leu Gly Arg Pro Asp Ala Glu Tyr Trp Asn Ser Gln Lys Asp Leu Leu  
   85                 90                 95  
  
 45   Glu Gln Lys Arg Ala Ala Val Asp Thr Tyr Cys Arg His Asn Tyr Gly  
   100                 105                 110  
  
 50   Val Gly Glu Ser Phe Thr Val Gln Arg Arg Gly Gly Ser Gly Gly  
   115                 120                 125  
  
 Ile Lys Glu Glu His Val Ile Ile Gln Ala Glu Phe Tyr Leu Asn Pro  
   130                 135                 140  
  
 55   Asp Gln Ser Gly Glu Phe Met Phe Asp Phe Asp Gly Asp Glu Ile Phe  
   145                 150                 155                 160  
  
 His Val Asp Met Ala Lys Lys Glu Thr Val Trp Arg Leu Glu Glu Phe  
   165                 170                 175

Gly Arg Phe Ala Ser Phe Glu Ala Gln Gly Ala Leu Ala Asn Ile Ala  
                  180                     185                 190  
 5 Val Asp Lys Ala Asn Leu Glu Ile Met Thr Lys Arg Ser Asn Tyr Thr  
                  195                     200                 205  
 Pro Ile Thr Asn  
                  210  
 10  
 <210> C0596  
 <211> 212  
 <212> PRT  
 15 <213> Homo sapiens  
 Met Gly Asp Thr Gly Arg Ser Phe Thr Leu Ala Ser Ser Glu Thr Gly  
                  5                     10                 15  
 20 Val Gly Ala Ser Gly Gly Ser Gly Gly Gly Asp Thr Arg  
                  20                     25                 30  
 Pro Arg Phe Leu Glu Gln Val Lys His Glu Cys His Phe Phe Asn Gly  
                  35                     40                 45  
 25 Thr Glu Arg Val Arg Phe Leu Asp Arg Tyr Phe Tyr His Gln Glu Glu  
                  50                     55                 60  
 Tyr Val Arg Phe Asp Ser Asp Val Gly Glu Tyr Arg Ala Val Thr Glu  
 30           65                     70                 75                 80  
 Leu Gly Arg Pro Asp Ala Glu Tyr Trp Asn Ser Gln Lys Asp Leu Leu  
                  85                     90                 95  
 35 Glu Gln Lys Arg Ala Ala Val Asp Thr Tyr Cys Arg His Asn Tyr Gly  
                  100                    105                110  
 Val Gly Glu Ser Phe Thr Val Gln Arg Arg Gly Gly Ser Ile  
                  115                    120                 125  
 40 Lys Glu Glu His Val Ile Ile Gln Ala Glu Phe Tyr Leu Asn Pro Asp  
                  130                    135                 140  
 Gln Ser Gly Glu Phe Met Phe Asp Phe Asp Gly Asp Glu Ile Phe His  
 45           145                    150                 155                 160  
 Val Asp Met Ala Lys Lys Glu Thr Val Trp Arg Leu Glu Glu Phe Gly  
                  165                    170                 175  
 50 Arg Phe Ala Ser Phe Glu Ala Gln Gly Ala Leu Ala Asn Ile Ala Val  
                  180                    185                 190  
 Asp Lys Ala Asn Leu Glu Ile Met Thr Lys Arg Ser Asn Tyr Thr Pro  
                  195                    200                 205  
 55 Ile Thr Asn  
                  210

77

&lt;210&gt; CO595

&lt;211&gt; 211

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

5

Met	Gly	Asp	Thr	Gly	Arg	Ser	Phe	Thr	Leu	Ala	Ser	Ser	Glu	Thr	Gly
							5				10			15	

Val	Gly	Ala	Ser	Gly	Gly	Gly	Ser	Gly	Gly	Gly	Gly	Asp	Thr	Arg
							20		25			30		

Pro	Arg	Phe	Leu	Glu	Gln	Val	Lys	His	Glu	Cys	His	Phe	Phe	Asn	Gly
							35		40			45			

15	Thr	Glu	Arg	Val	Arg	Phe	Leu	Asp	Arg	Tyr	Phe	Tyr	His	Gln	Glu
							50		55			60			

Tyr	Val	Arg	Phe	Asp	Ser	Asp	Val	Gly	Glu	Tyr	Arg	Ala	Val	Thr	Glu
							65		70			75			80

20	Leu	Gly	Arg	Pro	Asp	Ala	Glu	Tyr	Trp	Asn	Ser	Gln	Lys	Asp	Leu
							85			90			95		

25	Glu	Gln	Lys	Arg	Ala	Ala	Val	Asp	Thr	Tyr	Cys	Arg	His	Asn	Tyr	Gly
							100			105			110			

30	Val	Gly	Glu	Ser	Phe	Thr	Val	Gln	Arg	Arg	Gly	Gly	Gly	Ile	Lys
							115		120			125			

35	Glu	Glu	His	Val	Ile	Ile	Gln	Ala	Glu	Phe	Tyr	Leu	Asn	Pro	Asp	Gln
							130		135			140				

40	Ser	Gly	Glu	Phe	Met	Phe	Asp	Phe	Gly	Asp	Glu	Ile	Phe	His	Val
							145		150			155			160

45	Asp	Met	Ala	Lys	Lys	Glu	Thr	Val	Trp	Arg	Leu	Glu	Glu	Phe	Gly	Arg
							165		170					175		

50	Phe	Ala	Ser	Phe	Glu	Ala	Gln	Gly	Ala	Leu	Ala	Asn	Ile	Ala	Val	Asp
							180			185			190			

55	Lys	Ala	Asn	Leu	Glu	Ile	Met	Thr	Lys	Arg	Ser	Asn	Tyr	Thr	Pro	Ile
							195		200			205				

45	Thr	Asn
		210

&lt;210&gt; CO593

&lt;211&gt; 214

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

50	Met	Gly	Asp	Thr	Gly	Arg	Ser	Phe	Thr	Leu	Ala	Ser	Ser	Glu	Thr	Gly
							5			10			15			

55	Val	Gly	Ala	Ser	Gly	Gly	Ser	Gly	Gly	Gly	Asp	Thr	Arg	
							20		25			30		

78

	Pro Arg Phe Leu Glu Gln Val Lys His Glu Cys His Phe Phe Asn Gly			
	35	40	45	
5	Thr Glu Arg Val Arg Phe Leu Asp Arg Tyr Phe Tyr His Gln Glu Glu			
	50	55	60	
	Tyr Val Arg Phe Asp Ser Asp Val Gly Glu Tyr Arg Ala Val Thr Glu			
	65	70	75	80
10	Leu Gly Arg Pro Asp Ala Glu Tyr Trp Asn Ser Gln Lys Asp Leu Leu			
	85	90	95	
	Glu Gln Lys Arg Ala Ala Val Asp Thr Tyr Cys Arg His Asn Tyr Gly			
	100	105	110	
15	Val Gly Glu Ser Phe Thr Val Gln Arg Arg Val Tyr Pro Glu Val Thr			
	115	120	125	
20	Val Ile Lys Glu Glu His Val Ile Ile Gln Ala Glu Phe Tyr Leu Asn			
	130	135	140	
	Pro Asp Gln Ser Gly Glu Phe Met Phe Asp Phe Asp Gly Asp Glu Ile			
	145	150	155	160
25	Phe His Val Asp Met Ala Lys Lys Glu Thr Val Trp Arg Leu Glu Glu			
	165	170	175	
	Phe Gly Arg Phe Ala Ser Phe Glu Ala Gln Gly Ala Leu Ala Asn Ile			
	180	185	190	
30	Ala Val Asp Lys Ala Asn Leu Glu Ile Met Thr Lys Arg Ser Asn Tyr			
	195	200	205	
	Thr Pro Ile Thr Asn			
35	210			
	<210> CG585			
40	<211> 215			
	<212> PRT			
	<213> Homo sapiens			
	Met Gly Asp Thr Gly Arg Ser Phe Thr Leu Ala Ser Ser Glu Thr Gly			
	5	10	15	
45	Val Gly Ala Ser Gly Gly Ser Gly Gly Gly Asp Thr Arg			
	20	25	30	
50	Pro Arg Phe Leu Glu Gln Val Lys His Glu Cys His Phe Phe Asn Gly			
	35	40	45	
	Thr Glu Arg Val Arg Phe Leu Asp Arg Tyr Phe Tyr His Gln Glu Glu			
	50	55	60	
55	Tyr Val Arg Phe Asp Ser Asp Val Gly Glu Tyr Arg Ala Val Thr Glu			
	65	70	75	80
	Leu Gly Arg Pro Asp Ala Glu Tyr Trp Asn Ser Gln Lys Asp Leu Leu			
	85	90	95	

Glu Gln Lys Arg Ala Ala Val Asp Thr Tyr Cys Arg His Asn Tyr Gly  
 100 105 110

5 Val Gly Glu Ser Phe Thr Val Gln Arg Arg Phe Asp Ala Pro Ser Pro  
 115 120 125

Leu Pro Ile Lys Glu Glu His Val Ile Ile Gln Ala Glu Phe Tyr Leu  
 130 135 140

10 Asn Pro Asp Gln Ser Gly Glu Phe Met Phe Asp Phe Asp Gly Asp Glu  
 145 150 155 160

15 Ile Phe His Val Asp Met Ala Lys Lys Glu Thr Val Trp Arg Leu Glu  
 165 170 175

Glu Phe Gly Arg Phe Ala Ser Phe Glu Ala Gln Gly Ala Leu Ala Asn  
 180 185 190

20 Ile Ala Val Asp Lys Ala Asn Leu Glu Ile Met Thr Lys Arg Ser Asn  
 195 200 205

Tyr Thr Pro Ile Thr Asn  
 210

25

<210> CO584  
 <211> 214  
 <212> PRT  
 30 <213> Homo sapiens

Met Gly Asp Thr Gly Arg Ser Phe Thr Leu Ala Ser Ser Glu Thr Gly  
 5 10 15

35 Val Gly Ala Ser Gly Gly Ser Gly Gly Gly Asp Thr Arg  
 20 25 30

Pro Arg Phe Leu Glu Gln Val Lys His Glu Cys His Phe Phe Asn Gly  
 35 40 45

40 Thr Glu Arg Val Arg Phe Leu Asp Arg Tyr Phe Tyr His Gln Glu Glu  
 50 55 60

45 Tyr Val Arg Phe Asp Ser Asp Val Gly Glu Tyr Arg Ala Val Thr Glu  
 65 70 75 80

Leu Gly Arg Pro Asp Ala Glu Tyr Trp Asn Ser Gln Lys Asp Leu Leu  
 85 90 95

50 Glu Gln Lys Arg Ala Ala Val Asp Thr Tyr Cys Arg His Asn Tyr Gly  
 100 105 110

Val Gly Glu Ser Phe Thr Val Gln Arg Arg Ser Gly Gly Ser Gly Gly  
 115 120 125

55 Ser Ile Lys Glu Glu His Val Ile Ile Gln Ala Glu Phe Tyr Leu Asn  
 130 135 140

Pro Asp Gln Ser Gly Glu Phe Met Phe Asp Phe Asp Gly Asp Glu Ile

		80	
145	150	155	160
Phe His Val Asp Met Ala Lys Lys Glu Thr Val Trp Arg Leu Glu Glu			
	165	170	175
5	Phe Gly Arg Phe Ala Ser Phe Glu Ala Gln Gly Ala Leu Ala Asn Ile		
	180	185	190
10	Ala Val Asp Lys Ala Asn Leu Glu Ile Met Thr Lys Arg Ser Asn Tyr		
	195	200	205
	Thr Pro Ile Thr Asn		
	210		
15	<210> CO583		
	<211> 214		
	<212> PRT		
20	<213> Homo sapiens		
	Met Gly Asp Thr Gly Arg Ser Phe Thr Leu Ala Ser Ser Glu Thr Gly		
	5	10	15
25	Val Gly Ala Ser Gly Gly Ser Gly Gly Gly Asp Thr Arg		
	20	25	30
	Pro Arg Phe Leu Glu Gln Val Lys His Glu Cys His Phe Phe Asn Gly		
	35	40	45
30	Thr Glu Arg Val Arg Phe Leu Asp Arg Tyr Phe Tyr His Gln Glu Glu		
	50	55	60
	Tyr Val Arg Phe Asp Ser Asp Val Gly Glu Tyr Arg Ala Val Thr Glu		
	65	70	75
35	Leu Gly Arg Pro Asp Ala Glu Tyr Trp Asn Ser Gln Lys Asp Leu Leu		
	85	90	95
40	Glu Gln Lys Arg Ala Ala Val Asp Thr Tyr Cys Arg His Asn Tyr Gly		
	100	105	110
	Val Gly Glu Ser Phe Thr Val Gln Arg Arg Thr Ser Gly Gly Gly		
	115	120	125
45	Ser Ile Lys Glu Glu His Val Ile Ile Gln Ala Glu Phe Tyr Leu Asn		
	130	135	140
	Pro Asp Gln Ser Gly Glu Phe Met Phe Asp Phe Asp Gly Asp Glu Ile		
50	145	150	155
	160		
	Phe His Val Asp Met Ala Lys Lys Glu Thr Val Trp Arg Leu Glu Glu		
	165	170	175
55	Phe Gly Arg Phe Ala Ser Phe Glu Ala Gln Gly Ala Leu Ala Asn Ile		
	180	185	190
	Ala Val Asp Lys Ala Asn Leu Glu Ile Met Thr Lys Arg Ser Asn Tyr		
	195	200	205

81

Thr Pro Ile Thr Asn  
210

Val Gly Ala Ser Gly Gly Gly Ser Gly Gly Gly Asp Thr Arg  
 20 25 30

5 Pro Arg Phe Leu Glu Gln Val Lys His Glu Cys His Phe Phe Asn Gly  
 35 40 45

Thr Glu Arg Val Arg Phe Leu Asp Arg Tyr Phe Tyr His Gln Glu Glu  
 50 55 60

10 Tyr Val Arg Phe Asp Ser Asp Val Gly Glu Tyr Arg Ala Val Thr Glu  
 65 70 75 80

Leu Gly Arg Pro Asp Ala Glu Tyr Trp Asn Ser Gln Lys Asp Leu Leu  
 15 85 90 95

Glu Gln Lys Arg Ala Ala Val Asp Thr Tyr Cys Arg His Asn Tyr Gly  
 100 105 110

20 Val Gly Glu Ser Phe Thr Val Gln Arg Arg Gly Ser Pro Pro Gly Gly  
 115 120 125

Pro Pro Gly Ser Ile Lys Glu Glu His Val Ile Ile Gln Ala Glu Phe  
 130 135 140

25 Tyr Leu Asn Pro Asp Gln Ser Gly Glu Phe Met Phe Asp Phe Asp Gly  
 145 150 155 160

30 Asp Glu Ile Phe His Val Asp Met Ala Lys Lys Glu Thr Val Trp Arg  
 165 170 175

Leu Glu Glu Phe Gly Arg Phe Ala Ser Phe Glu Ala Gln Gly Ala Leu  
 180 185 190

35 Ala Asn Ile Ala Val Asp Lys Ala Asn Leu Glu Ile Met Thr Lys Arg  
 195 200 205

Ser Asn Tyr Thr Pro Ile Thr Asn  
 210 215

40 <210> CO580  
 <211> 221  
 <212> PRT  
 45 <213> Homo sapiens

Met Gly Asp Thr Gly Arg Ser Phe Thr Leu Ala Ser Ser Glu Thr Gly  
 5 10 15

50 Val Gly Ala Ser Gly Gly Ser Gly Gly Gly Asp Thr Arg  
 20 25 30

Pro Arg Phe Leu Glu Gln Val Lys His Glu Cys His Phe Phe Asn Gly  
 35 40 45

55 Thr Glu Arg Val Arg Phe Leu Asp Arg Tyr Phe Tyr His Gln Glu Glu  
 50 55 60

Tyr Val Arg Phe Asp Ser Asp Val Gly Glu Tyr Arg Ala Val Thr Glu

		83		
	65	70	75	80
	Leu Gly Arg Pro Asp Ala Glu Tyr Trp Asn Ser Gln Lys Asp Leu Leu			
	85		90	95
5	Glu Gln Lys Arg Ala Ala Val Asp Thr Tyr Cys Arg His Asn Tyr Gly			
	100		105	110
	Val Gly Glu Ser Phe Thr Val Gln Arg Arg Gly Ser Pro Gly Gly Gly			
10	115	120	125	
	Gly Ser Gly Gly Pro Gly Ser Ile Lys Glu Glu His Val Ile Ile			
	130	135	140	
15	Gln Ala Glu Phe Tyr Leu Asn Pro Asp Gln Ser Gly Glu Phe Met Phe			
	145	150	155	160
	Asp Phe Asp Gly Asp Glu Ile Phe His Val Asp Met Ala Lys Lys Glu			
	165		170	175
20	Thr Val Trp Arg Leu Glu Glu Phe Gly Arg Phe Ala Ser Phe Glu Ala			
	180		185	190
	Gln Gly Ala Leu Ala Asn Ile Ala Val Asp Lys Ala Asn Leu Glu Ile			
25	195	200	205	
	Met Thr Lys Arg Ser Asn Tyr Thr Pro Ile Thr Asn			
	210	215	220	
30	<210> CO567			
	<211> 221			
	<212> PRT			
	<213> Homo sapiens			
35	Met Gly Asp Thr Gly Arg Ser Phe Thr Leu Ala Ser Ser Glu Thr Gly			
	5		10	15
	Val Gly Ala Ser Gly Gly Gly Ser Gly Gly Gly Asp Thr Arg			
40	20	25	30	
	Pro Arg Phe Leu Glu Gln Val Lys His Glu Cys His Phe Phe Asn Gly			
	35	40	45	
45	Thr Glu Arg Val Arg Phe Leu Asp Arg Tyr Phe Tyr His Gln Glu Glu			
	50	55	60	
	Tyr Val Arg Phe Asp Ser Asp Val Gly Glu Tyr Arg Ala Val Thr Glu			
	65	70	75	80
50	Leu Gly Arg Pro Asp Ala Glu Tyr Trp Asn Ser Gln Lys Asp Leu Leu			
	85		90	95
	Glu Gln Lys Arg Ala Ala Val Asp Thr Tyr Cys Arg His Asn Tyr Gly			
55	100	105	110	
	Val Gly Glu Ser Phe Thr Val Gln Arg Arg Thr Ser Gly Gly Gly			
	115	120	125	

84

	Ser	Gly	Gly	Gly	Gly	Ser	Ser	Ser	Ile	Lys	Glu	Glu	His	Val	Ile	Ile
	130					135				140						
5	Gln	Ala	Glu	Phe	Tyr	Leu	Asn	Pro	Asp	Gln	Ser	Gly	Glu	Phe	Met	Phe
	145					150				155				160		
	Asp	Phe	Asp	Gly	Asp	Glu	Ile	Phe	His	Val	Asp	Met	Ala	Lys	Glu	
						165				170				175		
10	Thr	Val	Trp	Arg	Leu	Glu	Glu	Phe	Gly	Arg	Phe	Ala	Ser	Phe	Glu	Ala
						180				185				190		
	Gln	Gly	Ala	Leu	Ala	Asn	Ile	Ala	Val	Asp	Lys	Ala	Asn	Leu	Glu	Ile
						195				200				205		
15	Met	Thr	Lys	Arg	Ser	Asn	Tyr	Thr	Pro	Ile	Thr	Asn				
						210				215				220		

I-As MBP. $\beta$ 1 $\beta$ 2 $\alpha$ 1 $\alpha$ 2.C<sub>K</sub> nucleotide sequence

20	gcggccgcca	ccatggagac	agacacactc	ctgctatggg	tactgctgct	ctgggttcca	60
	ggttccactg	gtgacttcaa	gaacattgtg	acacctcgaa	caccacctcc	agctagcggaa	120
	ggggccggaa	gcggcggagg	gggagactcc	gaaaggcatt	tcgtgttcca	gttcaagggc	180
	gagtgctact	tcaccaaacgg	gacgcagcgc	atacgatctg	tggacagata	catctacaac	240
25	cgggaggagt	acctgcgtt	cgacagcgcac	gtggcgaggt	accgcgcggt	gaccgagctg	300
	ggccggccag	accccggagta	ctacaataag	cagtacctgg	agcaaacgcg	ggccgagctg	360
	gacacggtgt	gcagacacaa	ctacgagggg	gtggagaccc	acacccctct	gcggcggctt	420
	gaacagccca	atgtcgcat	ctccctgtcc	aggacagagg	ccctaaccac	ccacaacact	480
	ctggctctgct	cagtgacacaga	tttctaccacca	gccaagatca	aagtgcgcgtg	gttccggaat	540
30	ggccaggagg	agacgggtggg	ggtctcatcc	acacagctta	ttaggaatgg	ggactggacc	600
	ttccaggtcc	tggtcatgct	ggagatgacc	cctcggcggg	gagaggtctt	cacccgtccac	660
	gtggagcatc	cgagcctgaa	gagccccatc	actgtggagt	ggacttagtgg	tggcgggtggc	720
	agccggcgtg	gtggttccgg	tggcggcgggt	tctggcgggt	gcgggttccctc	gagtgaagac	780
	gacattgagg	ccgaccacgt	aggcgtctat	ggtacaactg	tatatcagtc	tcctggagac	840
35	attggccagt	acacacatga	atttcatggt	gatgagtggt	tctatgtgga	tttgataaag	900
	aaggagacta	tctggatgct	tcctgagttt	ggccaattga	caagcttga	cccccaaggt	960
	ggactgcaaa	acatagctac	agaaaaataac	accttgggaa	tcttgactaa	gaggtcaaata	1020
	tccaccccaag	ctaccaatga	ggctccctaa	gcgactgtgt	tccccaagtc	ccctgtgtg	1080
40	ctgggtcagc	ccaacaccct	catctgcttt	gtggacaaca	tcttccctcc	tgtatcaac	1140
	atcacatggc	tcagaatata	taagtcaagtc	acagacggcg	tttatgagac	cagttccctt	1200
	gtcaaccgtg	accattccctt	ccacaagctg	tcttatctca	ccttcataccc	ttctgacgt	1260
	gatattttag	actgcaaggt	ggagcactgg	ggcctggagg	agccgggttct	gaaacactgg	1320
	gctagcggag	ggggcggaaag	cggcggaggg	ggagctgatg	ctgcaccaac	tgtatccatc	1380
45	ttcccaccat	ccagtgagca	gttaacatct	ggaggtgcct	cagtcgtgt	tttcttgaac	1440
	aacttctacc	ccaaagacat	caatgtcaag	tggaaaggattg	atggcagtg	acgacaaaat	1500
	ggcgtctgta	acagttggac	tgatcaggac	agcaaagaca	gcacccatcag	catgagcagc	1560
	accctcacgt	tgaccaagga	cgagtatgaa	cgacataaca	gctataccctg	tgaggccact	1620
	cacaagacat	caacttcacc	cattgtcaag	agcttcaaca	ggaatgagtg	ttagggtacc	1680

50 I-As MBP. $\beta$ 1 $\beta$ 2 $\alpha$ 1 $\alpha$ 2.C<sub>K</sub> amino acid sequence

Met	Glu	Thr	Asp	Thr	Leu	Leu	Leu	Trp	Val	Leu	Leu	Leu	Trp	Val	Pro
5								10					15		

55	Gly	Ser	Thr	Gly	Asp	Phe	Lys	Asn	Ile	Val	Thr	Pro	Arg	Thr	Pro	Pro
								20		25			30			

85

Pro Ala Ser Gly Gly Gly Ser Gly Gly Gly Asp Ser Glu Arg  
                  35                        40                        45

5 His Phe Val Phe Gln Phe Lys Gly Glu Cys Tyr Phe Thr Asn Gly Thr  
       50                    55                    60

Gln Arg Ile Arg Ser Val Asp Arg Tyr Ile Tyr Asn Arg Glu Glu Tyr  
       65                    70                    75                    80

10 Leu Arg Phe Asp Ser Asp Val Gly Glu Tyr Arg Ala Val Thr Glu Leu  
       85                    90                    95

Gly Arg Pro Asp Pro Glu Tyr Tyr Asn Lys Gln Tyr Leu Glu Gln Thr  
 15          100                    105                    110

Arg Ala Glu Leu Asp Thr Val Cys Arg His Asn Tyr Glu Gly Val Glu  
       115                    120                    125

20 Thr His Thr Ser Leu Arg Arg Leu Glu Gln Pro Asn Val Val Ile Ser  
       130                    135                    140

Leu Ser Arg Thr Glu Ala Leu Asn His His Asn Thr Leu Val Cys Ser  
 25          145                    150                    155                    160

Val Thr Asp Phe Tyr Pro Ala Lys Ile Lys Val Arg Trp Phe Arg Asn  
       165                    170                    175

30 Gly Gln Glu Glu Thr Val Gly Val Ser Ser Thr Gln Leu Ile Arg Asn  
       180                    185                    190

Gly Asp Trp Thr Phe Gln Val Leu Val Met Leu Glu Met Thr Pro Arg  
       195                    200                    205

35 Arg Gly Glu Val Tyr Thr Cys His Val Glu His Pro Ser Leu Lys Ser  
       210                    215                    220

Pro Ile Thr Val Glu Trp Thr Ser Gly Gly Ser Gly Gly Gly Gly  
 40          225                    230                    235                    240

Gly Ser Gly Gly Ser Gly Gly Ser Ser Ser Glu Asp  
       245                    250                    255

Asp Ile Glu Ala Asp His Val Gly Val Tyr Gly Thr Thr Val Tyr Gln  
 45          260                    265                    270

Ser Pro Gly Asp Ile Gly Gln Tyr Thr His Glu Phe Asp Gly Asp Glu  
       275                    280                    285

50 Trp Phe Tyr Val Asp Leu Asp Lys Lys Glu Thr Ile Trp Met Leu Pro  
       290                    295                    300

Glu Phe Gly Gln Leu Thr Ser Phe Asp Pro Gln Gly Gly Leu Gln Asn  
 55          305                    310                    315                    320

Ile Ala Thr Gly Lys Tyr Thr Leu Gly Ile Leu Thr Lys Arg Ser Asn  
       325                    330                    335

Ser Thr Pro Ala Thr Asn Glu Ala Pro Gln Ala Thr Val Phe Pro Lys

	86			
	340	345	350	
	Ser Pro Val Leu Leu Gly Gln Pro Asn Thr Leu Ile Cys Phe Val Asp			
	355	360	365	
5	Asn Ile Phe Pro Pro Val Ile Asn Ile Thr Trp Leu Arg Asn Ser Lys			
	370	375	380	
10	Ser Val Thr Asp Gly Val Tyr Glu Thr Ser Phe Leu Val Asn Arg Asp			
	385	390	395	400
	His Ser Phe His Lys Leu Ser Tyr Leu Thr Phe Ile Pro Ser Asp Asp			
	405	410	415	
15	Asp Ile Tyr Asp Cys Lys Val Glu His Trp Gly Leu Glu Glu Pro Val			
	420	425	430	
	Leu Lys His Trp Ala Ser Gly Gly Gly Ser Gly Gly Gly Ala			
	435	440	445	
20	Asp Ala Ala Pro Thr Val Ser Ile Phe Pro Pro Ser Ser Glu Gln Leu			
	450	455	460	
	Thr Ser Gly Gly Ala Ser Val Val Cys Phe Leu Asn Asn Phe Tyr Pro			
25	465	470	475	480
	Lys Asp Ile Asn Val Lys Trp Lys Ile Asp Gly Ser Glu Arg Gln Asn			
	485	490	495	
30	Gly Val Leu Asn Ser Trp Thr Asp Gln Asp Ser Lys Asp Ser Thr Tyr			
	500	505	510	
	Ser Met Ser Ser Thr Leu Thr Leu Thr Lys Asp Glu Tyr Glu Arg His			
	515	520	525	
35	Asn Ser Tyr Thr Cys Glu Ala Thr His Lys Thr Ser Thr Ser Pro Ile			
	530	535	540	
	Val Lys Ser Phe Asn Arg Asn Glu Cys			
40	545	550		

&lt;210&gt; CO528-AC

&lt;211&gt; 600

45 &lt;212&gt; DNA

&lt;213&gt; Homo sapiens

atgggggaca ccgggtcgca g cttcacccctg gcctccagcg agaccggcgt ggggtgggtggc 60  
 ggttcgcgtc cacgtttctt ggaacagggtt aaacatgagt gtcattttt caatgggacg 120  
 50 gaacgcgtgc gttttctgga tcgttacttt tatcaccaaag aggaatacgt acgcttcgac 180  
 agcgatgtgg gccaatatacg tgcggtcacg gaactgggtc gtcctgatgc cgaataactgg 240  
 aacagtcaaga aggacttact ggagcagaaaa cgtgcagcgg tggatacccta ttgccgcccac 300  
 aattacggcg ttgggtgaaag cttcacagtc cagcgtcgcg gtggcatcaa agaagagcat 360  
 55 gtgattatcc aggcggaaatt ctatctgaat ccggatcaat cgggcgaatt catgtttgac 420  
 ttcgatggtg atgagatttt ccatgttgat atggcaaaga aagaaacggt ctggcgctta 480  
 gagaatttg gcccgtttgc ctcgttcgaaa gctcaaggcg cattggccaa cattgctgtg 540  
 gataaagcga acctggaaat catgacaaaaa cgctccaaact atactccgat taccaattaa 600

<210> CO608-AC  
 <211> 642  
 <212> DNA  
 5 <213> Homo sapiens

```

atgggggaca ccgtcgac cttcacccctg gcctccagcg agaccggcgt gggtgcttct 60
ggcgggggcg gttcggcg tgggggtgac acccgccac gtttcttggaa acaggtaaa 120
catgagtgtc atttttcaa tggacggaa cgctgcgtt ttctggatcg ttacttttat 180
10 caccaagagg aatacgtacg ctgcacacgc gatgtggcgt aatatcgatc ggtcacggaa 240
ctgggtcgtc ctgatgccga atactggaaac agtcagaagg acttactggaa gcagaaaacgt 300
gcagcggtgg atacctattg ccgcacaaat tacggcggtt gtgaaagctt cacagtccag 360
cgtcgcacta gtggtggcgg tgctctatc aaagaagagc atgtgattat ccaggcggaa 420
ttctatctga atccggatca atcgggcaaa ttcatgtttt acttcgatgg tgatgagatt 480
15 ttccatgttg atatggaaa gaaagaaaacg gtctggcgct tagaggaatt tggccgctt 540
gcctcggtcg aagctcaagg cgattggcc aacattgctg tggataaaagc gaacctggaa 600
atcatgacaa aacgctccaa ctatactccg attaccaatt aa 642
  
```

20 <210> CO528  
 <211> 600  
 <212> DNA  
 <213> Homo sapiens

```

atgggggaca ccggaagatc gttcacactc gcatcatcag agacaggagt aggaggagga 60
ggatcgac cacgttctt ggagcagggtt aaacatgagt gtcatttctt caacgggacg 120
gagcgggtgc ggttccttga cagatacttc tatcaccaag aggagtagt ggcgttcgac 180
agcgacgtgg gggagtaccg ggcgttgcac gagctgggc ggcgtatgc cgagtactgg 240
aacagccaga gggacccctt ggagcagaag cggccgcgg tggacaccta ctgcagacac 300
25 aactacgggg ttggtgagag ctgcacagtg cagcggcggag gaggtatcaa agaagaacat 360
gtgatcatcc aggccgagtt ctatctgaat cctgaccaat caggcgaggat tatgtttgac 420
tttgcgttg atgagatttt ccatgtggat atggcaaaaga aggagacggt ctggcggctt 480
gaagaatttgc gacgatttgc cagctttagt gctcaaggat cattggccaa catagctgtg 540
gacaaagcca acctggaaat catgacaaag cgctccaact atactccgat caccatcaa 600
  
```

35 <210> CO608  
 <211> 630  
 <212> DNA  
 <213> Homo sapiens

```

ATGGGGGACACCCGCAGCTTCACCCCTGGCCTCCAGCGAGACCGGCGTGGGCCTAGCGGAGGGGGCGGAAGC
GGCGGAGGGGGGCCACGTTCTTGAGCAGGTTAACATGAGTGTCAATTCTCAACGGGACGGAGCGGGTG
45 CGGTTCTGGACAGATACTTCTATCACCAAGAGGGACTCGTGCCTCGACAGCGACGTGGGGAGTACCGG
GCGGTGACGGAGCTGGGGCGCTGATGCCGAGTACTGGAACAGCCAGAAGGACCTCCTGGAGCAGAACCGG
GCCGGTGGACACCTACTGCAGACACAACACTACGGGTTGGTGAGAGCTTCACAGTGCAGCGGGAACTAGT
GGTGGCGGTGGCAGCATCAAAGAAGAACATGTGATCATCCAGGCCAGTTCTATCTGAATCCTGACCAATCA
GGCGAGTTTATGTTGACTTGTGGTGTGAGATTTCCATGTGGATATGGCAAAGAAGGAGACGGTCTGG
50 CGGCTTGAAGAATTGGACATTGCCAGCTTGAGGCTCAAGGTGCATTGGCCAACATAGCTGTGGACAAA
GCCAACCTGGAAATCATGACAAAGCGCTCAAACATACCTCCGATCACCAATTAA
  
```

<210> CO 608 variation  
 <211> 642  
 <212> DNA--CO608  
 <213> Homo sapiens

```

ATGGGGGACACCGGTCGAGCTTCACCCCTGGCCTCCAGCGAGACCGGCGTGGGCCTAGCGGAGGGGGCGGA
AGCGGGAGGGGGACACCCGACCGACGTTCTTGAGCAGGTTAACATGAGTGTCAATTCTCAACGGG
  
```

88

ACGGAGCGGGTGCCTCGAACAGATACTTCTATCACCAAGAGGAGTACGTGCCCTCGACAGCGACGTG  
GGGGAGTACCGGGCGGTGACGGAGCTGGGCGGCCGTATGCCAGTACTGGAACAGCCAGAAGGACCTCTG  
GAGCAGAACGGGCGCGGTGACACCTACTGCAGACACAACTAGGGGTTGGTGAGAGCTTCACAGTGCAG  
CGGCGAACATAGTGGTGGCGGTGGCAGCATCAAAGAAGAACATGTGATCATCCAGGGCGAGTTCTATCTGAAT  
CCTGACCAATCAGGCAGATTATGTTGACTTGATGGTGATGAGATTTCATGTGGATATGGCAAAGAAG  
GAGACGGTCTGGCGGCTGAAAGATTGGACGATTGCCAGTTGAGGCTCAAGGTGCATTGGCCAACATA  
GCTGTGGACAAAGCCAACCTGGAAATCATGACAAAGCGCTCCAACATACTCCGATCACCAATTAA

10 <210> CO528-AC  
<211> 2aa  
<212> PRT  
<213> Homo sapiens

15 Met Gly Asp Thr Gly Arg Ser Phe Thr Leu Ala Ser Ser Glu Thr Gly  
5 10 15

Val Gly Gly Gly Ser Arg Pro Arg Phe Leu Glu Gln Val Lys His  
20 25 30

20 Glu Cys His Phe Phe Asn Gly Thr Glu Arg Val Arg Phe Leu Asp Arg  
35 40 45

Tyr Phe Tyr His Gln Glu Glu Tyr Val Arg Phe Asp Ser Asp Val Gly  
           50                 55                 60

Glu Tyr Arg Ala Val Thr Glu Leu Gly Arg Pro Asp Ala Glu Tyr Trp  
65 70 75 80

30 Asn Ser Gln Lys Asp Leu Leu Glu Gln Lys Arg Ala Ala Val Asp Thr  
85 90 95

Tyr Cys Arg His Asn Tyr Gly Val Gly Glu Ser Phe Thr Val Gln Arg  
100 105 110

35 Arg Gly Gly Ile Lys Glu Glu His Val Ile Ile Gln Ala Glu Phe Tyr  
115 120 125

Leu Asn Pro Asp Gln Ser Gly Glu Phe Met Phe Asp Phe Asp Gly Asp  
130 135 140

**145**                    **150**                    **155**                    **160**

45 Glu Glu Phe Gly Arg Phe Ala Ser Phe Glu Ala Gln GIY Ala Leu Ala  
 165 170 175

Asn Ile Ala Val Asp Lys Ala Asn Leu Glu Ile Met Thr Lys Arg Ser

50

Asn Tyr Thr Pro Ile Thr Asn  
195 .

55 <210> C0608-AC  
<211> 214  
<212> PRT  
<213> Homo sapiens

89

Met Gly Asp Thr Gly Arg Ser Phe Thr Leu Ala Ser Ser Glu Thr Gly  
                       5                         10                         15

Val Gly Ala Ser Gly Gly Ser Gly Gly Gly Asp Thr Arg  
   5                  20                  25                         30

Pro Arg Phe Leu Glu Gln Val Lys His Glu Cys His Phe Phe Asn Gly  
                   35                        40                         45

10   Thr Glu Arg Val Arg Phe Leu Asp Arg Tyr Phe Tyr His Gln Glu Glu  
       50                                 55                         60

Tyr Val Arg Phe Asp Ser Asp Val Gly Glu Tyr Arg Ala Val Thr Glu  
   65                    70                    75                         80

15   Leu Gly Arg Pro Asp Ala Glu Tyr Trp Asn Ser Gln Lys Asp Leu Leu  
       85                    90                                 95

20   Glu Gln Lys Arg Ala Ala Val Asp Thr Tyr Cys Arg His Asn Tyr Gly  
       100                    105                         110

Val Gly Glu Ser Phe Thr Val Gln Arg Arg Thr Ser Gly Gly Gly  
   115                    120                                 125

25   Ser Ile Lys Glu Glu His Val Ile Ile Gln Ala Glu Phe Tyr Leu Asn  
       130                    135                         140

Pro Asp Gln Ser Gly Glu Phe Met Phe Asp Phe Asp Gly Asp Glu Ile  
   145                    150                            155                 160

30   Phe His Val Asp Met Ala Lys Lys Glu Thr Val Trp Arg Leu Glu Glu  
       165                    170                         175

Phe Gly Arg Phe Ala Ser Phe Glu Ala Gln Gly Ala Leu Ala Asn Ile  
 35   180                    185                         190

Ala Val Asp Lys Ala Asn Leu Glu Ile Met Thr Lys Arg Ser Asn Tyr  
   195                    200                         205

40   Thr Pro Ile Thr Asn  
       210

45   <210> CO608  
 <211> 209  
 <212> PRT  
 <213> Homo sapiens

50   MGDTRSFTLASSETGVGASGGGGGGGGPRFLEQVKHECHFFNGTERVRFLDRYFYHQEEYVRFDSDVGEYR  
 AVTELGRPDAEYWNSQKDLLEQKRAAVDTYCRHNYVGESFTVQRTSGGGGSIKEEHVIIQAEFYLNPDQS  
 GEFMFDFDGDEIFHVDMAKKETVWRLEEFGRFASFEAQGALANIAVDKANLEIMTKRSNYTPITN

55   <210> CO608-variation  
 <211> 211  
 <212> PRT  
 <213> Homo sapiens

90

MGDTGRSFTLASSETGVGASGGGGGGGGDTRPRFLEQVKHECHFFNGTERVRFLDRYFYHQEEYVRFDSDV  
 GEYRAVTELGRPDAEYWNSQKDLLEQKRAAVDTYCRHNYGVGESFTVQRRTSGGGSIKEEHVIIQAEFYLN  
 PDQSGEFMFDFDGDEIFHVDMAKKETVWRLEEFGRFASFEAQGALANIADKANLEIMTKRSNYTPIT

5

&lt;210&gt; C0528

&lt;211&gt; 200

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

10

Met	Gly	Asp	Thr	Gly	Arg	Ser	Phe	Thr	Leu	Ala	Ser	Ser	Glu	Thr	Gly
							5						10		15

15

Val	Gly	Gly	Gly	Gly	Ser	Arg	Pro	Arg	Phe	Leu	Glu	Gln	Val	Lys	His
							20					25		30	

Glu	Cys	His	Phe	Phe	Asn	Gly	Thr	Glu	Arg	Val	Arg	Phe	Leu	Asp	Arg
							35					40		45	

20

Tyr	Phe	Tyr	His	Gln	Glu	Glu	Tyr	Val	Arg	Phe	Asp	Ser	Asp	Val	Gly
							50					55		60	

Glu	Tyr	Arg	Ala	Val	Thr	Glu	Leu	Gly	Arg	Pro	Asp	Ala	Glu	Tyr	Trp
							65					70		80	

25

Asn	Ser	Gln	Arg	Asp	Leu	Leu	Glu	Gln	Lys	Arg	Ala	Ala	Val	Asp	Thr
							85					90		95	

30

Tyr	Cys	Arg	His	Asn	Tyr	Gly	Val	Gly	Glu	Ser	Phe	Thr	Val	Gln	Arg
							100					105		110	

Arg	Gly	Gly	Ile	Lys	Glu	Glu	His	Val	Ile	Ile	Gln	Ala	Glu	Phe	Tyr
							115					120		125	

35

Leu	Asn	Pro	Asp	Gln	Ser	Gly	Glu	Phe	Met	Phe	Asp	Phe	Asp	Gly	Asp
							130					135		140	

Glu	Ile	Phe	His	Val	Asp	Met	Ala	Lys	Lys	Glu	Thr	Val	Trp	Arg	Leu
							145					150		155	

40

Glu	Glu	Phe	Gly	Arg	Phe	Ala	Ser	Phe	Glu	Ala	Gln	Gly	Ala	Leu	Ala
							165					170		175	

45

Asn	Ile	Ala	Val	Asp	Lys	Ala	Asn	Leu	Glu	Ile	Met	Thr	Lys	Arg	Ser
							180					185		190	

Asn	Tyr	Thr	Pro	Ile	Thr	Asn
						195

50

&lt;210&gt; IAS MBP1-14 CH1.CH2.CH3

&lt;211&gt; 2346

&lt;212&gt; DNA

&lt;213&gt; murine

55

gcggccgcca	ccatggagac	agacacactc	ctgctatggg	tactgctgct	ctgggttcca	60
gtttccactg	gtgacatggc	gtcacagaag	agaccctccc	agaggcacgg	atccaaggct	120
agcggagggg	gcggaagcgg	cggaggggga	gactccgaaa	gcatattcg	gttccagttc	180

91

	aaggcgagt	gctacttcac	caacgggacg	cagcgcatac	gatctgtgga	cagatacac	240
	tacaaccggg	aggagtacct	gcmcctcgac	agcgcacgtgg	gcgagttaccc	cgccgtgacc	300
	gagctggggc	ggccagaccc	cgagttactac	aataagcagt	acctggagca	aacgcgggccc	360
5	gagctggaca	cggtgtcgag	acacaactac	gaggggggtgg	agacccacac	ctccctgcgg	420
	cggcttgaac	agcccaatgt	cgtcatctcc	ctgtccagga	cagaggccct	caaccaccac	480
	aacactctgg	tctgctcagt	gacagattt	tacccagcca	agatcaaagt	gcgctgggtc	540
	cggaaatggcc	aggaggagac	ggtgggggttc	tcatccacac	agcttattag	aatggggac	600
	tggaccttcc	aggtccttgtt	catgctggag	atgaccctc	ggcgggggaga	ggtctacacc	660
10	tgcacacgtgg	agcattccgag	cctgaagagc	cccatctactg	tggagtgac	tagtggtggc	720
	ggtggcagcg	gcgggttgtgg	ttccgggtggc	ggcggttctg	gcgggtggcgg	ttccctcgagt	780
	gaagacgaca	ttgaggccga	ccacgttaggc	gtctatggta	caactgtata	tcagtcct	840
	ggagacattt	gccagtacac	acatgaattt	gatgggtatg	agtggttcta	tgtggacttg	900
	gataagaagg	agactatctg	gatgcttcct	gagttggcc	aattgacaag	ctttgacccc	960
15	caaggtggac	tgcaaaaacat	agctacagga	aaatacacctt	tgggaatctt	gactaagagg	1020
	tcaatttcca	ccccagctac	caatgaggct	cctcaagcga	ctgtgttccc	caagtcccct	1080
	gtgtgtctgg	gtcagccaa	caccctcattt	tgctttgtgg	acaacatctt	ccctccctgt	1140
	atcaacatca	catggctcag	aaatagtaag	tcagtcacag	acggcgttta	tgagaccagc	1200
	ttccctgtca	accgtgacca	ttcccttccac	aagctgtctt	atctcaccctt	catcccttct	1260
20	gacgatgata	tttatgactg	caaggtggag	cactggggcc	tggaggagcc	ggttctgaaa	1320
	cactgggcta	gcggaggggg	cggaagcggc	ggagggggag	ccaaaacgac	accccccattt	1380
	gtctatccac	tggcccttgg	atctgctgccc	caaactaact	ccatgggtgac	cctgggatgc	1440
	ctggtaagg	gttattttcc	tgagccagtg	acagtgcac	ggaactctgg	atccctgtcc	1500
	agcgggtgtc	acaccccttcc	agctgtcttg	cagtctgacc	tctacactct	gagcagctca	1560
25	gtgactgtcc	cctccagcac	ctggcccagc	gagaccgtca	cctgcaacgt	tgcacccccc	1620
	gccagcagca	ccaagggtgg	caagaaaattt	gtgcccaggg	attgtggttt	taagcettgc	1680
	atatgtacag	tcccagaagt	atcatctgtc	ttcatcttcc	ccccaaagcc	caaggatgt	1740
	ctcaccattt	ctctgactcc	taaggtcag	tgtgtgtgg	tagacatcag	caaggatgtat	1800
	cccgaggatcc	agttcagctg	gtttgttagat	gatgtggagg	tgcacacagc	tcagacgcaa	1860
30	ccccgggagg	agcagttcaa	cagcactttc	cgctcaagtca	gtgaacttcc	catcatgcac	1920
	caggactggc	tcaatggcaa	ggagttcaaa	tgcagggtca	acagtgcage	ttccctgtcc	1980
	cccatcgaga	aaaccatctc	aaaaacccaa	ggcagaccga	aggctccaca	ggtgtacacc	2040
	attccacctc	ccaaggagca	gatggccaag	gataaagtca	gtctgacctt	catgataaca	2100
	gacttctcc	ctgaagacat	tactgtggag	tggcagttgg	atgggcagcc	agcggagaac	2160
35	tacaagaaca	ctcagcccat	catggacaca	gatggcttctt	acttcgttca	cagcaagctc	2220
	aatgtgcaga	agagcaactg	ggaggcagga	aataacttca	cctgctctgt	gttacatgag	2280
	ggctctgcaca	accaccatac	tgagaagagc	ctctccact	ctccctggtaa	atgatctgg	2340
	acctgc						2346

40 &lt;210&gt; IAS MRP 1-14 CH1.H

&lt;211&gt; 1701

&lt;212&gt; DNA

&lt;213&gt; murine

45	gcggccgcca	ccatggagac	agacacactc	ctgctatggg	tactgtctgt	ctgggttcca	60
	ggttccactg	gtgacatggc	gtcacagaag	agaccctccc	agaggcacgg	atccaaggct	120
	agcggagggg	gcggaaagcgg	cggagggggg	gactccgaaa	ggcatttctgt	gttccagttc	180
	aaggcgagt	gtctacttcac	caacgggacg	cagcgcatac	gatctgtgg	cagatacac	240
	tacaaccggg	aggagtacct	gcmcctcgac	agcgcacgtgg	gcgagttaccc	cgccgtgacc	300
50	gagctggggc	ggccagaccc	cgagtactac	aataagcagt	acctggagca	aacgcgggccc	360
	gagctggaca	cggtgtcgag	acacaactac	gaggggggtgg	agacccacac	ctccctgcgg	420
	cggcttgaac	agcccaatgt	cgtcatctcc	ctgtccagga	cagaggccct	caaccaccac	480
	aacactctgg	tctgctcagt	gacagattt	tacccagcca	agatcaaagt	gcgctgggtc	540
	cggaatggcc	aggaggagac	ggtgggggtc	tcatccacac	agcttattag	aatggggac	600
55	tggaccttcc	aggtecttgtt	catgtgtgg	atgacccttc	ggcgffffgaga	ggtctacacc	660
	tgcacacgtgg	agcatccgag	cctgaagagc	cccatctactg	tggagtgac	tagtggtggc	720
	ggtggcagcg	gcgggtgggtgg	ttccgggtggc	ggcggttctg	gcgggtggcgg	ttccctcgagt	780
	gaagacgaca	ttgaggccga	ccacgttaggc	gtctatggta	caactgtata	tcagtcct	840
	ggagacattt	gccagttacac	acatgaattt	gatgggtatg	agtggttctt	tgtggacttg	900

92

	gataagaagg	agactatctg	gatgcttccc	gagtttgcc	aattgacaag	cttgacc	960
	caagggtggac	tgcaaaaacat	agctacagga	aaatacacct	tggaaatctt	gactaaggagg	1020
	tcaaattcca	ccccagctac	caatgagggct	cctcaagcga	ctgtgttccc	caagtccccc	1080
	gtgctgtgg	gtcagccaa	caccctcatc	tgctttgtgg	acaacatctt	ccctccctgtg	1140
5	atcaacatca	catggctcag	aaatagtaag	tcagtcacag	acggcggtta	tgagaccaggc	1200
	ttccttgtca	accgtgacca	ttccttccac	aagctgttctt	atctcacctt	catcccttct	1260
	gacgatgata	tttatgactg	caaggtggag	cactggggcc	tggaggagcc	ggttctgaaa	1320
	cactgggcta	gcggaggggg	cggaagcggc	ggagggggag	ccaaaacgcac	accccccattt	1380
10	gtctatccac	tggcccctgg	atctgtgcc	caaactaact	ccatgggtac	cctgggatgc	1440
	ctgggtcaagg	gctattttccc	tgagccagtg	acagtgcacct	ggaactctgg	atccctgtcc	1500
	agcgggtgtgc	acacccccc	agctgtcctg	cagtctgacc	tctacactct	gagcagctca	1560
	gtgactgtcc	cctccagcac	ctggcccccagc	gagaccgtca	cctgcaacgt	tgcccacccg	1620
	gccagcagca	ccaagggtgga	caagaaaatt	gtgcccaggg	attgtggttg	taagccttgc	1680
15	atatgtacag	tctaaggta	c				1701

<210> IAS MBP 90-101 CH1.H.CH2  
<211> 2053  
<212> DNA  
20 <213> murine

	gcggccgcca	ccatggagac	agacacactc	ctgctatggg	tactgctgct	ctgggttcca	60
	ggttccactg	gtgacttcaa	gaacatttg	acacctcgaa	caccacctcc	agctagcgga	120
	gggggcggaa	gcggcggagg	gggagactcc	gaaaggcatt	tcgtgttcca	gtcaagggc	180
25	gagtgtact	tcaccaacgg	gacgcagcgc	atacgatctg	tggacagata	catctacaac	240
	cgggaggagt	acctgcgtt	cgacagcgac	gtggcgagt	accgcgcggt	gaccgagctg	300
	gggcggccag	accccgagta	ctacaataag	cagtacctgg	agcaaacgeg	ggccgagctg	360
	gacacggtgt	gcagacacaa	ctacgagggg	gtggagaccc	acacccctt	gcggcggctt	420
30	gaacagccca	atgtcgcat	ctcccgttcc	aggacagagg	ccctcaacca	ccacaacact	480
	ctgggtctgct	cagtgacaga	tttctaccca	gccaagatca	aagtgcgctg	gttccggaat	540
	ggccaggagg	agacgggtgg	ggtctcatcc	acacagctta	ttaggaatgg	ggactggacc	600
	ttccagggtcc	tggtcatgct	ggagatgacc	cctccggcggg	gagaggctta	cacccgtccac	660
35	gtggagcattc	cgaggctgaa	gagccccatc	actgtggagt	ggactagtgg	tggcggtggc	720
	agcggcgggt	gtgggtccgg	tggcggcgggt	tctggcgggt	gcccccttc	gagtgaagac	780
	gacattgagg	ccgaccacgt	aggcgtctat	ggtacaactg	tatatcagtc	tccctggagac	840
	attggccagt	acacacatga	atttgaatgg	gatgagtggt	tctatgtgga	cttggataag	900
40	aaggagacta	tctggatgct	tcctgagttt	ggccaattga	caagcttga	cccccaaggt	960
	ggactgcaaaa	acatagctac	aggaaaaatac	accttgggaa	tcttactaa	gagggtcaaat	1020
	tccacccccc	ctaccaatga	ggctcctcaa	gcgactgtgt	tccccaaagtc	ccctgtgctg	1080
	ctgggtcagc	ccaaacaccct	catctgcttt	gtggacaaca	tcttcctcc	tgtgatcaac	1140
45	atcacatggc	tcagaaaatag	taagtcagtc	acagacggcg	tttatgagac	cagttccctt	1200
	gtcaaccgtg	accattcctt	ccacaagctg	tcttatctca	ccttcatccc	ttctgacgat	1260
	gatattttatg	actgcaaggt	ggagcaactgg	ggcctggagg	agccgggttct	gaaacactgg	1320
	gctagcggag	ggggcggaaag	cgccggaggg	ggagccaaaa	caacaccccc	atcagtttat	1380
50	ccactggccc	ctgggtgtgg	agataacaact	ggttcctccg	tgactctggg	atgcctggtc	1440
	aagggtact	tccctgagtc	agtgactgtg	acttggaaact	ctggctccct	gtccagcagt	1500
	gtgcacaccc	tcccagctct	cctgcagttc	ggactctaca	ctatgagcag	ctcagtgact	1560
	gtccccctcca	gcacctggcc	aagtcaagacc	gtcacctgca	gcgttgccta	cccagccagc	1620
55	agcaccacgg	tggacaaaaaa	acttggagccc	agccccccca	tttcaacaat	caacccctgt	1680
	cctccatgca	aggagtgtca	caaattgccc	gctccctaacc	tggaggggtgg	accatccgtc	1740
	ttcatcttcc	ctccaaatat	caaggatgtt	ctcatgatct	ccctgacacc	caaggtcact	1800
	tgtgtgtgttgg	tggatgtgag	cgaggatgac	ccagacgtcc	agatcagctg	gtttgtgaac	1860
	aacgtgaaag	tacacacagc	tcagacacaa	accatagag	aggattacaa	cagtactatc	1920
	cgggtgtca	gcacccccc	catccagcac	caggactgg	tgagtggcaa	ggagttcaaa	1980
	tgcaaggtca	acaacaaaga	cctcccatca	cccatcgaga	gaaccatctc	aaaaattaaa	2040
	tagggtaccc	cga					2053

<210> IAS MBP 90-101 CH1.H

&lt;211&gt; 1707

&lt;212&gt; DNA

&lt;213&gt; murine

5   gcggccgcca ccatggagac agacacactc ctgctatggg tactgctgct ctgggttcca 60  
   ggttccactg gtgacttcaa gaacattgtg acaccccgaa caccacctcc agcttagcgct 120  
   agcggaggggg gcggaagcg  cgagggggg  gactccgaaa  ggcatttcgt  gttccagtcc 180  
   aaggggcgagt gctacttca  caacgggac  cagcgcatac  gatctgtgga  cagatacatc 240  
   tacaaccgggg aggagtacct  gwgcttcgac  agcgcacgtgg  gcgagtgacc  cgccgtgacc 300  
 10   gagctggggc  ggccagaccc  cgagttactac  aataagcagt  acctggagca  aacggggccc 360  
   gagctggaca  cggtgtgcag  acacaactac  gaggggggtgg  agacccacac  ctccctgcgg 420  
   cggcttgaac  agcccaatgt  cgtcatctcc  ctgtccagga  cagaggccct  caaccaccac 480  
   aacactctgg  tctgctcagt  gacagattt  tacccagcca  agatcaaagt  gcgctggttc 540  
   cggaatggcc  aggaggagac  ggtgggggtc  tcatccacac  agcttattag  aatggggac 600  
 15   tggaccttcc  aggccttgg  catgctggag  atgaccctc  ggcggggaga  ggtctacacc 660  
   tgccacgtgg  agcatccgag  cctgaagagc  cccatcactg  tggagtggac  tagtgggtgc 720  
   ggtggcagcg  gccccgtgg  ttccgggtgg  ggcggttctg  gccccgtgg  ttccctcgagt 780  
   gaagacgaca  ttgaggccga  ccacgttaggc  gtctatggta  caactgtata  tcagtcct 840  
 20   ggagacattg  gccagttacac  acatgaattt  gatgggtatg  agtggttcta  tgtggacttg 900  
   gataagaagg  agactatctg  gatgcttcct  gagttggcc  aattgacaag  cttaagcttt 960  
   gaccggcaag  gtggactgca  aaacatagct  acagggaaat  acacccctgg  aattttgact 1020  
   aagaggtcaa  attccaccc  agctaccaat  gaggctcc  aagcgtactgt  gttcccaag 1080  
   tccctgtgc  tgctgggtca  gccccacacc  ctcatctgct  ttgtggacaa  catctccct 1140  
   cctgtatca  acatcacatg  gctcagaaat  agtaagtcag  tcacagacgg  cggttatgag 1200  
 25   accagcttcc  ttgtcaaccc  tgaccattcc  ttccacaagg  tgttttatct  cacccatc 1260  
   ccttctgacg  atgatattt  tgactgcaag  gtggagcact  ggggcctgg  ggagccgg 1320  
   ctgaaacact  gggctagcg  aggggggcg  agcggcg  ggggagccaa  aacgacaccc 1380  
   ccatctgtct  atccactggc  ccctggatct  gctcccaaa  ctaactccat  ggtgaccctg 1440  
 30   ggatgcctgg  tcaagggtca  tttccctgag  ccagtgcac  tgacctggaa  ctctggatcc 1500  
   ctgtccagcg  gtgtgcacac  cttcccagct  gtccctgcgt  ctgacccct  cactctgagc 1560  
   agctcagtga  ctgtccctc  cagcacctgg  cccagcgaga  ccgtcacctg  caacgttgcc 1620  
   caccggcca  gcagcacca  ggtggacaag  aaaattgtgc  ccaggattg  tggttgc 1680  
   ccttgcata  gtacagtcta  agttacc  1707

35

&lt;210&gt; MBP 1-14 CK

&lt;211&gt; 1686

&lt;212&gt; DNA

&lt;213&gt; murine

40

  gccccggcca  ccatggagac  agacacactc  ctgctatggg  tactgctgct  ctgggttcca 60  
   ggttccactg  gtgacatggc  gtcacagaag  agacccctccc  agaggcaccgg  atccaaaggct 120  
   agcggaggggg  gccccgg  cgagggggg  gactccgaaa  ggcatttcgt  gttccagtcc 180  
   aaggggcgagt  gctacttca  caacgggac  cagcgcatac  gatctgtgga  cagatacatc 240  
   tacaaccgggg aggagtacct  gwgcttcgac  agcgcacgtgg  gccccgtgg  ttccctcgagt 300  
   gagctggggc  ggccagaccc  cgagttactac  aataagcagt  acctggagca  aacggggccc 360  
   gagctggaca  cggtgtgcag  acacaactac  gaggggggtgg  agacccacac  ctccctgcgg 420  
   cggcttgaac  agcccaatgt  cgtcatctcc  ctgtccagga  cagaggccct  caaccaccac 480  
   aacactctgg  tctgctcagt  gacagattt  tacccagcca  agatcaaagt  gccccgtgg 540  
   cggaatggcc  aggaggagac  ggtgggggtc  tcatccacac  agcttattag  aatggggac 600  
   tggaccttcc  aggccttgg  catgctggag  atgaccctc  ggcggggaga  ggtctacacc 660  
   tgccacgtgg  agcatccgag  cctgaagagc  cccatcactg  tggagtggac  tagtgggtgc 720  
   ggtggcagcg  gccccgtgg  ttccgggtgg  ggcggttctg  gccccgtgg  ttccctcgagt 780  
   gaagacgaca  ttgaggccga  ccacgttaggc  gtctatggta  caactgtata  tcagtcct 840  
 55   ggagacattg  gccagttacac  acatgaattt  gatgggtatg  agtggttcta  tgtggacttg 900  
   gataagaagg  agactatctg  gatgcttcct  gagttggcc  aattgacaag  cttgcaccc 960  
   caaggtggac  tgccaaacat  agctacagga  aaatacacct  tggttgc  gactaagagg 1020  
   tccaaatttca  ccccagctac  caatgaggct  cctcaagcg  ctgtgttccc  caagtcct 1080  
   gtgtgtgtgg  gtcagccaa  caccctcata  tgctttgtgg  acaacatctt  ccctccgtg 1140

94

atcaacatca catggctcag aaatagtaag tcagtcacag acggcggtta tgagaccagg 1200  
 ttccttgcac accgtgacca ttccctccac aagctgtctt atctcacctt catcccttct 1260  
 gacgatgata tttatgactg caaggtggag cactggggcc tggaggagcc ggttctgaaa 1320  
 5 cactgggcta gcggaggggg cgaaagcggc ggagggggag ctgatgctgc accaactgta 1380  
 tccatcttcc caccatccag tgagcagtta acatctggag gtgcctcagt cgtgtgttcc 1440  
 ttgaacaact tctacccaa agacatcaat gtcaagtgga agattgtatgg cagtgaacga 1500  
 caaaatggcg tcctgaacag ttggactgt caggacagca aagacagcac ctacagcatg 1560  
 agcagcaccc tcacgttgac caaggacgag tatgaacgac ataacagcta tacctgttag 1620  
 10 gccactcaca agacatcaac ttccaccatt gtcaagagct tcaacaggaa tgagtgttag 1680  
 ggtacc 1686

<210> MBP 1-14 CH1.H.CH2  
 <211> 2059  
 15 <212> DNA  
 <213> murine

gcggccgcca ccatggagac agacacactc ctgctatgg tactgctgct ctgggttcca 60  
 20 ggttccactg gtgacatggc gtcacagaag agaccctccc agaggcacgg atccaaggct 120  
 agcgaggggg gcggaagcgg cgagggggg gactccgaaa ggcatttcgt gttccagttc 180  
 aaggcgagt gctacttcac caacgggacg cagcgcatac gatctgtgga cagatacatc 240  
 tacaaccggg aggagtacct ggcgttcgac agcgcacgtgg gcgagtaccc cgccgtgacc 300  
 gagctggggc ggccagaccc cgagtaactac aataagcagt acctggagca aacgcggggc 360  
 gagctggaca cggtgtcag acacaactac gaggggggtgg agacccacac ctccctgcgg 420  
 25 cggcttgaac agcccaatgt cgtcatctcc ctgtccagga cagaggccct caaccaccac 480  
 aacactctgg tctgctcagt gacagattt taccaggcca agatcaaagt ggcgtggtc 540  
 cggaaatggcc aggaggagac ggtgggggtc tcatccacac agcttattag gaatggggac 600  
 tggaccttcc aggtccctgg catgctggag atgacccttc ggcggggaga ggtctacacc 660  
 tgcacacgtgg agcatccgag cctgaagagc cccatcaactg tggagtggac tagtgggtggc 720  
 30 ggtggcagcg gcggtgggtt ttccgggtggc ggcgggttctg gcggtggccg ttcctcgagt 780  
 gaagacgaca ttgagggcga ccacgttaggc gtctatggta caactgtata tcagtcct 840  
 ggagacattt gccagttacac acatgaattt gatgggtatg agtgggttca tggacttg 900  
 gataagaagg agactatctg gatgcttcct gagttggcc aattgacaag ctttgacccc 960  
 caaggtggac tgcaaaacat agctacagga aaatacacct tggaatctt gactaagagg 1020  
 35 tcaaaattcca cccccagttac caatgaggct cctcaagcga ctgtgttccc caagtcct 1080  
 gtgctgtgg gtcagccaa caccctcattt tgctttgtgg acaacatctt ccctcctgtg 1140  
 atcaacatca catggctcag aaatagtaag tcagtcacag acggcggtta tgagaccagg 1200  
 ttcccttgcac accgtgacca ttccctccac aagctgtctt atctcacctt catcccttct 1260  
 gaggatgata tttatgactg caaggtggag cactggggcc tggaggagcc ggttctgaaa 1320  
 40 cactgggcta ggggggggg cgaaagcggc ggagggggag cccaaacaaac acccccatca 1380  
 gtcttatccac tggcccttgg gtgtggagat acaactgggtt cctccgtgac tctggatgc 1440  
 ctggcaggacttcc tcagtcagtg actgtgactt ggaactctgg ctccctgtcc 1500  
 agcagtgtgc acaccccttcc agtcttcctg cagtcgtggac ttcacactat gagcagctca 1560  
 gtgactgtcc cttccacgttcc cttccacgttcc cttccacgttcc cttccacgttcc 1620  
 45 gccagcagca ccacgggtgg aaaaaaaaaactt gagcccaagcg ggcccatattc aacaatcaac 1680  
 ccctgttcc tcgttccatcc aataatcaag gatgtactca tgatctccct gacacccaag 1740  
 tcgttccatcc aataatcaag gatgtactca tgatctccct gacacccaag 1800  
 gtacgtgtg tgggtggaa tggagcggag gatgaccccg acgtccagat cagctgggtt 1860  
 gtgaacaacg tggaaagtaca cacagtcag acacaaaccc atagagagga ttacaacagt 1920  
 50 actatccggg tggtcagcac cttccatcc cttccatcc cttccatcc 1980  
 ttcaaaatgca aggtcaacaa caaagacctc ccatcaccctt cttccatcc 2040  
 attaaatagg gtaccccgaa 2059

55 <210> MBP 90-101 CH1.H.CH2.CH3  
 <211> 2343  
 <212> DNA--  
 <213> murine

95

	gcggccgcca	ccatggagac	agacacactc	ctgctatggg	tactgctgt	ctgggttcca	60
	ggttccactg	gtgacttcaa	gaacatttg	acacctcgaa	caccacctcc	agctagcgga	120
	gggggcggaa	gcggcggagg	gggagactcc	gaaaggcatt	tcgtgttcca	gttcaagggc	180
5	gagtgtact	tcaccaacgg	gacgcagcgc	atacgatctg	tggacagata	catctacaac	240
	cgggaggagt	acctgcgtt	cgacagcgc	gtggcgagt	accgcgcggt	gaccgagctg	300
	gggcggccag	accccggta	ctacaataag	cagtacctgg	agcaaacgcg	ggccgagctg	360
	gacacgacgt	gcagacacaa	ctacgagggg	gtggagaccc	acacccct	gcggcggctt	420
	gaacagccca	atgtcgcat	ctccctgtcc	aggacagagg	ccctaacc	ccacaacact	480
10	ctggtctgt	cagtacaga	tttctaccca	gccaagatca	aagtgcgt	gttccggaat	540
	ggccaggagg	agacggtggg	ggtctcatcc	acacagctta	ttaggaatgg	ggactggacc	600
	ttccagggtcc	tggtcatgt	ggagatgacc	cctcggcggg	gagaggtcta	ccactgcctac	660
	gtggagcattc	cgaggctgaa	gagccccatc	actgtggagt	gfactgtgg	tggcggtggc	720
	agcggcgggt	gtgggttccgg	tggcgccgg	tctggcggt	gcgggttcc	gagtgaagac	780
15	gacattgagg	ccgaccacgt	aggcgtctat	ggtacaactg	tatatcagtc	tcctggagac	840
	attggccagt	acacacatga	atttgatgg	gatgagtgg	tctatgtgga	cttggataag	900
	aaggagacta	tctggatgt	tctctgagtt	ggccaattga	caagcttga	cccccaaggt	960
	ggactgc当地	acatagctac	agaaaatac	accttggaa	tcttactaa	gaggtcaa	1020
20	tccacccccc	ctaccaatga	ggctcctcaa	gctactgtgt	tccccaagtc	ccctgtgctg	1080
	ctgggtcagc	ccaacaccct	catctgc	gtggacaaca	tcttccctcc	tgtgatcaac	1140
	atcacatggc	tcagaatag	taagtca	acagacggcg	tttatgagac	cagttcc	1200
	gtcaaccgtg	accattcc	ccacaagctg	tcttatctca	ccttcatccc	ttctgacgt	1260
	gatattttag	actgcaaggt	ggagca	ggcttgagg	agccgg	ttct	1320
	gctagcggag	ggggcggaa	cgccggagg	agcttagcc	aaacgacacc	cccatctgtc	1380
25	tatccactgg	cccttgatc	tgtgtccaa	actaactcc	ttgtgacc	ggatgcctg	1440
	gtcaaggggct	atttccctga	gccagtgaca	gtgac	actctggatc	cctgtcc	1500
	ggtgtcaca	ccttcc	tgccctgc	tctgac	ctt	acactctgag	1560
	actgtcc	ccagcac	gtcc	accgtcac	gcaacgttgc	ccacccggcc	1620
	agcagcacca	agg	ggacaa	aaaattgtg	cccagg	gtgg	1680
30	tgtacagtcc	cagaagtatc	atctgtctc	atcttcc	caaagccaa	ggatgtgtc	1740
	accattactc	tgactctaa	ggcacgtgt	ttgtgtt	acatcag	ggatgatccc	1800
	gagg	tcag	ttgt	gttagatgat	gtggagg	acacagctc	1860
	cg	gg	gg	gtt	gtt	gacgca	1920
	gactggctca	atggcaagga	gttcaat	agg	gtt	gtt	1980
35	atcgagaaaa	ccatctccaa	aacc	aaagg	cc	cc	2040
	ccac	cc	cc	cc	cc	cc	2100
	agg	agg	agg	agg	agg	agg	2160
	ttcttcc	ttcttcc	ttcttcc	ttcttcc	ttcttcc	ttcttcc	2220
	aag	aag	aag	aag	aag	aag	2280
40	gtcagaaga	gcaactggg	ggcaggaa	actt	actt	actt	2340
	ctgcacaacc	accatactga	gaagac	ctt	ctt	ctt	2343

&lt;210&gt; IASMBP 1-14 CH1.CH2.CH3

&lt;211&gt; 679

45 <212> PRT--  
<213> murine

Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro

5

10

15

50 Gly Ser Thr Gly Asp Met Ala Ser Gln Lys Arg Pro Ser Gln Arg His  
20 25 30

Gly Ser Lys Ala Ser Gly Gly Ser Gly Gly Gly Gly Asp Ser

35

40

45

Glu Arg His Phe Val Phe Gln Phe Lys Gly Glu Cys Tyr Phe Thr Asn

50

55

60

96

Gly Thr Gln Arg Ile Arg Ser Val Asp Arg Tyr Ile Tyr Asn Arg Glu  
 65 70 75 80

5 Glu Tyr Leu Arg Phe Asp Ser Asp Val Gly Glu Tyr Arg Ala Val Thr  
 85 90 95

Glu Leu Gly Arg Pro Asp Pro Glu Tyr Tyr Asn Lys Gln Tyr Leu Glu  
 100 105 110

10 Gln Thr Arg Ala Glu Leu Asp Thr Val Cys Arg His Asn Tyr Glu Gly  
 115 120 125

Val Glu Thr His Thr Ser Leu Arg Arg Leu Glu Gln Pro Asn Val Val  
 130 135 140

15 Ile Ser Leu Ser Arg Thr Glu Ala Leu Asn His His Asn Thr Leu Val  
 145 150 155 160

20 Cys Ser Val Thr Asp Phe Tyr Pro Ala Lys Ile Lys Val Arg Trp Phe  
 165 170 175

Arg Asn Gly Gln Glu Glu Thr Val Gly Val Ser Ser Thr Gln Leu Ile  
 180 185 190

25 Arg Asn Gly Asp Trp Thr Phe Gln Val Leu Val Met Leu Glu Met Thr  
 195 200 205

Pro Arg Arg Gly Glu Val Tyr Thr Cys His Val Glu His Pro Ser Leu  
 210 215 220

30 Lys Ser Pro Ile Thr Val Glu Trp Thr Ser Gly Gly Gly Ser Gly  
 225 230 235 240

35 Gly Gly Ser Gly Gly Ser Gly Gly Ser Ser Ser Ser  
 245 250 255

Glu Asp Asp Ile Glu Ala Asp His Val Gly Val Tyr Gly Thr Thr Val  
 260 265 270

40 Tyr Gln Ser Pro Gly Asp Ile Gly Gln Tyr Thr His Glu Phe Asp Gly  
 275 280 285

Asp Glu Trp Phe Tyr Val Asp Leu Asp Lys Lys Glu Thr Ile Trp Met  
 290 295 300

45 Leu Pro Glu Phe Gly Gln Leu Thr Ser Phe Asp Pro Gln Gly Gly Leu  
 305 310 315 320

50 Gln Asn Ile Ala Thr Gly Lys Tyr Thr Leu Gly Ile Leu Thr Lys Arg  
 325 330 335

Ser Asn Ser Thr Pro Ala Thr Asn Glu Ala Pro Gln Ala Thr Val Phe  
 340 345 350

55 Pro Lys Ser Pro Val Leu Leu Gly Gln Pro Asn Thr Leu Ile Cys Phe  
 355 360 365

Val Asp Asn Ile Phe Pro Pro Val Ile Asn Ile Thr Trp Leu Arg Asn  
 370 375 380

Ser Lys Ser Val Thr Asp Gly Val Tyr Glu Thr Ser Phe Leu Val Asn  
 385 390 395 400

5 Arg Asp His Ser Phe His Lys Leu Ser Tyr Leu Thr Phe Ile Pro Ser  
 405 410 415

Asp Asp Asp Ile Tyr Asp Cys Lys Val Glu His Trp Gly Leu Glu Glu  
 420 425 430

10 Pro Val Leu Lys His Trp Ala Ser Gly Gly Gly Ser Gly Gly Gly  
 435 440 445

Gly Ala Lys Thr Thr Pro Pro Ser Val Tyr Pro Leu Ala Pro Gly Cys  
 15 450 455 460

Gly Asp Thr Thr Gly Ser Ser Val Thr Leu Gly Cys Leu Val Lys Gly  
 465 470 475 480

20 Tyr Phe Pro Glu Ser Val Thr Val Thr Trp Asn Ser Gly Ser Leu Ser  
 485 490 495

Ser Ser Val His Thr Phe Pro Ala Leu Leu Gln Ser Gly Leu Tyr Thr  
 500 505 510

25 Met Ser Ser Ser Val Thr Val Pro Ser Ser Thr Trp Pro Ser Gln Thr  
 515 520 525

30 Val Thr Cys Ser Val Ala His Pro Ala Ser Ser Thr Thr Val Asp Lys  
 530 535 540

Lys Leu Glu Pro Ser Gly Pro Ile Ser Thr Ile Asn Pro Cys Pro Pro  
 545 550 555 560

35 Cys Lys Glu Cys His Lys Cys Pro Ala Pro Asn Leu Glu Gly Gly Pro  
 565 570 575

Ser Val Phe Ile Phe Pro Pro Asn Ile Lys Asp Val Leu Met Ile Ser  
 580 585 590

40 Leu Thr Pro Lys Val Thr Cys Val Val Val Asp Val Ser Glu Asp Asp  
 595 600 605

45 Pro Asp Val Gln Ile Ser Trp Phe Val Asn Asn Val Glu Val His Thr  
 610 615 620

Ala Gln Thr Gln Thr His Arg Glu Asp Tyr Asn Ser Thr Ile Arg Val  
 625 630 635 640

50 Val Ser Thr Leu Pro Ile Gln His Gln Asp Trp Met Ser Gly Lys Glu  
 645 650 655

Phe Lys Cys Lys Val Asn Asn Lys Asp Leu Pro Ser Pro Ile Glu Arg  
 660 665 670

55 Thr Ile Ser Lys Ile Lys  
 675

98

&lt;210&gt; IAS MBP 1-14 CH1.H

&lt;211&gt; 677

&lt;212&gt; PRT--

&lt;213&gt; murine

5

	Met	Glu	Thr	Asp	Thr	Leu	Leu	Leu	Trp	Val	Leu	Leu	Leu	Trp	Val	Pro
						5				10						15

10	Gly	Ser	Thr	Gly	Asp	Phe	Lys	Asn	Ile	Val	Thr	Pro	Arg	Thr	Pro	Pro
						20			25				30			

	Pro	Ala	Ser	Gly	Gly	Gly	Ser	Gly	Gly	Gly	Asp	Ser	Glu	Arg		
							35		40			45				

15	His	Phe	Val	Phe	Gln	Phe	Lys	Gly	Glu	Cys	Tyr	Phe	Thr	Asn	Gly	Thr
							50		55			60				

	Gln	Arg	Ile	Arg	Ser	Val	Asp	Arg	Tyr	Ile	Tyr	Asn	Arg	Glu	Glu	Tyr
							65		70			75		80		

20	Leu	Arg	Phe	Asp	Ser	Asp	Val	Gly	Glu	Tyr	Arg	Ala	Val	Thr	Glu	Leu
							85		90			95				

25	Gly	Arg	Pro	Asp	Pro	Glu	Tyr	Tyr	Asn	Lys	Gln	Tyr	Leu	Glu	Gln	Thr
							100		105			110				

	Arg	Ala	Glu	Leu	Asp	Thr	Val	Cys	Arg	His	Asn	Tyr	Glu	Gly	Val	Glu
							115		120			125				

30	Thr	His	Thr	Ser	Leu	Arg	Arg	Leu	Glu	Gln	Pro	Asn	Val	Val	Ile	Ser
							130		135			140				

	Leu	Ser	Arg	Thr	Glu	Ala	Leu	Asn	His	His	Asn	Thr	Leu	Val	Cys	Ser
							145		150			155		160		

35	Val	Thr	Asp	Phe	Tyr	Pro	Ala	Lys	Ile	Lys	Val	Arg	Trp	Phe	Arg	Asn
							165		170			175				

40	Gly	Gln	Glu	Glu	Thr	Val	Gly	Val	Ser	Ser	Thr	Gln	Leu	Ile	Arg	Asn
							180		185			190				

	Gly	Asp	Trp	Thr	Phe	Gln	Val	Leu	Val	Met	Leu	Glu	Met	Thr	Pro	Arg
							195		200			205				

45	Arg	Gly	Glu	Val	Tyr	Thr	Cys	His	Val	Glu	His	Pro	Ser	Leu	Lys	Ser
							210		215			220				

	Pro	Ile	Thr	Val	Glu	Trp	Thr	Ser	Gly	Gly	Gly	Ser	Gly	Gly	Gly	Gly
							225		230			235		240		

50	Gly	Ser	Gly	Gly	Gly	Ser	Gly	Gly	Gly	Gly	Ser	Ser	Ser	Glu	Asp	
							245		250			255				

	Asp	Ile	Glu	Ala	Asp	His	Val	Gly	Val	Tyr	Gly	Thr	Thr	Val	Tyr	Gln
							260		265			270				

	Ser	Pro	Gly	Asp	Ile	Gly	Gln	Tyr	Thr	His	Glu	Phe	Asp	Gly	Asp	Glu
							275		280			285				

99

Trp Phe Tyr Val Asp Leu Asp Lys Lys Glu Thr Ile Trp Met Leu Pro  
 290 295 300

5 Glu Phe Gly Gln Leu Thr Ser Phe Asp Pro Gln Gly Gly Leu Gln Asn  
 305 310 315 320

Ile Ala Thr Gly Lys Tyr Thr Leu Gly Ile Leu Thr Lys Arg Ser Asn  
 325 330 335

10 Ser Thr Pro Ala Thr Asn Glu Ala Pro Gln Ala Thr Val Phe Pro Lys  
 340 345 350

Ser Pro Val Leu Leu Gly Gln Pro Asn Thr Leu Ile Cys Phe Val Asp  
 355 360 365

15 Asn Ile Phe Pro Pro Val Ile Asn Ile Thr Trp Leu Arg Asn Ser Lys  
 370 375 380

20 Ser Val Thr Asp Gly Val Tyr Glu Thr Ser Phe Leu Val Asn Arg Asp  
 385 390 395 400

His Ser Phe His Lys Leu Ser Tyr Leu Thr Phe Ile Pro Ser Asp Asp  
 405 410 415

25 Asp Ile Tyr Asp Cys Lys Val Glu His Trp Gly Leu Glu Pro Val  
 420 425 430

Leu Lys His Trp Ala Ser Gly Gly Ser Gly Gly Gly Ala  
 435 440 445

30 Lys Thr Thr Pro Pro Ser Val Tyr Pro Leu Ala Pro Gly Cys Gly Asp  
 450 455 460

35 Thr Thr Gly Ser Ser Val Thr Leu Gly Cys Leu Val Lys Gly Tyr Phe  
 465 470 475 480

Pro Glu Ser Val Thr Val Thr Trp Asn Ser Gly Ser Leu Ser Ser Ser  
 485 490 495

40 Val His Thr Phe Pro Ala Leu Leu Gln Ser Gly Leu Tyr Thr Met Ser  
 500 505 510

Ser Ser Val Thr Val Pro Ser Ser Thr Trp Pro Ser Gln Thr Val Thr  
 515 520 525

45 Cys Ser Val Ala His Pro Ala Ser Ser Thr Thr Val Asp Lys Lys Leu  
 530 535 540

50 Glu Pro Ser Gly Pro Ile Ser Thr Ile Asn Pro Cys Pro Pro Cys Lys  
 545 550 555 560

Glu Cys His Lys Cys Pro Ala Pro Asn Leu Glu Gly Gly Pro Ser Val  
 565 570 575

55 Phe Ile Phe Pro Pro Asn Ile Lys Asp Val Leu Met Ile Ser Leu Thr  
 580 585 590

Pro Lys Val Thr Cys Val Val Asp Val Ser Glu Asp Asp Pro Asp  
 595 600 605

100

Val Gln Ile Ser Trp Phe Val Asn Asn Val Glu Val His Thr Ala Gln  
 610 615 620

5 Thr Gln Thr His Arg Glu Asp Tyr Asn Ser Thr Ile Arg Val Val Ser  
 625 630 635 640

Thr Leu Pro Ile Gln His Gln Asp Trp Met Ser Gly Lys Glu Phe Lys  
 645 650 655

10 Cys Lys Val Asn Asn Lys Asp Leu Pro Ser Pro Ile Glu Arg Thr Ile  
 660 665 670

15 Ser Lys Ile Lys  
 675

<210> IAS MBP 90-101 CH1.H.CH2

<211> 563

20 <212> PRT--

<213> murine

Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro  
 5 10 15

25 Gly Ser Thr Gly Asp Phe Lys Asn Ile Val Thr Pro Arg Thr Pro Pro  
 20 25 30

30 Pro Ala Ser Ala Ser Gly Gly Gly Ser Gly Gly Gly Asp Ser  
 35 40 45

Glu Arg His Phe Val Phe Gln Phe Lys Gly Glu Cys Tyr Phe Thr Asn  
 50 55 60

35 Gly Thr Gln Arg Ile Arg Ser Val Asp Arg Tyr Ile Tyr Asn Arg Glu  
 65 70 75 80

Glu Tyr Leu Arg Phe Asp Ser Asp Val Gly Glu Tyr Arg Ala Val Thr  
 85 90 95

40 Glu Leu Gly Arg Pro Asp Pro Glu Tyr Tyr Asn Lys Gln Tyr Leu Glu  
 100 105 110

45 Gln Thr Arg Ala Glu Leu Asp Thr Val Cys Arg His Asn Tyr Glu Gly  
 115 120 125

Val Glu Thr His Thr Ser Leu Arg Arg Leu Glu Gln Pro Asn Val Val  
 130 135 140

50 Ile Ser Leu Ser Arg Thr Glu Ala Leu Asn His His Asn Thr Leu Val  
 145 150 155 160

Cys Ser Val Thr Asp Phe Tyr Pro Ala Lys Ile Lys Val Arg Trp Phe  
 165 170 175

55 Arg Asn Gly Gln Glu Glu Thr Val Gly Val Ser Ser Thr Gln Leu Ile  
 180 185 190

Arg Asn Gly Asp Trp Thr Phe Gln Val Leu Val Met Leu Glu Met Thr

	101		
	195	200	205
	Pro Arg Arg Gly Glu Val Tyr Thr Cys His Val Glu His Pro Ser Leu		
5	210                           215                           220		
	Lys Ser Pro Ile Thr Val Glu Trp Thr Ser Gly Gly Gly Ser Gly		
	225                           230                           235                           240		
10	Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Ser Ser		
	245                           250                           255		
	Glu Asp Asp Ile Glu Ala Asp His Val Gly Val Tyr Gly Thr Thr Val		
	260                           265                           270		
15	Tyr Gln Ser Pro Gly Asp Ile Gly Gln Tyr Thr His Glu Phe Asp Gly		
	275                           280                           285		
	Asp Glu Trp Phe Tyr Val Asp Leu Asp Lys Lys Glu Thr Ile Trp Met		
20	290                           295                           300		
	Leu Pro Glu Phe Gly Gln Leu Thr Ser Leu Ser Phe Asp Pro Gln Gly		
	305                           310                           315                           320		
25	Gly Leu Gln Asn Ile Ala Thr Gly Lys Tyr Thr Leu Gly Ile Leu Thr		
	325                           330                           335		
	Lys Arg Ser Asn Ser Thr Pro Ala Thr Asn Glu Ala Pro Gln Ala Thr		
	340                           345                           350		
30	Val Phe Pro Lys Ser Pro Val Leu Leu Gly Gln Pro Asn Thr Leu Ile		
	355                           360                           365		
	Cys Phe Val Asp Asn Ile Phe Pro Pro Val Ile Asn Ile Thr Trp Leu		
35	370                           375                           380		
	Arg Asn Ser Lys Ser Val Thr Asp Gly Val Tyr Glu Thr Ser Phe Leu		
	385                           390                           395                           400		
40	Val Asn Arg Asp His Ser Phe His Lys Leu Ser Tyr Leu Thr Phe Ile		
	405                           410                           415		
	Pro Ser Asp Asp Asp Ile Tyr Asp Cys Lys Val Glu His Trp Gly Leu		
	420                           425                           430		
45	Glu Glu Pro Val Leu Lys His Trp Ala Ser Gly Gly Ser Gly		
	435                           440                           445		
	Gly Gly Gly Ala Lys Thr Thr Pro Pro Ser Val Tyr Pro Leu Ala Pro		
50	450                           455                           460		
	Gly Ser Ala Ala Gln Thr Asn Ser Met Val Thr Leu Gly Cys Leu Val		
	465                           470                           475                           480		
55	Lys Gly Tyr Phe Pro Glu Pro Val Thr Val Thr Trp Asn Ser Gly Ser		
	485                           490                           495		
	Leu Ser Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Asp Leu		
	500                           505                           510		

102

Tyr Thr Leu Ser Ser Ser Val Thr Val Pro Ser Ser Thr Trp Pro Ser  
 515 520 525

5 Glu Thr Val Thr Cys Asn Val Ala His Pro Ala Ser Ser Thr Lys Val  
 530 535 540

Asp Lys Lys Ile Val Pro Arg Asp Cys Gly Cys Lys Pro Cys Ile Cys  
 545 550 555 560

10 Thr Val

<210> IAS MBP 90-101 CH1.H

15 <211> 556

<212> PRT

<213> murine

20 Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro  
 5 10 15

Gly Ser Thr Gly Asp Met Ala Ser Gln Lys Arg Pro Ser Gln Arg His  
 20 25 30

25 Gly Ser Lys Ala Ser Gly Gly Ser Gly Gly Gly Asp Ser  
 35 40 45

Glu Arg His Phe Val Phe Gln Phe Lys Gly Glu Cys Tyr Phe Thr Asn  
 50 55 60

30 Gly Thr Gln Arg Ile Arg Ser Val Asp Arg Tyr Ile Tyr Asn Arg Glu  
 65 70 75 80

35 Glu Tyr Leu Arg Phe Asp Ser Asp Val Gly Glu Tyr Arg Ala Val Thr  
 85 90 95

Glu Leu Gly Arg Pro Asp Pro Glu Tyr Tyr Asn Lys Gln Tyr Leu Glu  
 100 105 110

40 Gln Thr Arg Ala Glu Leu Asp Thr Val Cys Arg His Asn Tyr Glu Gly  
 115 120 125

Val Glu Thr His Thr Ser Leu Arg Arg Leu Glu Gln Pro Asn Val Val  
 130 135 140

45 Ile Ser Leu Ser Arg Thr Glu Ala Leu Asn His His Asn Thr Leu Val  
 145 150 155 160

50 Cys Ser Val Thr Asp Phe Tyr Pro Ala Lys Ile Lys Val Arg Trp Phe  
 165 170 175

Arg Asn Gly Gln Glu Glu Thr Val Gly Val Ser Ser Thr Gln Leu Ile  
 180 185 190

55 Arg Asn Gly Asp Trp Thr Phe Gln Val Leu Val Met Leu Glu Met Thr  
 195 200 205

Pro Arg Arg Gly Glu Val Tyr Thr Cys His Val Glu His Pro Ser Leu  
 210 215 220

103

Lys Ser Pro Ile Thr Val Glu Trp Thr Ser Gly Gly Gly Ser Gly  
 225 230 235 240

5 Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Ser Ser  
 245 250 255

Glu Asp Asp Ile Glu Ala Asp His Val Gly Val Tyr Gly Thr Thr Val  
 260 265 270

10 Tyr Gln Ser Pro Gly Asp Ile Gly Gln Tyr Thr His Glu Phe Asp Gly  
 275 280 285

15 Asp Glu Trp Phe Tyr Val Asp Leu Asp Lys Lys Glu Thr Ile Trp Met  
 290 295 300

Leu Pro Glu Phe Gly Gln Leu Thr Ser Phe Asp Pro Gln Gly Gly Leu  
 305 310 315 320

20 Gln Asn Ile Ala Thr Gly Lys Tyr Thr Leu Gly Ile Leu Thr Lys Arg  
 325 330 335

Ser Asn Ser Thr Pro Ala Thr Asn Glu Ala Pro Gln Ala Thr Val Phe  
 340 345 350

25 Pro Lys Ser Pro Val Leu Leu Gly Gln Pro Asn Thr Leu Ile Cys Phe  
 355 360 365

30 Val Asp Asn Ile Phe Pro Pro Val Ile Asn Ile Thr Trp Leu Arg Asn  
 370 375 380

Ser Lys Ser Val Thr Asp Gly Val Tyr Glu Thr Ser Phe Leu Val Asn  
 385 390 395 400

35 Arg Asp His Ser Phe His Lys Leu Ser Tyr Leu Thr Phe Ile Pro Ser  
 405 410 415

Asp Asp Asp Ile Tyr Asp Cys Lys Val Glu His Trp Gly Leu Glu Glu  
 420 425 430

40 Pro Val Leu Lys His Trp Ala Ser Gly Gly Ser Gly Gly Gly  
 435 440 445

45 Gly Ala Asp Ala Ala Pro Thr Val Ser Ile Phe Pro Pro Ser Ser Glu  
 450 455 460

Gln Leu Thr Ser Gly Gly Ala Ser Val Val Cys Phe Leu Asn Asn Phe  
 465 470 475 480

50 Tyr Pro Lys Asp Ile Asn Val Lys Trp Lys Ile Asp Gly Ser Glu Arg  
 485 490 495

Gln Asn Gly Val Leu Asn Ser Trp Thr Asp Gln Asp Ser Lys Asp Ser  
 500 505 510

55 Thr Tyr Ser Met Ser Ser Thr Leu Thr Leu Thr Lys Asp Glu Tyr Glu  
 515 520 525

Arg His Asn Ser Tyr Thr Cys Glu Ala Thr His Lys Thr Ser Thr Ser

	104			
	530	535	540	
	Pro Ile Val Lys Ser Phe Asn Arg Asn Glu Cys			
5	545	550	555	
	<210> IAS MBP 1-14 CK			
	<211> 775			
	<212> PRT			
10	<213> murine			
	Thr Met Glu Thr Asp Thr Leu Leu Leu Trp Val			
	5	10	15	
15	Pro Gly Ser Thr Gly Asp Met Ala Ser Gln Lys Arg Pro Ser Gln Arg			
	20	25	30	
	His Gly Ser Lys Ala Ser Gly Gly Ser Gly Gly Gly Asp			
	35	40	45	
20	Ser Glu Arg His Phe Val Phe Gln Phe Lys Gly Glu Cys Tyr Phe Thr			
	50	55	60	
25	Asn Gly Thr Gln Arg Ile Arg Ser Val Asp Arg Tyr Ile Tyr Asn Arg			
	65	70	75	80
	Glu Glu Tyr Leu Arg Phe Asp Ser Asp Val Gly Glu Tyr Arg Ala Val			
	85	90	95	
30	Thr Glu Leu Gly Arg Pro Asp Pro Glu Tyr Tyr Asn Lys Gln Tyr Leu			
	100	105	110	
	Glu Gln Thr Arg Ala Glu Leu Asp Thr Val Cys Arg His Asn Tyr Glu			
	115	120	125	
35	Gly Val Glu Thr His Thr Ser Leu Arg Arg Leu Glu Gln Pro Asn Val			
	130	135	140	
40	Val Ile Ser Leu Ser Arg Thr Glu Ala Leu Asn His His Asn Thr Leu			
	145	150	155	160
	Val Cys Ser Val Thr Asp Phe Tyr Pro Ala Lys Ile Lys Val Arg Trp			
	165	170	175	
45	Phe Arg Asn Gly Gln Glu Glu Thr Val Gly Val Ser Ser Thr Gln Leu			
	180	185	190	
	Ile Arg Asn Gly Asp Trp Thr Phe Gln Val Leu Val Met Leu Glu Met			
	195	200	205	
50	Thr Pro Arg Arg Gly Glu Val Tyr Thr Cys His Val Glu His Pro Ser			
	210	215	220	
	Leu Lys Ser Pro Ile Thr Val Glu Trp Thr Ser Gly Gly Gly Ser			
55	225	230	235	240
	Gly Gly Gly Ser Gly Gly Ser Gly Gly Gly Ser Ser			
	245	250	255	

105

	Ser	Glu	Asp	Asp	Ile	Glu	Ala	Asp	His	Val	Gly	Val	Tyr	Gly	Thr	Thr
	260					265										270
5	Val	Tyr	Gln	Ser	Pro	Gly	Asp	Ile	Gly	Gln	Tyr	Thr	His	Glu	Phe	Asp
	275					280									285	
	Gly	Asp	Glu	Trp	Phe	Tyr	Val	Asp	Leu	Asp	Lys	Lys	Glu	Thr	Ile	Trp
	290					295									300	
10	Met	Leu	Pro	Glu	Phe	Gly	Gln	Leu	Thr	Ser	Phe	Asp	Pro	Gln	Gly	Gly
	305						310				315				320	
	Leu	Gln	Asn	Ile	Ala	Thr	Gly	Lys	Tyr	Thr	Leu	Gly	Ile	Leu	Thr	Lys
						325				330				335		
15	Arg	Ser	Asn	Ser	Thr	Pro	Ala	Thr	Asn	Glu	Ala	Pro	Gln	Ala	Thr	Val
	340						345								350	
20	Phe	Pro	Lys	Ser	Pro	Val	Leu	Leu	Gly	Gln	Pro	Asn	Thr	Leu	Ile	Cys
	355						360							365		
	Phe	Val	Asp	Asn	Ile	Phe	Pro	Pro	Val	Ile	Asn	Ile	Thr	Trp	Leu	Arg
	370					375								380		
25	Asn	Ser	Lys	Ser	Val	Thr	Asp	Gly	Val	Tyr	Glu	Thr	Ser	Phe	Leu	Val
	385					390					395				400	
	Asn	Arg	Asp	His	Ser	Phe	His	Lys	Leu	Ser	Tyr	Leu	Thr	Phe	Ile	Pro
						405				410				415		
30	Ser	Asp	Asp	Asp	Ile	Tyr	Asp	Cys	Lys	Val	Glu	His	Trp	Gly	Leu	Glu
	420						425							430		
35	Glu	Pro	Val	Leu	Lys	His	Trp	Ala	Ser	Gly	Gly	Gly	Ser	Gly	Gly	
	435					440								445		
	Gly	Gly	Ala	Lys	Thr	Thr	Pro	Pro	Ser	Val	Tyr	Pro	Leu	Ala	Pro	Gly
	450						455							460		
40	Ser	Ala	Ala	Gln	Thr	Asn	Ser	Met	Val	Thr	Leu	Gly	Cys	Leu	Val	Lys
	465					470					475				480	
	Gly	Tyr	Phe	Pro	Glu	Pro	Val	Thr	Val	Thr	Trp	Asn	Ser	Gly	Ser	Leu
	485						490							495		
45	Ser	Ser	Gly	Val	His	Thr	Phe	Pro	Ala	Val	Leu	Gln	Ser	Asp	Leu	Tyr
	500						505							510		
50	Thr	Leu	Ser	Ser	Ser	Val	Thr	Val	Pro	Ser	Ser	Thr	Trp	Pro	Ser	Glu
	515					520								525		
	Thr	Val	Thr	Cys	Asn	Val	Ala	His	Pro	Ala	Ser	Ser	Thr	Lys	Val	Asp
	530					535								540		
55	Lys	Lys	Ile	Val	Pro	Arg	Asp	Cys	Gly	Cys	Lys	Pro	Cys	Ile	Cys	Thr
	545					550					555				560	
	Val	Pro	Glu	Val	Ser	Ser	Val	Phe	Ile	Phe	Pro	Pro	Lys	Pro	Lys	Asp
	565						570							575		

106

Val Leu Thr Ile Thr Leu Thr Pro Lys Val Thr Cys Val Val Val Asp  
 580 585 590

5 Ile Ser Lys Asp Asp Pro Glu Val Gln Phe Ser Trp Phe Val Asp Asp  
 595 600 605

Val Glu Val His Thr Ala Gln Thr Gln Pro Arg Glu Glu Gln Phe Asn  
 610 615 620

10 Ser Thr Phe Arg Ser Val Ser Glu Leu Pro Ile Met His Gln Asp Trp  
 625 630 635 640

Leu Asn Gly Lys Glu Phe Lys Cys Arg Val Asn Ser Ala Ala Phe Pro  
 15 645 650 655

Ala Pro Ile Glu Lys Thr Ile Ser Lys Thr Lys Gly Arg Pro Lys Ala  
 660 665 670

20 Pro Gln Val Tyr Thr Ile Pro Pro Pro Lys Glu Gln Met Ala Lys Asp  
 675 680 685

Lys Val Ser Leu Thr Cys Met Ile Thr Asp Phe Phe Pro Glu Asp Ile  
 690 695 700

25 Thr Val Glu Trp Gln Trp Asn Gly Gln Pro Ala Glu Asn Tyr Lys Asn  
 705 710 715 720

Thr Gln Pro Ile Met Asp Thr Asp Gly Ser Tyr Phe Val Tyr Ser Lys  
 30 725 730 735

Leu Asn Val Gln Lys Ser Asn Trp Glu Ala Gly Asn Thr Phe Thr Cys  
 740 745 750

35 Ser Val Leu His Glu Gly Leu His Asn His His Thr Glu Lys Ser Leu  
 755 760 765

Ser His Ser Pro Gly Lys  
 40 770

<210> IAS MBP 1-14 CH1.H.CH2  
 <211> 561  
 <212> PRT  
 45 <213> murine

Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro  
 5 10 15

50 Gly Ser Thr Gly Asp Met Ala Ser Gln Lys Arg Pro Ser Gln Arg His  
 20 25 30

Gly Ser Lys Ala Ser Gly Gly Ser Gly Gly Gly Asp Ser  
 35 40 45

55 Glu Arg His Phe Val Phe Gln Phe Lys Gly Glu Cys Tyr Phe Thr Asn  
 50 55 60

Gly Thr Gln Arg Ile Arg Ser Val Asp Arg Tyr Ile Tyr Asn Arg Glu

	65	70	75	80
			107	
	Glu Tyr Leu Arg Phe Asp Ser Asp Val Gly Glu Tyr Arg Ala Val Thr			
	85		90	95
5	Glu Leu Gly Arg Pro Asp Pro Glu Tyr Tyr Asn Lys Gln Tyr Leu Glu			
	100		105	110
10	Gln Thr Arg Ala Glu Leu Asp Thr Val Cys Arg His Asn Tyr Glu Gly			
	115		120	125
	Val Glu Thr His Thr Ser Leu Arg Arg Leu Glu Gln Pro Asn Val Val			
	130		135	140
15	Ile Ser Leu Ser Arg Thr Glu Ala Leu Asn His His Asn Thr Leu Val			
	145		150	160
	Cys Ser Val Thr Asp Phe Tyr Pro Ala Lys Ile Lys Val Arg Trp Phe			
20	165		170	175
	Arg Asn Gly Gln Glu Glu Thr Val Gly Val Ser Ser Thr Gln Leu Ile			
	180		185	190
25	Arg Asn Gly Asp Trp Thr Phe Gln Val Leu Val Met Leu Glu Met Thr			
	195		200	205
	Pro Arg Arg Gly Glu Val Tyr Thr Cys His Val Glu His Pro Ser Leu			
	210		215	220
30	Lys Ser Pro Ile Thr Val Glu Trp Thr Ser Gly Gly Gly Ser Gly			
	225		230	240
	Gly Gly Gly Ser Gly Gly Ser Gly Gly Gly Ser Ser Ser			
35	245		250	255
	Glu Asp Asp Ile Glu Ala Asp His Val Gly Val Tyr Gly Thr Thr Val			
	260		265	270
40	Tyr Gln Ser Pro Gly Asp Ile Gly Gln Tyr Thr His Glu Phe Asp Gly			
	275		280	285
	Asp Glu Trp Phe Tyr Val Asp Leu Asp Lys Lys Glu Thr Ile Trp Met			
	290		295	300
45	Leu Pro Glu Phe Gly Gln Leu Thr Ser Phe Asp Pro Gln Gly Gly Leu			
	305		310	320
	Gln Asn Ile Ala Thr Gly Lys Tyr Thr Leu Gly Ile Leu Thr Lys Arg			
50	325		330	335
	Ser Asn Ser Thr Pro Ala Thr Asn Glu Ala Pro Gln Ala Thr Val Phe			
	340		345	350
55	Pro Lys Ser Pro Val Leu Leu Gly Gln Pro Asn Thr Leu Ile Cys Phe			
	355		360	365
	Val Asp Asn Ile Phe Pro Pro Val Ile Asn Ile Thr Trp Leu Arg Asn			
	370		375	380

108

Ser Lys Ser Val Thr Asp Gly Val Tyr Glu Thr Ser Phe Leu Val Asn			
385	390	395	400
Arg Asp His Ser Phe His Lys Leu Ser Tyr Leu Thr Phe Ile Pro Ser			
5	405	410	415
Asp Asp Asp Ile Tyr Asp Cys Lys Val Glu His Trp Gly Leu Glu Glu			
420	425	430	
Pra Val Leu Lys His Trp Ala Ser Gly Gly Gly Ser Gly Gly Gly			
10	435	440	445
Gly Ala Lys Thr Thr Pro Pro Ser Val Tyr Pro Leu Ala Pro Gly Ser			
15	450	455	460
Ala Ala Gln Thr Asn Ser Met Val Thr Leu Gly Cys Leu Val Lys Gly			
465	470	475	480
Tyr Phe Pro Glu Pro Val Thr Val Thr Trp Asn Ser Gly Ser Leu Ser			
20	485	490	495
Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Asp Leu Tyr Thr			
500	505	510	
Leu Ser Ser Ser Val Thr Val Pro Ser Ser Thr Trp Pro Ser Glu Thr			
25	515	520	525
Val Thr Cys Asn Val Ala His Pro Ala Ser Ser Thr Lys Val Asp Lys			
30	530	535	540
Lys Ile Val Pro Arg Asp Cys Gly Cys Lys Pro Cys Ile Cys Thr Val			
545	550	555	560
 35 <210> IAS MBP 90-101 CH1.H.CH2.CH3			
<211> 773			
<212> PRT			
<213> murine			
 40 Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro			
5 10 15			
 Gly Ser Thr Gly Asp Phe Lys Asn Ile Val Thr Pro Arg Thr Pro Pro			
20 25 30			
 45 Pro Ala Ser Gly Gly Ser Gly Gly Gly Asp Ser Glu Arg			
35 40 45			
 50 His Phe Val Phe Gln Phe Lys Gly Glu Cys Tyr Phe Thr Asn Gly Thr			
50 55 60			
 55 Gln Arg Ile Arg Ser Val Asp Arg Tyr Ile Tyr Asn Arg Glu Glu Tyr			
65 70 75 80			
 55 Leu Arg Phe Asp Ser Asp Val Gly Glu Tyr Arg Ala Val Thr Glu Leu			
85 90 95			
 Gly Arg Pro Asp Pro Glu Tyr Tyr Asn Lys Gln Tyr Leu Glu Gln Thr			
100 105 110			

109

Arg Ala Glu Leu Asp Thr Thr Cys Arg His Asn Tyr Glu Gly Val Glu  
 115 120 125  
 5 Thr His Thr Ser Leu Arg Arg Leu Glu Gln Pro Asn Val Val Ile Ser  
 130 135 140  
 Leu Ser Arg Thr Glu Ala Leu Asn His His Asn Thr Leu Val Cys Ser  
 145 150 155 160  
 10 Val Thr Asp Phe Tyr Pro Ala Lys Ile Lys Val Arg Trp Phe Arg Asn  
 165 170 175  
 Gly Gln Glu Glu Thr Val Gly Val Ser Ser Thr Gln Leu Ile Arg Asn  
 15 180 185 190  
 Gly Asp Trp Thr Phe Gln Val Leu Val Met Leu Glu Met Thr Pro Arg  
 195 200 205  
 20 Arg Gly Glu Val Tyr Thr Cys His Val Glu His Pro Ser Leu Lys Ser  
 210 215 220  
 Pro Ile Thr Val Glu Trp Thr Ser Gly Gly Gly Ser Gly Gly Gly  
 225 230 235 240  
 25 Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Ser Ser Glu Asp  
 245 250 255  
 Asp Ile Glu Ala Asp His Val Gly Val Tyr Gly Thr Thr Val Tyr Gln  
 30 260 265 270  
 Ser Pro Gly Asp Ile Gly Gln Tyr Thr His Glu Phe Asp Gly Asp Glu  
 275 280 285  
 35 Trp Phe Tyr Val Asp Leu Asp Lys Lys Glu Thr Ile Trp Met Leu Pro  
 290 295 300  
 Glu Phe Gly Gln Leu Thr Ser Phe Asp Pro Gln Gly Gly Leu Gln Asn  
 305 310 315 320  
 40 Ile Ala Thr Gly Lys Tyr Thr Leu Gly Ile Leu Thr Lys Arg Ser Asn  
 325 330 335  
 Ser Thr Pro Ala Thr Asn Glu Ala Pro Gln Ala Thr Val Phe Pro Lys  
 45 340 345 350  
 Ser Pro Val Leu Leu Gly Gln Pro Asn Thr Leu Ile Cys Phe Val Asp  
 355 360 365  
 50 Asn Ile Phe Pro Pro Val Ile Asn Ile Thr Trp Leu Arg Asn Ser Lys  
 370 375 380  
 Ser Val Thr Asp Gly Val Tyr Glu Thr Ser Phe Leu Val Asn Arg Asp  
 385 390 395 400  
 55 His Ser Phe His Lys Leu Ser Tyr Leu Thr Phe Ile Pro Ser Asp Asp  
 405 410 415  
 Asp Ile Tyr Asp Cys Lys Val Glu His Trp Gly Leu Glu Pro Val

		110		
	420		425	430
	Leu Lys His Trp Ala Ser Gly Gly Gly Ser Gly Gly Ser Leu			
	435		440	445
5	Ala Lys Thr Thr Pro Pro Ser Val Tyr Pro Leu Ala Pro Gly Ser Ala			
	450		455	460
	Ala Gln Thr Asn Ser Met Val Thr Leu Gly Cys Leu Val Lys Gly Tyr			
10	465		470	475
	Phe Pro Glu Pro Val Thr Val Thr Trp Asn Ser Gly Ser Leu Ser Ser			
	485		490	495
15	Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Asp Leu Tyr Thr Leu			
	500		505	510
	Ser Ser Ser Val Thr Val Pro Ser Ser Thr Trp Pro Ser Glu Thr Val			
20	515		520	525
	Thr Cys Asn Val Ala His Pro Ala Ser Ser Thr Lys Val Asp Lys Lys			
	530		535	540
	Ile Val Pro Arg Asp Cys Gly Cys Lys Pro Cys Ile Cys Thr Val Pro			
25	545		550	555
	Glu Val Ser Ser Val Phe Ile Phe Pro Pro Lys Pro Lys Asp Val Leu			
	565		570	575
30	Thr Ile Thr Leu Thr Pro Lys Val Thr Cys Val Val Val Asp Ile Ser			
	580		585	590
	Lys Asp Asp Pro Glu Val Gln Phe Ser Trp Phe Val Asp Asp Val Glu			
35	595		600	605
	Val His Thr Ala Gln Thr Gln Pro Arg Glu Glu Gln Phe Asn Ser Thr			
	610		615	620
	Phe Arg Ser Val Ser Glu Leu Pro Ile Met His Gln Asp Trp Leu Asn			
40	625		630	635
	Gly Lys Glu Phe Lys Cys Arg Val Asn Ser Ala Ala Phe Pro Ala Pro			
	645		650	655
45	Ile Glu Lys Thr Ile Ser Lys Thr Lys Gly Arg Pro Lys Ala Pro Gln			
	660		665	670
	Val Tyr Thr Ile Pro Pro Lys Glu Gln Met Ala Lys Asp Lys Val			
50	675		680	685
	Ser Leu Thr Cys Met Ile Thr Asp Phe Phe Pro Glu Asp Ile Thr Val			
	690		695	700
	Glu Trp Gln Trp Asn Gly Gln Pro Ala Glu Asn Tyr Lys Asn Thr Gln			
55	705		710	715
	Pro Ile Met Asp Thr Asp Gly Ser Tyr Phe Val Tyr Ser Lys Leu Asn			
	725		730	735

111

Val Gln Lys Ser Asn Trp Glu Ala Gly Asn Thr Phe Thr Cys Ser Val  
740 745 750

5 Leu His Glu Gly Leu His Asn His His Thr Glu Lys Ser Leu Ser His  
 755 760 765

Ser Pro Gly Lys  
770

10 <210> pCRC203  
<2II> 609  
<212> DNA  
<213> Murine

15 <400> 1

	catatgttca	agaacattgt	gacacctcga	acaccacctc	caggaggagg	atccggagac	60
	tccgaaaggc	atttcgtgtt	ccagttcaag	ggcgagtgtc	acttcaccaa	cgggacgcag	120
	cgcatacgtat	ctgtggacag	atacatctac	aaccgggagg	agtacctgcg	cttcgacagc	180
	gacgtggcg	agtaccgcgc	ggtgaccgag	ctggggcgcc	cagaccgcga	gtactacaat	240
20	aaggcgttacc	tggagcaaacc	gcggggccgag	ctggacacgg	tgtgcagaca	caactacgag	300
	gggggtggaga	cccacacctc	cctgcggcg	cttggaggtg	aagacgacat	tgaggccgac	360
	cacgttaggcg	tctatggtac	aactgtatat	cagtcctcgt	gagacattgg	ccagtacaca	420
	catgaattttg	atggtgatga	gtggttctat	gtggacttgg	ataagaagga	gactatctgg	480
	atgcttcctg	agtttggcca	attgacaagc	tttgacccccc	aagggtggact	gcaaaaacata	540
25	gctacaggaa	aatacacctt	gggaatcttgc	actaagaggt	caaattccac	cccgactacc	600
	aatctcgag						609

<210> pCRC201  
<211> 614  
<212> DNA  
<213> Murine

35	<400> 2	catatgttca agaacattgt gacacctcga acaccacctc caggaggagg atccggagac 60
	tccgaaaggc atttcgtgtt ccagttcaag ggcgagtgtct acttcaccaa cgggacgcag 120	
	cgcatacgt ctgtggacag atacatctac aaccgggagg agtacctgct cttgcacagc 180	
	gacgtggcgc agtaccgcgc ggtgaccgag ctggggcggc cagaccccga gtactacaat 240	
	aaggcgttacc tggagcaaac gcgggcccgg ctggacacgg tgtgcagaca caactacgag 300	
40	gggggtggaga cccacacctc cctgcggcgg ctggaggtg aagacgacat tgaggccgac 360	
	cacgttaggcg tctatggta aactgtatat cagtcctctg gagacattgg ccagtacaca 420	
	catgaatttg atgggtatga gtggttctat gtggacttgg ataagaagga gactatctgg 480	
	atgcttcctg agtttggcca attgacaagc ttgaccccc aaggtggact gcaaaacata 540	
	gctacaggaa aatacacctt gggaatcttg actaagaggt caaattccac cccagctacc 600	
	aattaaggccg ccgc 614	

<210> pCRC199  
<211> 642  
<212> DNA  
<213> Murine

50

<400> 3

catatgttca

agcggcgagg

ttcaccaacg g

tacctgc

gaccggagt

tgca

ggcggtg

tatcagtctc

112

tatgtggact tggataagaa ggagactatc tggatgcttc ctgagtttg ccaattgaca 540  
 agctttgacc cccaaagggtgg actgcaaaaac atagctacag gaaaatacac cttgggaatc 600  
 ttgactaaga ggtcaaattc caccggcagct accaatctcg ag 642

5 <210> pCRC197  
 <211> 647  
 <212> DNA  
 <213> Murine

10 <400> 4  
 catatgttca agaacattgt gacacctcgaaacaccacccctc tagctagcggggggggggggg 60  
 agccggcgag ggggagactc cggaaaggcat ttctgttcc agtttaaagg cgagtgcgtac 120  
 ttccaccaacg ggacgcagcg catacgatct gtggacagat acatctacaa ccgggaggag 180  
 tacctgcgtc tcgacagcga cgtggggcgg taccgcgcgg tgaccgagct gggggggcca 240  
 15 gaccccgagt actacaataa gcagtacatc gagcaaacgc gggccggagct ggacacgggtg 300  
 tgcagacaca actacgaggg ggtggagacc cacacccccc tgcggcggct tactagtgg 360  
 ggcgggtggca gcgaaagacga cattggggcc gaccacgttag ggcgtctatgg tacaactgt 420  
 tattcgtctc ctggagacat tggccagttac acacatgaat ttgatggtga tgagtgggtc 480  
 tatgtggact tggataagaa ggagactatc tggatgcttc ctgagtttg ccaattgaca 540  
 20 agctttgacc cccaaagggtgg actgcaaaaac atagctacag gaaaatacac cttgggaatc 600  
 ttgactaaga ggtcaaattc caccggcagct accaattaag cggccgc 647

<210> pCRC188  
 <211> 1698  
 25 <212> DNA  
 <213> Murine

<400> 5  
 gcggccgcca ccatggctct gcagatcccc agcctccccc tctcggctgc tgtgggtgg 60  
 30 ctgtatgtgc tgagcagccc aggactgag ggcttcaaga acattgtgac acctcgaaca 120  
 ccacccctccag ctagcggagg gggcggaaagc ggcggagggg gagaactccga aaggcatttc 180  
 gtgttccagt tcaagggcga gtgtacttcc accaacggga cgcagcgcac acgatctgt 240  
 gacagataca tctacaaccg ggaggagttac ctgcgttccg acagcgcacgt gggcgagtac 300  
 cgcgcgggtga ccgagctggg gcccggcagac cccgagttact acaataagca gtacctggag 360  
 35 caaacgcggg ccgagctgga cacgggtgtgc agacacaact acgaggggggt ggagacccac 420  
 acctccctgc ggcggcttga acagcccaat gtcgtcatct ccctgtccag gacagaggcc 480  
 ctcacccacc acaacactct ggtctgtca gtgacagatt tctacccacg caagatcaaa 540  
 gtgcgttgtt tccggaaatgg ccaggaggag acgggtgggg tctcatccac acagttatt 600  
 aggaatgggg actggacccctt ccaggtccctg gtcatgtctgg agatgacccc tcggcgggga 660  
 40 gaggtctaca cctgcccacgt ggagcatccg agcctgaaga gcccacatcac tgtggagtgg 720  
 actagtgggtg ggcgggtggcag cggcgggtggt ggttccgggtg gggcggttc tggcggtggc 780  
 ggttccctcga gtgaagacga cattggggcc gaccacgttag ggcgtctatgg tacaactgt 840  
 tattcgtctc ctggagacat tggccagttac acacatgaat ttgatggtga tgagtgggtc 900  
 tatgtggact tggataagaa ggagactatc tggatgcttc ctgagtttg ccaattgaca 960  
 45 agctttgacc cccaaagggtgg actgcaaaaac atagctacag gaaaatacac cttgggaatc 1020  
 ttgactaaga ggtcaaattc caccggcagct accaatggg ctcctcaagc gactgtggtc 1080  
 cccaaaggccc ctgtgtctgt ggttcagccc aacaccctca tctgtttgt ggacaacac 1140  
 ttccctccctg tgatcaacat cacatggctc agaaatagta agtcaagttac agacggcggt 1200  
 tatgagacca gcttccctgt caaccgtgac cattcctcc accaagctgtc ttatctcacc 1260  
 50 ttcatccctt ctgacgtga tattttatgac tgcaaggtgg agcaactgggg cctggaggag 1320  
 ccgggtctga aacactggc tagcggagggg ggcggaaagcg gcccgggggg agctgtatgt 1380  
 gcaccaactg tatccatctt cccaccatcc agtggcgtt taacatctgg aggtgcctca 1440  
 gtcgtgtgtct tcttgaacaa cttctacccca aaagacatca atgtcaagtg gaagattgt 1500  
 ggcgtgtac gacaaaatgg cgtccgtac acgttgactg atcaggacag caaagacacg 1560  
 acctacagca tgagcagcac cctcacgttg accaaggacg agtatgaacg acataacacg 1620  
 tatacctgtg aggccactca caagacatca acttcaccca ttgtcaagag cttcaacagg 1680  
 aatgagtggtt agggtaac 1698

<210> pCRC187

&lt;211&gt; 1662

&lt;212&gt; DNA

&lt;213&gt; Murine

5 <400> 6  
 gcgcccccca ccatggctct gcagatcccc agcctccccc ttcggctgc tgtggtgtg 60  
 ctgtggtgc tgagcagccc agggactgag ggcttagcg gagggggccg aaggccgga 120  
 gggggagact ccgaaaggca ttctgtttc cagttcaagg gctgtgcata cttaccaac 180  
 gggacgcagc gcatacgtac tttggacaga tacatctaca accgggagga gtacctgcgc 240  
 10 ttcgacagcg acgtggcga gtaccgcgcg gtgaccgagc tggggccggcc agaccccgag 300  
 tactacaata agcagtaccc ggagcaaaacg cggggccgagc tggacacccgt gtgcagacac 360  
 aactacgagg ggggtggagac ccacacccctc ctgcggccggc ttgaacagcc caatgtcg 420  
 atctccctgt ccaggacaga gcccctcaac caccacaaca ctctggtctg ctcagtgaca 480  
 gatttctacc cagccaaagat caaatgtgcgc tggttccggta atggccagga ggagacgg 540  
 15 ggggtctcat ccacacagct tattaggaat ggggacttggga cttccagggt cctggtcatg 600  
 ctggagatga cccctcgccg gggagaggcc tacacccgtcc acgtggagca tccgagccctg 660  
 aagagccccca tcactgtggta ttggacttagt ggtggccggc gcagccgggg tgggtgttcc 720  
 ggtggccggc gttctggccg tggcggttcc tgcgttgcgg aacgacatttgaa gcccggacc 780  
 20 gtaggcgtct atggtacaac tgatatacg ttccttggag acattggcca gtacacacat 840  
 gaatttgatg gtgatgatg gtcttatgtg gacttggata agaaggagac tatctggatg 900  
 cttcctgagt ttggccaaatt gacaagcttt gaccccaag gtggactgca aaacatagct 960  
 acaggaaaat acaccccttggg aatcttgcact aagaggtcaa attcacccccc agctaccaat 1020  
 gaggctccctc aagcgactgt gtcccccaag tccctgtgc tgctgggtca gcccacacc 1080  
 25 ctcatctgtc ttgtggacaa catcttccct cctgtatgc acatcacatg gctcagaaat 1140  
 agtaagtctcg tcacagacgg cgtttatgc accagcttcc ttgtcaaccg tgaccattcc 1200  
 ttccacaaggc tttttatctt caccatcgtcc ccttctgacg atgatattta tgactgcaag 1260  
 gtggagcact ggggccttggaa ggagccgggtt ctgaaacact gggcttagccgg agggggccgga 1320  
 agcggccggag ggggagctga tgctgcacca actgtatcca tttcccccacc atccagttag 1380  
 30 cagttAACAT ctggaggtgc ctcagtcgtg tgcttcttgc acaacttcta ccccaaagac 1440  
 atcaatgtca agtggaaagat tgatggcagt gaacgacaaa atggcgtct gaacagttgg 1500  
 actgatcagg acagcaaaaga cagcacctac agcatgagca gcacccctcac gttgaccaag 1560  
 gacgagttatg aacgacataa cagctatacc tttggggccca ctcacaagac atcaacttca 1620  
 cccattgtca agagcttcaa caggaatgag ttttttttttcc 1662

35 <210> pCB229  
 <211> 1085  
 <212> DNA  
 <213> Murine

40 <400> 7  
 gaatttcggta ccaccatggc ttcgtcagatc cccaggccccc tccctctcgcc tgctgtgg 60  
 gtgtgtatgg tgctgagcag cccaggact gagggttca agaacattgt gacacccctcg 120  
 acaccaccc cagctagccg agggggccgaa agcggccggag ggggagactc cgaaaggcat 180  
 ttcgtgttcc agttcaaggcg cagttgtctac ttcaccaacg ggacgcagcc catacgatct 240  
 45 gtggacagat acatctacaa cccggggaggag tacctgcgt tgcacagccg cgtggccgg 300  
 taccggccgg tgaccggact gggccggccca gaccccgagt actacaataa gcagttaccc 360  
 gagccaaacgc gggccggact ggacacccgtg tgcagacaca actacgggg ggtggagacc 420  
 cacacccccc tgcggccggct tgaacagccca aatgtcgatc tccctctgtc caggacagag 480  
 gcccctcaacc accacaaacac ttcggtctgc tcagtgcacg atttctaccc agccaaagatc 540  
 50 aaagtgcgtc gttccggaa tggccaggag gagacgggtgg gggcttcatac cacacagctt 600  
 attaggaatg gggactggac cttccagggtc ctgggtcatgc tggagatgac ccctccggccgg 660  
 ggagaggctc acacccctca cgtggagcat ccgagccctga agagcccccacttgcgtgg 720  
 tggagggccac agtctgtatc tgccggccg ggttcgtctg atgtcgacc aactgtatcc 780  
 atctcccccac catccaggtaa gcaatgttaca ttcggagggtg ctcaggatgt gtgtttcttgc 840  
 55 aacaacttcttcc accccaaaga catcaatgtc aagtggaaaga ttgtatggcag tgaacgacaa 900  
 aatggcgatcc tgaacagttg gactgtatgc gacagccaaacg acacccctca cagcatgagc 960  
 agcacccctca cgttgcacca ggacgagttt gacacgacatac acagctatac ctgtgaggcc 1020  
 actcacaaga catcaacttc acccattgtc aagagcttca acaggaatgaa gtgtttagggcg 1080  
 gcccgc 1085

&lt;210&gt; pCB223

&lt;211&gt; 1676

&lt;212&gt; DNA

5 &lt;213&gt; Murine

&lt;400&gt; 8

gaattcggta ccatggctct gcagatcccc agcctcctcc tctcggtgc tgggtggtg 60

ctgatggtc tgagcagccc agggactgag ggcgaagacg acattgaggc cgaccacgt 120

10 ggcgtctatg gtacaactgt atatcgatct cctggagaca ttggccagta cacacatgaa 180

tttgatggtg atgagtggtt ctatgtggac ttggataaga aggagactat ctggatgctt 240

cctgagttt gccaattgac aagctttgac ccccaaggtg gactgcaaaa catagctaca 300

ggaaaataca ctttggaat ctgactaag aggtcaaatt ccacccagc taccaatgag 360

gctcctcaag cgactgtgtt ccccaagtcc cctgtgctgc tgggtcagcc caacaccctc 420

15 atctgctttg tggacaacat ctccctccct gtgatcaaca tcacatggct cagaaatagt 480

aagtcaactca cagacggcgt ttagagacc agcttccttgc tcaaccgtg ccattcctc 540

cacaagctgt cttatctcac ctcatccct tctgacgatg atatttatga ctgcaagggt 600

gagactggg gcctggagga gccgggtctg aaacactggg aacctgagat tccagccccc 660

atgtcagaag gatctgcca aacaacagcc ccatcggtct atccactgac ccctgtgtgt 720

20 ggagatacaa ctggctccctc ggtgactcta ggatgcctgg tcaagggtt tttccctgag 780

ccagtgacct tgacctggaa ctctggatcc ctgtccagtg gtgtgcacac cttcccaagct 840

gtcctgcagt ctgacctcta caccctcagc agctcaagtga ctgtAACCTC gagcacctgg 900

cccagccagt ccatcacctg caatgtggcc caccggcaaa gcagcaccaaa ggtggacaag 960

aaaattgagc ccagaggccc cacaatcaag ccctgtcctc catgcaaatg cccagcacct 1020

25 aaccccttgg gtggaccatc cgtcttcatc ttccctccaa agatcaaggaa tgtactcatg 1080

atctccctga gccccatagt cacatgtgtg gtgggtggatg tgagcgagga tgaccaggat 1140

gtccagatca gctggtttgt gaacaacgtg gaagtacaca cagctcagac acaaaccat 1200

agagaggatt acaacagtac tctccgggtg gtcagtgc ccccatcca gcaccaggac 1260

tggatgagtg gcaaggagtt caaatgcaag gtcaacaaca aagacctccc agcggccatc 1320

30 gagagaacca tctcaaaaacc caaagggtca gtaagagctc cacaggtata tgtcttcct 1380

ccaccagaag aagagatgac taagaaacag gtcactctga cctgcattgt cacagacttc 1440

atgcctgaag acatttacgt ggagtggacc aacaacggga aaacagagct aaactacaag 1500

aacactgaac cagtcctgga ctctgtatgg tcttacttca tgtacagcaa gctgagagt 1560

gaaaaagaaga actgggtgga aagaaatagc tactctgtt cagtggtcga cgagggctg 1620

35 cacaatcacc acacgactaa gagcttctcc cgactccgg gtaaatgagc ggccgc 1676

&lt;210&gt; pCB212

&lt;211&gt; 773

&lt;212&gt; DNA

40 &lt;213&gt; Murine

&lt;400&gt; 9

ccatggtaa gaaacagacc gctgttgcac tcgctctggc gtcctggct ctttctatga 60

ccccggcgt a cgtttcaag aacattgtga cacctcgaac accacccca gctagcggag 120

45 gggggcgaag cggcggaggg ggagactccg aaaggcattt cgtgttccag tttaaaggcg 180

agtgtactt caccacccgg acgcagcgc tacatctgt ggacagatac atctacaacc 240

gggaggagta cctgcgttgc gacagcgcac tggcgagta cccgcgggtg accgagctgg 300

ggcggccaga ccccgagttac tacaataagc agtacctggc gcaaaacgcgg gccgagctgg 360

50 acacgggtgt cagacacaac tacgaggggg tggagaccca cacccctccgt cggcggctt 420

gtggcgggtgg cagcggcggt ggtggttccg gtggcggcggt ttctggcggt ggcgggtccg 480

gtggcgggtgg cagcgaagac gacattgagg ccgaccacgt aggctgtat ggtacaactg 540

tatatcgatc tcctggagac attggccagt acacacatga atttgatgtt gatgagtggt 600

tctatgtgga cttggataag aaggagacta tctggatgt tcctgagttt ggccaattga 660

55 caagcttga ccccaaggt ggactgcaaa acatagctac agaaaataac accttggaa 720

tcttactaa gaggtcaaat tccacccca gttaccaatta aggtaccggc tcc 773

&lt;210&gt; pCB214

&lt;211&gt; 702

&lt;212&gt; DNA

115

<213> Murine

<400> 10

5	atgttcaaga	acatttgtgac	acctcgaaca	ccacacctccag	ctagcgagg	gggcggaagc	60
	ggcggagggg	gagactccga	aaggcatttc	gtgttccagt	ttaaaggcga	gtgtctacttc	120
	accaacggga	cgcagcgcata	acgatctgtg	gacagataca	tctacaaccg	ggaggagttac	180
	ctgcgcttcg	acagcgacgt	gggcgagttac	cgcgcgggtga	ccgagctggg	gcggccagac	240
	cccgagttact	acaataagca	gtacacctggag	caaaccgggg	ccgagctggaa	cacgggtgtgc	300
10	agacacaact	acgagggggt	ggagacccac	acctccctgc	ggcggcttgg	tggcgggtggc	360
	agcgggggtt	gtggttccgg	tggcggcggt	tctggcggtt	gcgggttccgg	tggcgggtggc	420
	agcgaaagac	acatttgaggc	cgaccacgtt	ggcgcttatgt	gtacaactgt	atatcgatct	480
	cctggagaca	ttggccagta	cacacatgaa	tttgatggtg	atgagtggtt	ctatgtggac	540
	ttggataaga	aggagactat	ctggatgttt	cctgagttt	gc当地attgac	aagctttgac	600
15	ccccaaagggt	gactgaaaaa	catagctaca	ggaaaataca	ccttgggaat	cttgactaag	660
	aggtaaaatt	ccaccccccagc	taccaattaa	ggtaccggat	cc		702

<210> PCB220

<211> 1013

<212> DNA

20 <213> Murine

<400> 11

```

gaattcggtt ccatggctct gcagatcccc agccctcctcc tctcggtgc tgggtgggtg 60
ctgatgggtc tgacgagccc agggacttag ggcgaagacg acattgaggc cgaccacgta 120
ggcgctatg gtacaactgt atatcgatct cctggagaca ttggccagta cacacatgaa 180
tttgatgggt atgagtggtt ctatgtggac ttggataaga aggagactat ctggatgctt 240
cctgagttt gccaattgac aagcttgac ccccaaggtg gactgcaaaa catagctaca 300
ggaaaataca ctttggaat cttgactaag agtcaaaatt ccaccccgac taccatgag 360
gctcctcaag cgactgtgtt ccccaagtcc cctgtgctgc tgggtcagcc caacaccctc 420
atctgctttg tggacaacat ctccccctt gtgatcaaca tcacatggct cagaaatagt 480
aagtcatgtca cagacggcgt ttatgagacc agtttccttgc tcaaccgtga ccattccccc 540
cacaagctgt cttatctcac cttcatccct tctgacgatg atatttatga ctgcaagggtg 600
gagcactggg gcctggagga gccgggtctg aaacactggg aacctgagat tccagcccccc 660
atgtcagaag gatccgccaa aacaacagcc ccatcggtct atccactggc ccctgtgtgt 720
ggagatacaa ctggctcctc ggtgactcta ggatgcctgg tcaagggtta tttccctgag 780
ccagtgcacct tgacctggaa ctctggatct ctgtccagtg gtgtgcacac cttcccagct 840
gtccctgcagt ctgacctcta caccctcagc agctcagtga ctgtAACCTC gagcacctgg 900
cccagccagt ccatcacctg caatgtggcc caccctggcaa gcagcacccaa ggtggacaag 960
aaaaattgagc ccaagggccc cacaatcaaq ccctatqctg catabcqccqcc cqcc 101

```

<210> pCR

<211> 207

<212> PRT

<213> Murine

-100- 13

Met Phe Lys Asn Ile Val Thr Pro Arg Thr Pro Pro Pro Gly Gly Gly  
5 10 15

50 Ser Gly Asp Ser Glu Arg His Phe Val Phe Gln Phe Lys Gly Glu Cys  
20 25 30

Tyr Phe Thr Asn Gly Thr Gln Arg Ile Arg Ser Val Asp Arg Tyr Ile  
           35                  40                           45

Tyr Asn Arg Glu Glu Tyr Leu Arg Phe Asp Ser Asp Val Gly Glu Tyr  
50 55 60

Arg Ala Val Thr Glu Leu Gly Arg Pro Asp Pro Glu Tyr Tyr Asp Lys

		116			
	65	70	75	80	
	Gln Tyr Leu Glu Gln Thr Arg Ala Glu Leu Asp Thr Val Cys Arg His				
	85		90	95	
5	Asn Tyr Glu Gly Val Glu Thr His Thr Ser Leu Arg Arg Leu Gly Gly				
	100		105	110	
10	Glu Asp Asp Ile Glu Ala Asp His Val Gly Val Tyr Gly Thr Thr Val				
	115		120	125	
	Tyr Gln Ser Pro Gly Asp Ile Gly Gln Tyr Thr His Glu Phe Asp Gly				
	130		135	140	
15	Asp Glu Trp Phe Tyr Val Asp Leu Asp Lys Lys Glu Thr Ile Trp Met				
	145		150	160	
	Leu Pro Glu Phe Gly Gln Leu Thr Ser Phe Asp Pro Gln Gly Gly Leu				
	165		170	175	
20	Gln Asn Ile Ala Thr Gly Lys Tyr Thr Leu Gly Ile Leu Thr Lys Arg				
	180		185	190	
25	Ser Asn Ser Thr Pro Ala Thr Asn His His His His His His				
	195		200	205	
	<210> pCRC201				
	<211> 201				
30	<212> PRT				
	<213> Murine				
	<400> 13				
35	Met Phe Lys Asn Ile Val Thr Pro Arg Thr Pro Pro Pro Gly Gly				
	5		10	15	
	Ser Gly Asp Ser Glu Arg His Phe Val Phe Gln Phe Lys Gly Glu Cys				
	20		25	30	
40	Tyr Phe Thr Asn Gly Thr Gln Arg Ile Arg Ser Val Asp Arg Tyr Ile				
	35		40	45	
	Tyr Asn Arg Glu Glu Tyr Leu Arg Phe Asp Ser Asp Val Gly Glu Tyr				
	50		55	60	
45	Arg Ala Val Thr Glu Leu Gly Arg Pro Asp Pro Glu Tyr Tyr Asn Lys				
	65		70	75	
50	Gln Tyr Leu Glu Gln Thr Arg Ala Glu Leu Asp Thr Val Cys Arg His				
	85		90	95	
	Asn Tyr Glu Gly Val Glu Thr His Thr Ser Leu Arg Arg Leu Gly Gly				
	100		105	110	
55	Glu Asp Asp Ile Glu Ala Asp His Val Gly Val Tyr Gly Thr Thr Val				
	115		120	125	
	Tyr Gln Ser Pro Gly Asp Ile Gly Gln Tyr Thr His Glu Phe Asp Gly				
	130		135	140	

117

Asp Glu Trp Phe Tyr Val Asp Leu Asp Lys Lys Glu Thr Ile Trp Met  
 145 150 155 160

5 Leu Pro Glu Phe Gly Gln Leu Thr Ser Phe Asp Pro Gln Gly Gly Leu  
 165 170 175

Gln Asn Ile Ala Thr Gly Lys Tyr Thr Leu Gly Ile Leu Thr Lys Arg  
 180 185 190

10 Ser Asn Ser Thr Pro Ala Thr Asn  
 195 200

15 <210> pCRC199  
 <211> 218  
 <212> PRT  
 <213> Murine

20 <400> 14  
 Met Phe Lys Asn Ile Val Thr Pro Arg Thr Pro Pro Pro Ala Ser Gly  
 5 10 15

25 Gly Gly Gly Ser Gly Gly Gly Asp Ser Glu Arg His Phe Val Phe  
 20 25 30

Gln Phe Lys Gly Glu Cys Tyr Phe Thr Asn Gly Thr Gln Arg Ile Arg  
 35 40 45

30 Ser Val Asp Arg Tyr Ile Tyr Asn Arg Glu Glu Tyr Leu Arg Phe Asp  
 50 55 60

Ser Asp Val Gly Glu Tyr Arg Ala Val Thr Glu Leu Gly Arg Pro Asp  
 65 70 75 80

35 Pro Glu Tyr Tyr Asn Lys Gln Tyr Leu Glu Gln Thr Arg Ala Glu Leu  
 85 90 95

40 Asp Thr Val Cys Arg His Asn Tyr Glu Gly Val Glu Thr His Thr Ser  
 100 105 110

Leu Arg Arg Leu Thr Ser Gly Gly Ser Glu Asp Asp Ile Glu  
 115 120 125

45 Ala Asp His Val Gly Val Tyr Gly Thr Thr Val Tyr Gln Ser Pro Gly  
 130 135 140

Asp Ile Gly Gln Tyr Thr His Glu Phe Asp Gly Asp Glu Trp Phe Tyr  
 145 150 155 160

50 Val Asp Leu Asp Lys Lys Glu Thr Ile Trp Met Leu Pro Glu Phe Gly  
 165 170 175

Gln Leu Thr Ser Phe Asp Pro Gln Gly Gly Leu Gln Asn Ile Ala Thr  
 180 185 190

Gly Lys Tyr Thr Leu Gly Ile Leu Thr Lys Arg Ser Asn Ser Thr Pro  
 195 200 205

118

Ala Thr Asn His His His His His His  
 210                                   215

5       <210> pCRC197  
 <211> 212  
 <212> PRT  
 <213> Murine

10      <400> 15  
 Met Phe Lys Asn Ile Val Thr Pro Arg Thr Pro Pro Pro Ala Ser Gly  
 5                                   10                                   15

15      Gly Gly Gly Ser Gly Gly Gly Asp Ser Glu Arg His Phe Val Phe  
 20                                   25                                   30

20      Gln Phe Lys Gly Glu Cys Tyr Phe Thr Asn Gly Thr Gln Arg Ile Arg  
 35                                   40                                   45

25      Ser Val Asp Arg Tyr Ile Tyr Asn Arg Glu Glu Tyr Leu Arg Phe Asp  
 50                                   55                                   60

30      Ser Asp Val Gly Glu Tyr Arg Ala Val Thr Glu Leu Gly Arg Pro Asp  
 65                                   70                                   75                           80

35      Pro Glu Tyr Tyr Asn Lys Gln Tyr Leu Glu Gln Thr Arg Ala Glu Leu  
 85                                   90                                   95

40      Asp Thr Val Cys Arg His Asn Tyr Glu Gly Val Glu Thr His Thr Ser  
 100                                   105                                   110

45      Leu Arg Arg Leu Thr Ser Gly Gly Gly Ser Glu Asp Asp Ile Glu  
 115                                   120                                   125

50      Ala Asp His Val Gly Val Tyr Gly Thr Thr Val Tyr Gln Ser Pro Gly  
 130                                   135                                   140

55      Asp Ile Gly Gln Tyr Thr His Glu Phe Asp Gly Asp Glu Trp Phe Tyr  
 145                                   150                                   155                           160

60      Val Asp Leu Asp Lys Lys Glu Thr Ile Trp Met Leu Pro Glu Phe Gly  
 165                                   170                                   175

65      Gln Leu Thr Ser Phe Asp Pro Gln Gly Gly Leu Gln Asn Ile Ala Thr  
 180                                   185                                   190

70      Gly Lys Tyr Thr Leu Gly Ile Leu Thr Lys Arg Ser Asn Ser Thr Pro  
 195                                   200                                   205

75      Ala Thr Asn  
 210

55      <210> pCRC188  
 <211> 548  
 <212> PRT  
 <213> Murine

<400> 16

119

Met Ala Leu Gln Ile Pro Ser Leu	Leu	Leu Ser Ala Ala Val Val Val	
5		10	15
Leu Met Val Leu Ser Ser Pro Gly	Thr	Glu Gly Ala Ser Gly Gly Gly	
20		25	30
Gly Ser Gly Gly Gly Asp Ser Glu	Arg His Phe Val Phe Gln Phe		
35	40	45	
Lys Gly Glu Cys Tyr Phe Thr Asn	Gly Thr Gln Arg Ile Arg Ser Val		
50	55	60	
Asp Arg Tyr Ile Tyr Asn Arg Glu	Glu Tyr Leu Arg Phe Asp Ser Asp		
65	70	75	80
Val Gly Glu Tyr Arg Ala Val Thr	Glu Leu Gly Arg Pro Asp Pro Glu		
85	90	95	
Tyr Tyr Asn Lys Gln Tyr Leu Glu	Gln Thr Arg Ala Glu Leu Asp Thr		
100	105	110	
Val Cys Arg His Asn Tyr Glu Gly	Val Glu Thr His Thr Ser Leu Arg		
115	120	125	
Arg Leu Glu Gln Pro Asn Val Val	Ile Ser Leu Ser Arg Thr Glu Ala		
130	135	140	
Leu Asn His His Asn Thr Leu Val	Cys Ser Val Thr Asp Phe Tyr Pro		
145	150	155	160
Ala Lys Ile Lys Val Arg Trp Phe	Arg Asn Gly Gln Glu Glu Thr Val		
165	170	175	
Gly Val Ser Ser Thr Gln Leu Ile	Arg Asn Gly Asp Trp Thr Phe Gln		
180	185	190	
Val Leu Val Met Leu Glu Met Thr	Pro Arg Arg Gly Glu Val Tyr Thr		
195	200	205	
Cys His Val Glu His Pro Ser Leu	Lys Ser Pro Ile Thr Val Glu Trp		
210	215	220	
Thr Ser Gly Gly Gly Ser Gly Gly	Gly Ser Gly Gly Gly Gly Gly Gly		
225	230	235	240
Ser Gly Gly Gly Ser Ser Ser Glu	Asp Asp Ile Glu Ala Asp His		
245	250	255	
Val Gly Val Tyr Gly Thr Thr Val	Tyr Gln Ser Pro Gly Asp Ile Gly		
260	265	270	
Gln Tyr Thr His Glu Phe Asp Gly	Asp Glu Trp Phe Tyr Val Asp Leu		
275	280	285	
Asp Lys Lys Glu Thr Ile Trp Met	Leu Pro Glu Phe Gly Gln Leu Thr		
290	295	300	
Ser Phe Asp Pro Gln Gly Gly Leu	Gln Asn Ile Ala Thr Gly Lys Tyr		
305	310	315	320

120

	Thr Leu Gly Ile Leu Thr Lys Arg Ser Asn Ser Thr Pro Ala Thr Asn		
	325	330	335
5	Glu Ala Pro Gln Ala Thr Val Phe Pro Lys Ser Pro Val Leu Leu Gly		
	340	345	350
	Gln Pro Asn Thr Leu Ile Cys Phe Val Asp Asn Ile Phe Pro Pro Val		
	355	360	365
10	Ile Asn Ile Thr Trp Leu Arg Asn Ser Lys Ser Val Thr Asp Gly Val		
	370	375	380
15	Tyr Glu Thr Ser Phe Leu Val Asn Arg Asp His Ser Phe His Lys Leu		
	385	390	395
	Ser Tyr Leu Thr Phe Ile Pro Ser Asp Asp Asp Ile Tyr Asp Cys Lys		
	405	410	415
20	Val Glu His Trp Gly Leu Glu Glu Pro Val Leu Lys His Trp Ala Ser		
	420	425	430
	Gly Gly Gly Ser Gly Gly Gly Ala Asp Ala Ala Pro Thr Val		
	435	440	445
25	Ser Ile Phe Pro Pro Ser Ser Glu Gln Leu Thr Ser Gly Gly Ala Ser		
	450	455	460
30	Val Val Cys Phe Leu Asn Asn Phe Tyr Pro Lys Asp Ile Asn Val Lys		
	465	470	475
	Trp Lys Ile Asp Gly Ser Glu Arg Gln Asn Gly Val Leu Asn Ser Trp		
	485	490	495
35	Thr Asp Gln Asp Ser Lys Asp Ser Thr Tyr Ser Met Ser Ser Thr Leu		
	500	505	510
	Thr Leu Thr Lys Asp Glu Tyr Glu Arg His Asn Ser Tyr Thr Cys Glu		
	515	520	525
40	Ala Thr His Lys Thr Ser Thr Ser Pro Ile Val Lys Ser Phe Asn Arg		
	530	535	540
45	Asn Glu Cys		
	545		
	<210> pCRC187		
	<211> 253		
50	<212> PRT		
	<213> Murine		
	<400> 17		
55	Met Gly Lys Lys Gln Thr Ala Val Ala Phe Ala Leu Ala Leu Ala		
	5	10	15
	Leu Ser Met Thr Pro Ala Tyr Ala Phe Lys Asn Ile Val Thr Pro Arg		
	20	25	30

121

	Thr	Pro	Pro	Pro	Ala	Ser	Gly	Gly	Gly	Gly	Ser	Gly	Gly	Gly	Gly	Asp
	35						35	40			45					
5	Ser	Glu	Aрг	His	Phe	Val	Phe	Gln	Phe	Lys	Gly	Glu	Cys	Tyr	Phe	Thr
	50						55			60						
	Asn	Gly	Thr	Gln	Arg	Ile	Arg	Ser	Val	Asp	Arg	Tyr	Ile	Tyr	Asn	Arg
	65					70				75			80			
10	Glu	Glu	Tyr	Leu	Arg	Phe	Asp	Ser	Asp	Val	Gly	Glu	Tyr	Arg	Ala	Val
						85				90			95			
	Thr	Glu	Leu	Gly	Arg	Pro	Asp	Pro	Glu	Tyr	Tyr	Asn	Lys	Gln	Tyr	Leu
						100			105			110				
15	Glu	Gln	Thr	Arg	Ala	Glu	Leu	Asp	Thr	Val	Cys	Arg	His	Asn	Tyr	Glu
						115			120			125				
20	Gly	Val	Glu	Thr	His	Thr	Ser	Leu	Arg	Arg	Leu	Gly	Gly	Gly	Ser	
						130			135			140				
	Gly	Gly	Gly	Ser	Gly	Gly	Gly	Ser	Gly	Gly	Gly	Gly	Gly	Ser	Gly	
	145					150				155			160			
25	Gly	Gly	Gly	Ser	Glu	Asp	Asp	Ile	Glu	Ala	Asp	His	Val	Gly	Val	Tyr
						165				170			175			
	Gly	Thr	Thr	Val	Tyr	Gln	Ser	Pro	Gly	Asp	Ile	Gly	Gln	Tyr	Thr	His
						180			185			190				
30	Glu	Phe	Asp	Gly	Asp	Glu	Trp	Phe	Tyr	Val	Asp	Leu	Asp	Lys	Lys	Glu
						195			200			205				
	Thr	Ile	Trp	Met	Leu	Pro	Glu	Phe	Gly	Gln	Leu	Thr	Ser	Phe	Asp	Pro
						210			215			220				
35	Gln	Gly	Gly	Leu	Gln	Asn	Ile	Ala	Thr	Gly	Lys	Tyr	Thr	Leu	Gly	Ile
						225			230			235			240	
40	Leu	Thr	Lys	Arg	Ser	Asn	Ser	Thr	Pro	Ala	Thr	Asn				
						245				250						
45	<210>	pCB229														
	<211>	354														
	<212>	PRT														
	<213>	Murine														
50	<400>	18														
	Met	Ala	Leu	Gln	Ile	Pro	Ser	Leu	Leu	Ser	Ala	Ala	Val	Val	Val	
						5				10			15			
	Leu	Met	Val	Leu	Ser	Ser	Pro	Gly	Thr	Glu	Gly	Phe	Lys	Asn	Ile	Val
						20			25			30				
55	Thr	Pro	Arg	Thr	Pro	Pro	Pro	Ala	Ser	Gly	Gly	Gly	Ser	Gly	Gly	
						35			40			45				
	Gly	Gly	Asp	Ser	Glu	Arg	His	Phe	Val	Phe	Gln	Phe	Lys	Gly	Glu	Cys

122

50	55	60	
Tyr Phe Thr Asn Gly Thr Gln Arg Ile Arg Ser Val Asp Arg Tyr Ile			
65	70	75	80
5 Tyr Asn Arg Glu Glu Tyr Leu Arg Phe Asp Ser Asp Val Gly Glu Tyr			
85	90	95	
10 Arg Ala Val Thr Glu Leu Gly Arg Pro Asp Pro Glu Tyr Tyr Asn Lys			
100	105	110	
Gln Tyr Leu Glu Gln Thr Arg Ala Glu Leu Asp Thr Val Cys Arg His			
115	120	125	
15 Asn Tyr Glu Gly Val Glu Thr His Thr Ser Leu Arg Arg Leu Glu Gln			
130	135	140	
Pro Asn Val Val Ile Ser Leu Ser Arg Thr Glu Ala Leu Asn His His			
145	150	155	160
20 Asn Thr Leu Val Cys Ser Val Thr Asp Phe Tyr Pro Ala Lys Ile Lys			
165	170	175	
25 Val Arg Trp Phe Arg Asn Gly Gln Glu Glu Thr Val Gly Val Ser Ser			
180	185	190	
Thr Gln Leu Ile Arg Asn Gly Asp Trp Thr Phe Gln Val Leu Val Met			
195	200	205	
30 Leu Glu Met Thr Pro Arg Arg Gly Glu Val Tyr Thr Cys His Val Glu			
210	215	220	
His Pro Ser Leu Lys Ser Pro Ile Thr Val Glu Trp Arg Ala Gln Ser			
225	230	235	240
35 Glu Ser Ala Arg Ser Gly Ser Ala Asp Ala Ala Pro Thr Val Ser Ile			
245	250	255	
40 Phe Pro Pro Ser Ser Glu Gln Leu Thr Ser Gly Gly Ala Ser Val Val			
260	265	270	
Cys Phe Leu Asn Asn Phe Tyr Pro Lys Asp Ile Asn Val Lys Trp Lys			
275	280	285	
45 Ile Asp Gly Ser Glu Arg Gln Asn Gly Val Leu Asn Ser Trp Thr Asp			
290	295	300	
50 Gln Asp Ser Lys Asp Ser Thr Tyr Ser Met Ser Ser Thr Leu Thr Leu			
305	310	315	320
Thr Lys Asp Glu Tyr Glu Arg His Asn Ser Tyr Thr Cys Glu Ala Thr			
325	330	335	
55 His Lys Thr Ser Thr Ser Pro Ile Val Lys Ser Phe Asn Arg Asn Glu			
340	345	350	
Cys			

123

<210> p/cb223  
 <211> 552  
 <212> PRT  
 5 <213> Murine

<400> 19  
 Met Ala Leu Gln Ile Pro Ser Leu Leu Leu Ser Ala Ala Val Val Val  
 5 10 15

10 Leu Met Val Leu Ser Ser Pro Gly Thr Glu Gly Glu Asp Asp Ile Glu  
 20 25 30

Ala Asp His Val Gly Val Tyr Gly Thr Thr Val Tyr Gln Ser Pro Gly  
 15 35 40 45

Asp Ile Gly Gln Tyr Thr His Glu Phe Asp Gly Asp Glu Trp Phe Tyr  
 50 55 60

20 Val Asp Leu Asp Lys Lys Glu Thr Ile Trp Met Leu Pro Glu Phe Gly  
 65 70 75 80

Gln Leu Thr Ser Phe Asp Pro Gln Gly Gly Leu Gln Asn Ile Ala Thr  
 85 90 95

25 Gly Lys Tyr Thr Leu Gly Ile Leu Thr Lys Arg Ser Asn Ser Thr Pro  
 100 105 110

Ala Thr Asn Glu Ala Pro Gln Ala Thr Val Phe Pro Lys Ser Pro Val  
 30 115 120 125

Leu Leu Gly Gln Pro Asn Thr Leu Ile Cys Phe Val Asp Asn Ile Phe  
 130 135 140

35 Pro Pro Val Ile Asn Ile Thr Trp Leu Arg Asn Ser Lys Ser Val Thr  
 145 150 155 160

Asp Gly Val Tyr Glu Thr Ser Phe Leu Val Asn Arg Asp His Ser Phe  
 165 170 175

40 His Lys Leu Ser Tyr Leu Thr Phe Ile Pro Ser Asp Asp Asp Ile Tyr  
 180 185 190

Asp Cys Lys Val Glu His Trp Gly Leu Glu Glu Pro Val Leu Lys His  
 45 195 200 205

Trp Glu Pro Glu Ile Pro Ala Pro Met Ser Glu Gly Ser Ala Lys Thr  
 210 215 220

50 Thr Ala Pro Ser Val Tyr Pro Leu Ala Pro Val Cys Gly Asp Thr Thr  
 225 230 235 240

Gly Ser Ser Val Thr Leu Gly Cys Leu Val Lys Gly Tyr Phe Pro Glu  
 245 250 255

55 Pro Val Thr Leu Thr Trp Asn Ser Gly Ser Leu Ser Ser Gly Val His  
 260 265 270

Thr Phe Pro Ala Val Leu Gln Ser Asp Leu Tyr Thr Leu Ser Ser Ser

	124		
	275	280	285
	Val Thr Val Thr Ser Ser	Thr Trp Pro Ser Gln Ser Ile Thr Cys Asn	
	290	295	300
5	Val Ala His Pro Ala Ser Ser	Thr Lys Val Asp Lys Lys Ile Glu Pro	
	305	310	315
	Arg Gly Pro Thr Ile Lys Pro Cys Pro	Pro Cys Lys Cys Pro Ala Pro	
10	325	330	335
	Asn Leu Leu Gly Gly Pro Ser Val Phe Ile Phe Pro Pro	Lys Ile Lys	
	340	345	350
15	Asp Val Leu Met Ile Ser Leu Ser Pro Ile Val Thr Cys	Val Val Val	
	355	360	365
	Asp Val Ser Glu Asp Asp Pro Asp Val Gln Ile Ser Trp	Phe Val Asn	
	370	375	380
20	Asn Val Glu Val His Thr Ala Gln Thr Gln Thr His Arg	Glu Asp Tyr	
	385	390	395
	Asn Ser Thr Leu Arg Val Val Ser Ala Leu Pro Ile Gln His	Gln Asp	
25	405	410	415
	Trp Met Ser Gly Lys Glu Phe Lys Cys Lys Val Asn Asn	Lys Asp Leu	
	420	425	430
30	Pro Ala Pro Ile Glu Arg Thr Ile Ser Lys Pro Lys Gly	Ser Val Arg	
	435	440	445
	Ala Pro Gln Val Tyr Val Leu Pro Pro Pro Glu Glu Met Thr	Lys	
	450	455	460
35	Lys Gln Val Thr Leu Thr Cys Met Val Thr Asp Phe Met Pro	Glu Asp	
	465	470	475
	480		
40	Ile Tyr Val Glu Trp Thr Asn Asn Gly Lys Thr Glu Leu Asn	Tyr Lys	
	485	490	495
	Asn Thr Glu Pro Val Leu Asp Ser Asp Gly Ser Tyr Phe Met	Tyr Ser	
	500	505	510
45	Lys Leu Arg Val Glu Lys Lys Asn Trp Val Glu Arg Asn Ser	Tyr Ser	
	515	520	525
	Cys Ser Val Val His Glu Gly Leu His Asn His His Thr Thr	Lys Ser	
	530	535	540
50	Phe Ser Arg Thr Pro Gly Lys		
	545	550	
55	<210> pCB212		
	<211> 331		
	<212> PRT		
	<213> Murine		

125

<400> 20  
Met Ala Leu Gln Ile Pro Ser Leu Leu Leu Ser Ala Ala Val Val Val  
5 10 15

5 Leu Met Val Leu Ser Ser Pro Gly Thr Glu Gly Glu Asp Asp Ile Glu  
20 25 30

Ala Asp His Val Gly Val Tyr Gly Thr Thr Val Tyr Gln Ser Pro Gly  
35 40 45

10 Asp Ile Gly Gln Tyr Thr His Glu Phe Asp Gly Asp Glu Trp Phe Tyr  
50 55 60

15 Val Asp Leu Asp Lys Lys Glu Thr Ile Trp Met Leu Pro Glu Phe Gly  
65 70 75 80

Gln Leu Thr Ser Phe Asp Pro Gln Gly Gly Leu Gln Asn Ile Ala Thr  
85 90 95

20 Gly Lys Tyr Thr Leu Gly Ile Leu Thr Lys Arg Ser Asn Ser Thr Pro  
100 105 110

Ala Thr Asn Glu Ala Pro Gln Ala Thr Val Phe Pro Lys Ser Pro Val  
115 120 125

25 Leu Leu Gly Gln Pro Asn Thr Leu Ile Cys Phe Val Asp Asn Ile Phe  
130 135 140

30 Pro Pro Val Ile Asn Ile Thr Trp Leu Arg Asn Ser Lys Ser Val Thr  
145 150 155 160

Asp Gly Val Tyr Glu Thr Ser Phe Leu Val Asn Arg Asp His Ser Phe  
165 170 175

35 His Lys Leu Ser Tyr Leu Thr Phe Ile Pro Ser Asp Asp Ile Tyr  
180 185 190

Asp Cys Lys Val Glu His Trp Gly Leu Glu Pro Val Leu Lys His  
195 200 205

40 Trp Glu Pro Glu Ile Pro Ala Pro Met Ser Glu Gly Ser Ala Lys Thr  
210 215 220

45 Thr Ala Pro Ser Val Tyr Pro Leu Ala Pro Val Cys Gly Asp Thr Thr  
225 230 235 240

Gly Ser Ser Val Thr Leu Gly Cys Leu Val Lys Gly Tyr Phe Pro Glu  
245 250 255

50 Pro Val Thr Leu Thr Trp Asn Ser Gly Ser Leu Ser Ser Gly Val His  
260 265 270

Thr Phe Pro Ala Val Leu Gln Ser Asp Leu Tyr Thr Leu Ser Ser Ser  
275 280 285

55 Val Thr Val Thr Ser Ser Thr Trp Pro Ser Gln Ser Ile Thr Cys Asn  
290 295 300

Val Ala His Pro Ala Ser Ser Thr Lys Val Asp Lys Lys Ile Glu Pro

	126		
	305	310	315
	Arg Gly Pro Thr Ile Lys Pro Cys Ala Ala		
	325	330	
5			
	<210> pCB214		
	<211> 234		
	<212> PRT		
10	<213> Murine		
	<400> 21		
	Met Phe Lys Asn Ile Val Thr Pro Arg Thr Pro Pro Pro Ala Ser Gly		
	5	10	15
15	Gly Gly Gly Ser Gly Gly Asp Ser Glu Arg His Phe Val Phe		
	20	25	30
	Gln Phe Lys Gly Glu Cys Tyr Phe Thr Asn Gly Thr Gln Arg Ile Arg		
20	35	40	45
	Ser Val Asp Arg Tyr Ile Tyr Asn Arg Glu Glu Tyr Leu Arg Phe Asp		
	50	55	60
25	Ser Asp Val Gly Glu Tyr Arg Ala Val Thr Glu Leu Gly Arg Pro Asp		
	65	70	75
	Pro Glu Tyr Tyr Asn Lys Gln Tyr Leu Glu Gln Thr Arg Ala Glu Leu		
	85	90	95
30	Asp Thr Val Cys Arg His Asn Tyr Glu Gly Val Glu Thr His Thr Ser		
	100	105	110
	Leu Arg Arg Leu Gly Gly Ser Gly Gly Ser Gly Gly		
35	115	120	125
	Gly Gly Ser Gly Gly Ser Gly Gly Ser Glu Asp Asp		
	130	135	140
40	Ile Glu Ala Asp His Val Gly Val Tyr Gly Thr Thr Val Tyr Gln Ser		
	145	150	155
	Pro Gly Asp Ile Gly Gln Tyr Thr His Glu Phe Asp Gly Asp Glu Trp		
	165	170	175
45	Phe Tyr Val Asp Leu Asp Lys Lys Glu Thr Ile Trp Met Leu Pro Glu		
	180	185	190
	Phe Gly Gln Leu Thr Ser Phe Asp Pro Gln Gly Leu Gln Asn Ile		
50	195	200	205
	Ala Thr Gly Lys Tyr Thr Leu Gly Ile Leu Thr Lys Arg Ser Asn Ser		
	210	215	220
55	Thr Pro Ala Thr Asn Gly Thr Gly Ser		
	225		

<210> pCB220

127

<211> 560  
<212> PRT  
<213> Murine

5 <400> 22  
Met Ala Leu Gln Ile Pro Ser Leu Leu Leu Ser Ala Ala Val Val Val  
5 10 15

10 Leu Met Val Leu Ser Ser Pro Gly Thr Glu Gly Phe Lys Asn Ile Val  
20 25 30

Thr Pro Arg Thr Pro Pro Pro Ala Ser Gly Gly Gly Ser Gly Gly  
35 40 45

15 Gly Gly Asp Ser Glu Arg His Phe Val Phe Gln Phe Lys Gly Glu Cys  
50 55 60

Tyr Phe Thr Asn Gly Thr Gln Arg Ile Arg Ser Val Asp Arg Tyr Ile  
65 70 75 80

20 Tyr Asn Arg Glu Glu Tyr Leu Arg Phe Asp Ser Asp Val Gly Glu Tyr  
85 90 95

Arg Ala Val Thr Glu Leu Gly Arg Pro Asp Pro Glu Tyr Tyr Asn Lys  
100 105 110

Gln Tyr Leu Glu Gln Thr Arg Ala Glu Leu Asp Thr Val Cys Arg His  
115 120 125

30 Asn Tyr Glu Gly Val Glu Thr His Thr Ser Leu Arg Arg Leu Glu Gln  
130 135 140

Pro Asn Val Val Ile Ser Leu Ser Arg Thr Glu Ala Leu Asn His His  
145 150 155 160

35 Asn Thr Leu Val Cys Ser Val Thr Asp Phe Tyr Pro Ala Lys Ile Lys  
165 170 175

40 Val Arg Trp Phe Arg Asn Gly Gln Glu Glu Thr Val Gly Val Ser Ser  
180 185 190

Thr Gln Leu Ile Arg Asn Gly Asp Trp Thr Phe Gln Val Leu Val Met  
195 200 205

45 Leu Glu Met Thr Pro Arg Arg Gly Glu Val Tyr Thr Cys His Val Glu  
210 215 220

His Pro Ser Leu Lys Ser Pro Ile Thr Val Glu Trp Thr Ser Gly Gly  
225 230 235 240

50 Gly Gly Ser Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly  
245 250 255

Gly Ser Ser Ser Glu Asp Asp Ile Glu Ala Asp His Val Gly Val Tyr  
55 260 265 270

Gly Thr Thr Val Tyr Gln Ser Pro Gly Asp Ile Gly Gln Tyr Thr His  
275 280 285

128

	Glu	Phe	Asp	Gly	Asp	Glu	Trp	Phe	Tyr	Val	Asp	Leu	Asp	Lys	Lys	Glu
	290					295						300				
5	Thr	Ile	Trp	Met	Leu	Pro	Glu	Phe	Gly	Gln	Leu	Thr	Ser	Phe	Asp	Pro
	305				310					315				320		
	Gln	Gly	Gly	Leu	Gln	Asn	Ile	Ala	Thr	Gly	Lys	Tyr	Thr	Leu	Gly	Ile
					325					330				335		
10	Leu	Thr	Lys	Arg	Ser	Asn	Ser	Thr	Pro	Ala	Thr	Asn	Glu	Ala	Pro	Gln
						340				345				350		
	Ala	Thr	Val	Phe	Pro	Lys	Ser	Pro	Val	Leu	Leu	Gly	Gln	Pro	Asn	Thr
						355				360				365		
15	Leu	Ile	Cys	Phe	Val	Asp	Asn	Ile	Phe	Pro	Pro	Val	Ile	Asn	Ile	Thr
						370				375				380		
20	Trp	Leu	Arg	Asn	Ser	Lys	Ser	Val	Thr	Asp	Gly	Val	Tyr	Glu	Thr	Ser
						385				390				400		
	Phe	Leu	Val	Asn	Arg	Asp	His	Ser	Phe	His	Lys	Leu	Ser	Tyr	Leu	Thr
						405				410				415		
25	Phe	Ile	Pro	Ser	Asp	Asp	Ile	Tyr	Asp	Cys	Lys	Val	Glu	His	Trp	
						420				425				430		
	Gly	Leu	Glu	Glu	Pro	Val	Leu	Lys	His	Trp	Ala	Ser	Gly	Gly	Gly	
						435				440				445		
30	Ser	Gly	Gly	Gly	Ala	Asp	Ala	Ala	Pro	Thr	Val	Ser	Ile	Phe	Pro	
						450				455				460		
	Pro	Ser	Ser	Glu	Gln	Leu	Thr	Ser	Gly	Gly	Ala	Ser	Val	Val	Cys	Phe
35						465				470				475		480
	Leu	Asn	Asn	Phe	Tyr	Pro	Lys	Asp	Ile	Asn	Val	Lys	Trp	Lys	Ile	Asp
						485				490				495		
40	Gly	Ser	Glu	Arg	Gln	Asn	Gly	Val	Leu	Asn	Ser	Trp	Thr	Asp	Gln	Asp
						500				505				510		
	Ser	Lys	Asp	Ser	Thr	Tyr	Ser	Met	Ser	Ser	Thr	Leu	Thr	Leu	Thr	Lys
						515				520				525		
45	Asp	Glu	Tyr	Glu	Arg	His	Asn	Ser	Tyr	Thr	Cys	Glu	Ala	Thr	His	Lys
						530				535				540		
50	Thr	Ser	Thr	Ser	Pro	Ile	Val	Lys	Ser	Phe	Asn	Arg	Asn	Glu	Cys	
						545				550				555		

WHAT IS CLAIMED IS:

- 1           1. A multimeric complex comprising a first recombinant single chain  
2       MHC class II molecule and a second recombinant single chain MHC class II molecule,  
3       wherein the first and the second single chain MHC class II molecule each comprise an  $\alpha 1$   
4       domain and a  $\beta 1$  domain linked via an amino acid linker and a multimerization domain,  
5       and wherein the first and the second single chain MHC class II molecule are linked via  
6       the multimerization domain to form a multimeric complex.
  
- 1           2. The multimeric complex of claim 1, wherein the first and the  
2       second single chain MHC class II molecules are each linked to an antigenic peptide via an  
3       amino acid linker.
  
- 1           3. The multimeric complex of claim 2, wherein the peptides are the  
2       same.
  
- 1           4. The multimeric complex of claim 2, wherein the peptides are from  
2       the same antigen.
  
- 1           5. The multimeric complex of claim 2, wherein the peptides are from  
2       different antigens.
  
- 1           6. The multimeric complex of claim 2, wherein the peptides are  
2       selected from the group consisting of MBP83-102Y83, PLP 40-60, PLP 89-106, PLP 95-  
3       117, and PLP 185-206.
  
- 1           7. The multimeric complex of claim 1, wherein the first and the  
2       second MHC class II molecules are from the same MHC class II allele.
  
- 1           8. The multimeric complex of claim 1, wherein the first and the  
2       second MHC class II molecules are from different MHC class II alleles.
  
- 1           9. The multimeric complex of claim 7 or 8, wherein the alleles are  
2       selected from the group consisting of DRB1\*1501 and DRB5\*0101.

1               10.     The multimeric complex of claim 7 or 8, wherein the first and the  
2     second single chain MHC class II molecules are each linked to an antigenic peptide via an  
3     amino acid linker.

1               11.     The multimeric complex of claim 10, wherein the peptides are the  
2     same.

1               12.     The multimeric complex of claim 10, wherein the peptides are  
2     from the same antigen.

1               13.     The multimeric complex of claim 10, wherein the peptides are  
2     from different antigens.

1               14.     The multimeric complex of claim 10, wherein the peptides are  
2     selected from the group consisting of MBP83-102Y83, PLP 40-60, PLP 89-106, PLP 95-  
3     117, and PLP 185-206.

1               15.     The multimeric complex of claim 1, wherein the first and second  
2     MHC class II molecules are from a human.

1               16.     The multimeric complex of claim 1, wherein the multimerization  
2     domains are covalently linked.

1               17.     The multimeric complex of claim 1, wherein the multimerization  
2     domains are non-covalently linked.

1               18.     The multimeric complex of claim 1, wherein the multimerization  
2     domain is a leucine zipper domain.

1               19.     The multimeric complex of claim 1, wherein the multimerization  
2     domain is an immunoglobulin domain.

1               20.     The multimeric complex of claim 19, wherein the immunoglobulin  
2     domain is a light chain constant domain or a heavy chain constant domain.

1           21.   The multimeric complex of claim 1, wherein the first or the second  
2   MHC class II molecule is selected from the group consisting of I-As MBP. $\beta$ 1 $\beta$ 2 $\alpha$ 1 $\alpha$ 2.C $\kappa$ ,  
3   I-As MBP. $\beta$ 1 $\beta$ 2 $\alpha$ 1 $\alpha$ 2.CH1.H, I-As MBP. $\beta$ 1 $\beta$ 2 $\alpha$ 1 $\alpha$ 2.CH1.H.CH2, and I-As  
4   MBP. $\beta$ 1 $\beta$ 2 $\alpha$ 1 $\alpha$ 2.CH1.H.CH2.CH3.

1           22.   The multimeric complex of claim 1, further comprising a third and  
2   a fourth MHC class II molecule, wherein the third and the fourth MHC class II molecule  
3   each comprise an  $\alpha$ 1 domain and a  $\beta$ 1 domain linked via an amino acid linker and a  
4   multimerization domain, and wherein the first, second, third and fourth single chain MHC  
5   class II molecules are linked via the multimerization domain to form a multimeric  
6   complex.

1           23.   The multimeric complex of claim 1, wherein the first and the  
2   second MHC class II molecules comprise  $\beta$ 1  $\beta$ 2 domains and  $\alpha$ 1  $\alpha$ 2 domains linked via an  
3   amino acid linker.

1           24.   The multimeric complex of claim 1 or 2, wherein the linker is  
2   selected from the group consisting of GG, GGGG, GGGGS, GGGSG, ASGGGSGGG,  
3   TSGGGGSGGGSSS, GSPGGGGSGGGPGS, GSPPGGPPGS, GSPGGGGPGS,  
4   TSGGGGS, SGGSGGS, FDAPSPLP, and VYPEVTV.

1           25.   The multimeric complex of claim 1 or 2, wherein the linker is from  
2   a CD4 molecule.

1           26.   The multimeric complex of claim 25, wherein the linker is selected  
2   from the group consisting of RNGQEEKAGVVSTGLI, RNGQETKAGVVSTGLI,  
3   YNQEEKAGGVSTGLI, FRNGQEEKAGVVSTGLI, FRNGQETKAGVVSTGLI,  
4   FYNQEEKAGGVSTGLI, and LNGQEEKAGMVSTGLI.

1           27.   The multimeric complex of claim 1, wherein the first or the second  
2   MHC class II molecule is selected from the group consisting of CO523, CO543, CO563,  
3   CO567, CO580, CO581, CO582, CO583, CO584, CO585, CO586, CO587, CO588,  
4   CO589, CO590, CO591, CO592, CO593, CO594, CO595, CO596, CO597, and CO608.

1               28.     The multimeric complex of claim 1, wherein the first and the  
2     second MHC class II molecule are independently selected from the group consisting of  
3     CO523, CO543, CO563, CO567, CO580, CO581, CO582, CO583, CO584, CO585,  
4     CO586, CO587, CO588, CO589, CO590, CO591, CO592, CO593, CO594, CO595,  
5     CO596, CO597, and CO608.

1               29.     The multimeric complex of claim 1, wherein the first MHC class II  
2     or the second MHC class II molecule is encoded by a nucleic acid that codons optimized  
3     for prokaryotic expression.

1               30.     The multimeric complex of claim 29, wherein the prokaryote is *E.*  
2     *coli*.

1               31.     The multimeric complex of claim 29, wherein the nucleic acid  
2     encoding the first or the second MHC class II molecule is selected from the group  
3     consisting of CO528-AC and CO608-AC.

1               32.     A pharmaceutical composition comprising the multimeric complex  
2     of claim 2.

1               33.     The pharmaceutical composition of claim 32, further comprising an  
2     adjuvant.

1               34.     A method of treating autoimmune disease in a subject, the method  
2     comprising administering an immunogenically effective amount of a pharmaceutical  
3     composition comprising the multimeric complex of claim 2.

1               35.     The method of claim 34, wherein the subject is a human.

1               36.     A recombinant nucleic acid encoding a single chain MHC class II  
2     molecule comprising an  $\alpha$ 1 domain and a  $\beta$ 1 domain linked via an amino acid linker,  
3     wherein the linker is selected from the group consisting of GG, GGGG, GGGGS,  
4     GGGSG, ASGGGSAGGG, TSAGGGSGGGSSS, GSPAGGGSGGGPGS,  
5     GSPPGGPPGS, GSPGGGGPGS, TSAGGGGS, SGGSGGS, FDAPSPLP, and VYPEVTV.

1           37. The nucleic acid of claim 36, wherein the MHC class II molecule is  
2 selected from the group consisting of CO523, CO543, CO563, CO567, CO580, CO581,  
3 CO582, CO583, CO584, CO585, CO586, CO587, CO588, CO589, CO590, CO591,  
4 CO592, CO593, CO594, CO595, CO596, CO597, and CO608.

1           38. A recombinant nucleic acid encoding a single chain MHC class II  
2 molecule comprising an  $\alpha_1$  domain and a  $\beta_1$  domain linked via an amino acid linker,  
3 wherein the linker is from a CD4 molecule.

1           39. The nucleic acid of claim 38, wherein the linker is selected from  
2 the group consisting of RNGQEEKAGVVSTGLI, RNGQETKAGVVSTGLI,  
3 YNQQEEKAGGVSTGLI, FRNGQEEKAGVVSTGLI, FRNGQETKAGVVSTGLI,  
4 FYNQEEKAGGVSTGLI, and LNGQEEKAGMVSTGLI.

1           40. A recombinant nucleic acid encoding a single chain MHC class II  
2 molecule selected from the group consisting of CO528-AC and CO608-AC.

1           41. A recombinant nucleic acid encoding a single chain MHC class II  
2 molecule selected from the group consisting I-As MBP. $\beta_1\beta_2\alpha_1\alpha_2.C\kappa$ , I-As  
3 MBP. $\beta_1\beta_2\alpha_1\alpha_2.CH1.H$ , I-As MBP. $\beta_1\beta_2\alpha_1\alpha_2.CH1.H.CH2$ , and I-As  
4 MBP. $\beta_1\beta_2\alpha_1\alpha_2.CH1.H.CH2.CH3$ .

1           42. A recombinant nucleic acid encoding a single chain MHC class II  
2 molecule selected from the group consisting CO523, CO543, CO563, CO567, CO580,  
3 CO581, CO582, CO583, CO584, CO585, CO586, CO587, CO588, CO589, CO590,  
4 CO591, CO592, CO593, CO594, CO595, CO596, CO597, and CO608.




Figure 1




Figure 2




Figure 3




Figure 4




Figure 5




Figure 6

The differentiation can be achieved by elemental composition of two different MHC peptide molecules can be achieved by the use of one common method by the expression of MHC Peptide molecules containing different domains. Example Luciferase zipper, CX (Glycine rich and light chain).




Figure 7





Figure 8

**Effect of different recombinant MHC class II molecules on the development of EAE (day +60)**

<b>EAE induction Day 0 &amp; 7</b>	<b>Treatment Day 1,4, 7 &amp; 11 10 ug/injection i.v.</b>	<b>Incidence of disease (%)</b>
Myelin 2 mg/mouse in CFA s.c.	none	12/16 (75%)
Myelin 2 mg/mouse in CFA s.c.	Monomer	2/12 (16%)
Myelin 2 mg/mouse in CFA s.c.	Dimer	2/6 (33%)
Myelin 2 mg/mouse in CFA s.c.	Tetramer	3/14 (21%)
Myelin 2 mg/mouse in CFA s.c.	Monomer Pool	2/16 (12%)
Myelin 2 mg/mouse in CFA s.c.	Half Anergix	2/16 (12%)
Myelin 2 mg/mouse in CFA s.c.	I-As peptide	9/16 (56%)
Myelin 2 mg/mouse in CFA s.c.	Empty Half Anergix	10/16 (62%)

# *I-A<sup>S</sup>MBP Molecules*

Figure 10



Coriex  
Redwood City

Figure 11

## Amino Acid sequence alignment of CO608 based LAS.MBP half Antigenix

Native IAS beta 1.PRO	M G S E R F K N I V T P R T P P A S G G G S G G G -	G D S E R H F V P Q F K G 13
mCO608 .PRO	M M M M M M	H F V P Q F K G 35
mCO608 A .pro	M M M M M M	H F V E Q F K G 31
mCO608 B.pro	M M M M M M	H F V E Q F K G 35
pcRC197.pro	M M M M M M	D S E R H F V E Q F K G 36
pcRC199.pro	M M M M M M	D S E R H F V E Q F K G 36
Native IAS beta 1.PRO	E C Y F T N G T Q R I R S V D R Y I Y N R E E Y L R F D S D V G E Y R A V T E L 53	
mCO608 .PRO	E C Y F T N G T Q R I R S V D R Y I Y N R E E Y L R F D S D V G E Y R A V T E L 75	
mCO608 A .pro	E C Y F T N G T Q R I R S V D R Y I Y N R E E Y L R F D S D V G E Y R A V T E L 71	
mCO608 B.pro	E C Y F T N G T Q R I R S V D R Y I Y N R E E Y L R F D S D V G E Y R A V T E L 75	
pcRC197.pro	E C Y F T N G T Q R I R S V D R Y I Y N R E E Y L R F D S D V G E Y R A V T E L 76	
Native IAS beta 1.PRO	G R P D P E Y Y N K Q Y L E Q T R A E L D T V C R H N Y E G V E T H T S L R R R -	92
mCO608 .PRO	G R P D P E Y Y N K Q Y L E Q T R A E L D T V C R H N Y E G V E T H T S L R R R -	115
mCO608 A .pro	G R P D P E Y Y N K Q Y L E Q T R A E L D T V C R H N Y E G V E T H T S L R R R -	111
mCO608 B.pro	G R P D P E Y Y N K Q Y L E Q T R A E L D T V C R H N Y E G V E T H T S L R R R -	115
pcRC197.pro	G R P D P E Y Y N K Q Y L E Q T R A E L D T V C R H N Y E G V E T H T S L R R R -	116
pcRC199.pro	G R P D P E Y Y N K Q Y L E Q T R A E L D T V C R H N Y E G V E T H T S L R R R -	116
Native IAS beta 1.PRO	T S G G G G S E D D I E A D H V G V Y G T T V Y Q S P G D I G Q Y T H H F D G D	92
mCO608 .PRO	T S G G G G S E D D I E A D H V G V Y G T T V Y Q S P G D I G Q Y T H H F D G D	155
mCO608 A .pro	T S G G G G S E D D I E A D H V G V Y G T T V Y Q S P G D I G Q Y T H H F D G D	151
mCO608 B.pro	T S G G G G S E D D I E A D H V G V Y G T T V Y Q S P G D I G Q Y T H H F D G D	155
pcRC197.pro	T S G G G G S E D D I E A D H V G V Y G T T V Y Q S P G D I G Q Y T H H F D G D	156
pcRC199.pro	T S G G G G S E D D I E A D H V G V Y G T T V Y Q S P G D I G Q Y T H H F D G D	156
Native IAS beta 1.PRO	E W F Y V D L D K K E T I W M L P E F G Q L T S F D P Q G G L Q N I A T G K Y T	92
mCO608 .PRO	E W F Y V D L D K K E T I W M L P E F G Q L T S F D P Q G G L Q N I A T G K Y T	195
mCO608 A .pro	E W F Y V D L D K K E T I W M L P E F G Q L T S F D P Q G G L Q N I A T G K Y T	191
mCO608 B.pro	E W F Y V D L D K K E T I W M L P E F G Q L T S F D P Q G G L Q N I A T G K Y T	195
pcRC197.pro	E W F Y V D L D K K E T I W M L P E F G Q L T S F D P Q G G L Q N I A T G K Y T	196
pcRC199.pro	E W F Y V D L D K K E T I W M L P E F G Q L T S F D P Q G G L Q N I A T G K Y T	196
Native IAS beta 1.PRO	- - - - - L	93
mCO608 .PRO	L G I L T K R S N S T P A T N -	211
mCO608 A .pro	L G I L T K R S N S T P A T N -	207
mCO608 B.pro	L G I L T K R S N S T P A T N -	211
pcRC197.pro	L G I L T K R S N S T P A T N -	212
pcRC199.pro	L G I L T K R S N S T P A T N -	218

Figure 12

## Amino Acid sequence alignment of C0561 based IAs.MBP half Anergix

Inte al application No.  
PCT/US01/09616

**A. CLASSIFICATION OF SUBJECT MATTER**

IPC(7) : A61K 35/28

US CL : 514/8, 903; 530/395, 402, 403; 424/88

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 514/8, 903; 530/395, 402, 403; 424/88

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

CAPLUS EMBASE BIOSIS MEDLINE WEST

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US 5,194,425 A (SHARMA et al.) 16 March 1993, entire patent	1-42
Y	US 5,284,935 A (CLARK et al.) 08 February 1994, entire patent	1-42
Y	US 6,015,884 A (SCHNECK et al.) 18 January 2000, entire patent	1-20

Further documents are listed in the continuation of Box C.  See patent family annex.

*A*	Special categories of cited documents:	*T*	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
*E*	document defining the general state of the art which is not considered to be of particular relevance	*X*	document of particular relevance, the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
*I*	earlier document published on or after the international filing date	*Y*	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
*O*	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*Z*	document member of the same patent family
*P*	document referring to an oral disclosure, use, exhibition or other means		
	document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search  16 JULY 2001	Date of mailing of the international search report  05 SEP 2001
---	---

Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703) 305-3230	Authorized officer  AMY DECLoux Telephone No. (703) 308-0196
---	---

